0001213900-22-072177.txt : 20221114 0001213900-22-072177.hdr.sgml : 20221114 20221114160555 ACCESSION NUMBER: 0001213900-22-072177 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221114 DATE AS OF CHANGE: 20221114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Generation Hemp, Inc. CENTRAL INDEX KEY: 0001527102 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 263119496 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55019 FILM NUMBER: 221385090 BUSINESS ADDRESS: STREET 1: 5128 HORSESHOE TRAIL CITY: DALLAS STATE: TX ZIP: 75209 BUSINESS PHONE: (469) 209-6154 MAIL ADDRESS: STREET 1: P.O. BOX 540308 CITY: DALLAS STATE: TX ZIP: 75354 FORMER COMPANY: FORMER CONFORMED NAME: Home Treasure Finders, Inc. DATE OF NAME CHANGE: 20110801 10-Q 1 f10q0922_generation.htm QUARTERLY REPORT
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2022

 

or

 

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from         to        

 

Commission File Number: 000-55019

 

GENERATION HEMP, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   26-3119496
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)
     
8533 Midway Road    
Dallas, Texas   75209
(Address of principal executive offices)   (Zip code)

 

(469) 209-6154

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
         

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No 

 

As of November 14, 2022, the registrant had 113,204,002 shares of common stock outstanding.

 

 

 

 

 

 

TABLE OF CONTENTS

 

    Page
     
  PART I. FINANCIAL INFORMATION  
Item 1. Financial Statements 1
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 15
Item 3. Quantitative and Qualitative Disclosures about Market Risk 20
Item 4. Controls and Procedures 20
     
  PART II. OTHER INFORMATION  
Item 1. Legal Proceedings 21
Item 1A. Risk Factors 21
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 21
Item 4. Mine Safety Disclosures 21
Item 6. Exhibits 21
     
SIGNATURES 22

 

i

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q (the “Quarterly Report”) includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of historical fact included in this report, regarding our strategy, future operations, financial position, estimated revenue, projected costs, prospects, plans and objectives of management are forward-looking statements. When used in this Quarterly Report, the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements described under, but not limited to, the heading “Item 1A. Risk Factors” included in the Annual Report of Generation Hemp, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2021 (the “Annual Report”) and our other filings with the Securities and Exchange Commission (“SEC”).

 

Forward-looking statements may include statements about:

 

  the marketability of our products;

 

  financial condition and liquidity of our customers;

 

  competition in the hemp markets;

 

  industry and market conditions;

 

  requisition of our services by major customers and our ability to renew processing and services contracts;

 

  credit and performance risks associated with customers, suppliers, banks and other financial counterparties;

 

  availability, timing of delivery and costs of key supplies, capital equipment or commodities;

 

  our future capital requirements and our ability to raise additional capital to finance our activities;

 

  the future trading of our common stock;

 

  legal and regulatory risks associated with OTC Markets;

 

  our ability to operate as a public company;

 

  our ability to protect our proprietary information;

 

  general economic and business conditions; the volatility of our operating results and financial condition;

 

ii

 

 

  our ability to attract or retain qualified senior management personnel and research and development staff;

 

  timing for completion of major acquisitions or capital projects;

  

  our ability to obtain additional financing on favorable terms, if required, to complete acquisitions as currently contemplated or to fund the operations and growth of our business;

 

  operating or other expenses or changes in the timing thereof;

 

  compliance with stringent laws and regulations, as well as changes in the regulatory environment, the adoption of new or revised laws, regulations and permitting requirements, especially with respect to the industry in which we operate;

 

  potential legal proceedings and regulatory inquiries against us; and

 

  other risks identified in this report that are not historical.

 

We caution you that these forward-looking statements are subject to a number of risks, uncertainties and assumptions, which are difficult to predict and many of which are beyond our control, including risks specific to the industry in which we operate. Moreover, we operate in a very competitive and rapidly changing environment and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this Quarterly Report are reasonable, we can give no assurance that these plans, intentions or expectations will be achieved or occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

 

All forward-looking statements, expressed or implied, included in this report are expressly qualified in their entirety by this cautionary statement and speak only as of the date of this Quarterly Report. This cautionary statement should also be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue.

 

Except as otherwise required by applicable law, we disclaim any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this report.

 

iii

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

Generation Hemp, Inc.

Unaudited Condensed Consolidated Balance Sheets

 

   September 30,   December 31, 
   2022   2021 
Assets        
Current Assets:        
Cash  $112,538   $20,656 
Accounts receivable   656,344    - 
Inventories   212,518    212,518 
Prepaid expenses   49,078    4,723 
Total current assets   1,030,478    237,897 
           
Property and equipment, net   2,276,815    2,580,662 
Operating lease right-of-use asset   188,090    263,065 
Intangible assets, net   1,418,025    1,857,908 
Goodwill   799,888    799,888 
Other assets   -    407,000 
           
Total Assets  $5,713,296   $6,146,420 
           
Liabilities and Equity (Deficit)          
Current Liabilities:          
Accounts payable  $1,037,275   $883,485 
Accrued liabilities   402,617    410,990 
Deferred revenue   100,311    - 
Payables to related parties   486,855    204,007 
Operating lease liability - related party   109,089    101,238 
Notes payable – related parties   3,357,620    2,183,551 
Other indebtedness - current   423,192    501,668 
Current liabilities of discontinued operations held for sale   144,441    153,482 
Total current liabilities   6,061,400    4,438,421 
Operating lease liability - related party, net of current portion   79,001    161,827 
Long-term liabilities of discontinued operations held for sale   199,046    162,948 
Total liabilities   6,339,447    4,763,196 
           
Commitments and contingencies   
 
    
 
 
           
Series B redeemable preferred stock, no par value, $10,000 stated value, 300 shares authorized, 118 and 135 shares issued and outstanding at September 30, 2022 and December 31, 2021   591,558    591,558 
           
Equity (Deficit):          
Preferred stock, $0.00001 par value; 200,000,000 shares authorized, none outstanding   -    - 
Common stock, $0.00001 par value; 200,000,000 shares authorized, 113,204,002 and 113,094,002 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively   1,132    1,131 
Additional paid-in capital   33,250,858    29,150,258 
Accumulated deficit   (34,224,154)   (28,118,245)
Generation Hemp equity (deficit)   (972,164)   1,033,144 
Noncontrolling interest   (245,545)   (241,478)
Total equity (deficit)   (1,217,709)   791,666 
           
Total Liabilities and Equity (Deficit)  $5,713,296   $6,146,420 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

1

 

 

Generation Hemp, Inc.

Unaudited Condensed Consolidated Statements of Operations

 

   For the three months ended
September 30,
   For the nine months ended
September 30,
 
   2022   2021   2022   2021 
Revenue:                
Post-harvest and midstream services  $1,227,123   $487,088   $1,559,056   $535,053 
Rental   22,500    15,000    67,500    60,000 
Total revenue   1,249,623    502,088    1,626,556    595,053 
                     
Costs and Expenses:                    
Cost of revenue (exclusive of items shown separately below)   375,269    279,621    644,113    549,881 
Depreciation and amortization   261,490    315,729    743,730    1,006,804 
Merger and acquisition costs   -    -    -    16,115 
Impairment expense   407,000    -    407,000    - 
General and administrative   1,933,281    1,128,298    5,825,809    2,763,529 
Total costs and expenses   2,977,040    1,723,648    7,620,652    4,336,329 
                     
Operating loss   (1,727,417)   (1,221,560)   (5,994,096)   (3,741,276)
                     
Other expense (income):                    
Other income   (378,304)   -    (378,304)   (25,424)
Change in fair value of marketable security   -    -    -    (11,770)
Interest expense   116,999    155,505    404,272    651,807 
Total other expense (income)   (261,305)   155,505    25,968    614,613 
                     
Loss from continuing operations   (1,466,112)   (1,377,065)   (6,020,064)   (4,355,889)
Income (loss) from discontinued operations   10,386    (1,630)   (29,877)   (11,349)
                     
Net loss  $(1,455,726)  $(1,378,695)  $(6,049,941)  $(4,367,238)
Less: net income (loss) attributable to noncontrolling interests   (58)   (1,137)   (4,067)   (284)
                     
Net loss attributable to Generation Hemp  $(1,455,668)  $(1,377,558)  $(6,045,874)  $(4,366,954)
                     
Earnings (loss) per common share:                    
Loss from continuing operations                    
Basic  $(0.01)  $(0.03)  $(0.05)  $(0.11)
Diluted  $(0.01)  $(0.03)  $(0.05)  $(0.11)
Loss from discontinued operations                    
Basic  $-   $-   $-   $- 
Diluted  $-   $-   $-   $- 
Earnings (loss) per share                    
Basic  $(0.01)  $(0.03)  $(0.05)  $(0.11)
Diluted  $(0.01)  $(0.03)  $(0.05)  $(0.11)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

2

 

 

Generation Hemp, Inc.

Unaudited Condensed Consolidated Statements of Equity (Deficit)

 

   Series B
Redeemable
Preferred Stock
   Series A
Preferred Stock
   Common Stock   Additional
Paid-In
   Accumulated   Noncontrolling   Total
Equity
 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Interest   (Deficit) 
                                         
Balance at January 1, 2021   135   $729,058    6,328,948   $4,975,503    17,380,317   $6,083,480   $4,436,018   $(18,220,705)  $(239,231)  $(2,964,935)
Acquisition of Certain Assets of Halcyon Thruput, LLC   -    -    -    -    6,250,000    2,500,000    -    -    -    2,500,000 
Issuances of common stock units   -    -    -    -    800,000    136,707    263,293    -    -    400,000 
Warrant exercises   -    -    -    -    8,428,976    4,771,669    (1,804,669)   -    -    2,967,000 
Issuance of common shares for Convertible Promissory Note   -    -    -    -    618,660    217,769    -    -    -    217,769 
Issuance of common shares for Senior Secured Promissory Note   -    -    -    -    1,000,000    1,942,500    -    -    -    1,942,500 
Series B preferred stock dividend   -    -    -    -    -    -    -    (20,250)   -    (20,250)
Stock-based compensation   -    -    -    -    500,000    42,250    -    -    -    42,250 
Net loss   -    -    -    -    -    -    -    (1,836,882)   3,668    (1,833,214)
                                                   
Balance at March 31, 2021   135    729,058    6,328,948    4,975,503    34,977,953    15,694,375    2,894,642    (20,077,837)   (235,563)   3,251,120 
Series B preferred stock redemptions   (17)   (137,500)   
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
 
Series B preferred stock dividend   -    -    -    -    -    -    -    (20,250)   -    (20,250)
Stock-based compensation   -    -    -    -    -    38,750    -    -    -    38,750 
Net loss   -    -    -    -    -    -    -    (1,152,514)   (2,815)   (1,155,329)
                                                   
Balance at June 30, 2021   118    591,558    6,328,948    4,975,503    34,977,953    15,733,125    2,894,642    (21,250,601)   (238,378)   2,114,291 
Common shares issued to vendor for services   -    -    -    -    125,000    117,500    -    -    -    117,500 
Issuance of common shares for extension of secured note   -    -    -    -    20,000    18,000    -    -    -    18,000 
Change in common stock par value due to change in corporate domicile   -    -    -    -    -    (15,868,273)   15,868,273    -    -    - 
Stock-based compensation   -    -    -    -    -    -    38,750    -    -    38,750 
Conversion of Series A preferred stock   
 
    
 
    (6,328,948)   (4,975,503)   75,947,376    759    4,974,744    -    -    - 
Series B preferred stock dividend   -    -    -    -    -    -    -    (16,125)   -    (16,125)
Net loss   -    -    -    -    -    -    -    (1,377,558)   (1,137)   (1,378,695)
                                                   
Balance at September 30, 2021   118   $591,558    -   $-    111,070,329   $1,111   $23,776,409   $(22,644,284)  $(239,515)  $893,721 
                                                   
Balance at January 1, 2022   118   $591,558    -   $-    113,094,002   $1,131   $29,150,258   $(28,118,245)  $(241,478)  $791,666 
Issuance of common shares for extension of secured note   -    -    -    -    20,000    -    11,480    -    -    11,480 
Modification of warrants for extension of promissory note to investor        
 
         
 
         
 
    68,756    
 
    
 
    68,756 
Series B preferred stock dividend   -    -    -    -    -    -    -    (20,992)   -    (20,992)
Stock-based compensation   -    -    -    -    -    -    1,315,750    -    -    1,315,750 
Net loss   -    -    -    -    -    -    -    (2,455,084)   (1,587)   (2,456,671)
                                                   
Balance at March 31, 2022   118    591,558    -    -    113,114,002    1,131    30,546,244    (30,594,321)   (243,065)   (290,011)
Issuance of common shares for extensions of secured note   -    -    -    -    40,000    1    26,000    -    -    26,001 
Series B preferred stock dividend   -    -    -    -    -    -    -    (19,375)   -    (19,375)
Stock-based compensation   -    -    -    -    -    -    1,315,750    -    -    1,315,750 
Net loss   -    -    -    -    -    -    -    (2,135,122)   (2,422)   (2,137,544)
                                                   
Balance at June 30, 2022   118    591,558    -    -    113,154,002    1,132    31,887,994    (32,748,818)   (245,487)   (1,105,179)
Issuance of common shares for extension of secured note   -    -    -    -    50,000    -    15,100    -    -    15,100 
Series B preferred stock dividend   -    -    -    -    -    -    -    (19,668)   -    (19,668)
Stock-based compensation   -    -    -    -    -    -    1,347,764    -    -    1,347,764 
Net loss   -    -    -    -    -    -    -    (1,455,668)   (58)   (1,455,726)
                                                   
Balance at September 30, 2022   118   $591,558    -   $-    113,204,002   $1,132   $33,250,858   $(34,224,154)  $(245,545)  $(1,217,709)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3

 

 

Generation Hemp, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

 

   For the nine months ended September 30, 
   2022   2021 
Cash Flows From Operating Activities        
Net loss  $(6,049,941)  $(4,367,238)
Loss from discontinued operations   (29,877)   (11,349)
Net loss from continuing operations   (6,020,064)   (4,355,889)
Adjustments to reconcile net loss from continuing operations to net cash from operating activities:          
Depreciation and amortization   743,730    1,006,804 
Impairment expense   407,000    
-
 
Amortization of debt discount   52,581    380,282 
Stock-based compensation   3,979,264    119,750 
Common shares issued to vendor for services   
-
    117,500 
Modification of warrants for extension of promissory note to investor   68,756    
-
 
Other income - PPP Loan forgiveness   
-
    (25,424)
Change in fair value of marketable securities   
-
    (11,770)
Changes in operating assets and liabilities:          
Accounts receivable   (656,344)   (52,195)
Prepaid expenses   (44,355)   (14,232)
Accounts payable and accrued liabilities   368,230    176,969 
Deferred revenue   100,311    
-
 
Net cash from operating activities – continuing operations   (1,000,891)   (2,658,205)
Net cash from operating activities – discontinued operations   (2,820)   
-
 
Net cash from operating activities   (1,003,711)   (2,658,205)
           
Cash Flows From Investing Activities          
Capital expenditures   
-
    (77,716)
Acquisition of certain assets of Halcyon Thruput, LLC, net of acquired cash of $224,530   
-
    (1,525,470)
Proceeds from sale of investment in common stock   
-
    34,847 
Net cash from investing activities – continuing operations   
-
    (1,568,339)
Net cash from investing activities – discontinued operations   
-
    
-
 
Net cash from investing activities   
-
    (1,568,339)
           
Cash Flows From Financing Activities          
Issuance of common stock units   
-
    350,000 
Redemptions of Series B preferred stock   
-
    (137,500)
Series B preferred stock dividends paid   
-
    (16,500)
Proceeds from warrant exercises   
-
    2,967,000 
Repayment of Halcyon bank note   
-
    (995,614)
Proceeds from notes payable - related parties   1,294,069    
-
 
Repayments of notes payable - related parties   (70,000)   
-
 
Proceeds from subordinated notes   
-
    620,000 
Repayment of subordinated notes   (50,000)   (1,100,000)
Payment of mortgage payable   (78,476)   (103,102)
Net cash from financing activities – continuing operations   1,095,593    1,584,284 
Net cash from financing activities – discontinued operations   
-
    
-
 
Net cash from financing activities   1,095,593    1,584,284 
           
Net change in cash   91,882    (2,642,260)
           
Cash, beginning of period   20,656    2,776,425 
Cash, end of period  $112,538   $134,165 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

 

Generation Hemp, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

 

1. Business

 

Generation Hemp, Inc. (the “Company”) was incorporated on August 21, 2021 in the State of Delaware. The Company was originally incorporated as Home Treasure Finders, Inc. (“HTF”) on July 28, 2008 in the State of Colorado. On November 27, 2019, HTF purchased approximately 94% of the common stock of Energy Hunter Resources, Inc. (“EHR”) in a series of transactions accounted for as a reverse merger. Upon closing, HTF changed its name to Generation Hemp, Inc.

 

On January 11, 2021, we completed the acquisition of certain assets of Halcyon Thruput, LLC (“Halcyon”). With this acquisition, we commenced providing post-harvest and midstream services to hemp growers by drying, processing, cleaning and stripping harvested hemp directly from the field and wetbaled at our 48,000 square foot leased facility located in Hopkinsville, Kentucky. The Company also offers safe storage services for processed hemp, which enables farmers to maximize strategic market timing. We market two retail products, Gas Monkey Spill-Jack, an all-natural, plant-based, sustainable, and biodegradable loose absorbent, and Rowdy Rooster, an animal bedding consumer goods product, each made from the hemp hurd byproduct that is produced from our hemp processing operations.

 

We also generate revenue from rental of our “Cannabis Zoned” (Hemp) warehouse property located in Denver, Colorado currently leased to an unaffiliated hemp seed company.

 

As of September 30, 2022, EHR held an approximate 8% working interest in an oil & gas property located in Cochran County, Texas within the Slaughter-Levelland Field of the San Andres formation in the Northwest Shelf of West Texas. EHR’s oil & gas activities are currently held for sale and are presented in these consolidated financial statements as discontinued operations for each of the periods presented.

 

Our management team has been and continues to actively review acquisition candidates involved in the hemp industry that operate within a number of vertical businesses, predominantly within the midstream sector that are attractive to us and are within the hemp supply chain. Additionally, the Company has been studying the Bitcoin mining space and anticipates future activity in this business sector.

 

Liquidity and Going Concern – The Company is dependent upon obtaining additional funding to continue ongoing operations and to pursue its strategy and execute its acquisition plans.

 

In the nine months ended September 30, 2022, the Company used $1.0 million of cash for its operating activities. At September 30, 2022, the Company’s current liabilities, including financing obligations due within one year, totaled $6.1 million as compared with its current assets of $1.0 million.

 

The Company will continue to pursue additional capital raising opportunities in order to fund future acquisitions and meet its obligations as they become due. We may not be successful in obtaining additional financing needed. In the event financing cannot be obtained, the Company may not be able to satisfy these plans and obligations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

2. Summary of Significant Accounting Policies

 

Basis of Presentation – These interim financial statements are unaudited and have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain disclosures have been condensed or omitted from these financial statements. Accordingly, they do not include all the information and notes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements, and should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021.

 

5

 

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, necessary to fairly present the financial position as of, and the results of operations for, all periods presented. In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the condensed consolidated financial statements and disclosures of contingencies. Actual results may differ from those estimates. The results for interim periods are not necessarily indicative of annual results. Certain reclassifications have been made to the prior period’s consolidated financial statements and related footnotes to conform them to the current period presentation. Intercompany balances and transactions between consolidated entities are eliminated.

 

Fair Value Measurement – Our financial assets and liabilities consist of cash, accounts receivable, accounts payable and indebtedness. The fair values of these instruments approximate their carrying amounts at each reporting date.

 

Deferred Revenue – In July 2022, the Company entered into an agreement for the sale of 66,782 pounds of dried hemp biomass from its inventories on-hand for a sales price of $1.50 per pound. Deliveries and payment of the $100,173 sales proceeds are scheduled monthly through December 2022 and are reported as deferred revenue in the consolidated balance sheets. We expect to recognize revenue for these amounts when the contract is completed and product is shipped in the fourth quarter of 2022.

 

Major Customer and Concentration of Credit Risk – We estimate an allowance for doubtful accounts based on an analysis of specific customers, taking into consideration the age of past due accounts and an assessment of the customer’s ability to pay. An allowance for doubtful accounts was not needed as of September 30, 2022 or December 31, 2021.

 

During the three and nine months ended September 30, 2022, one customer accounted for all of our post-harvest and midstream services revenue. A total of $656,344 was outstanding from this customer as a receivable at September 30, 2022.

 

Our rental revenue is derived from a single lessee on a commercial warehouse owned by the Company. There were no amounts due from this customer at September 30, 2022 or December 31, 2021.

 

Recent Accounting Pronouncements – There are no other new accounting pronouncements that are expected to have a material impact on the consolidated financial statements.

 

3. Property and Equipment

 

Property and equipment consisted of the following:

 

   Useful  September 30,   December 31, 
   Life (yrs)  2022   2021 
            
Land     $96,000   $96,000 
Warehouse  30   916,500    916,500 
Leasehold Improvements  3   473,601    473,601 
Machinery and equipment   5-7   1,506,447    1,506,447 
Vehicles  4   149,440    149,440 
Computer equipment and software  3   46,825    46,825 
Office furniture and equipment   3-5   17,294    17,294 
Subtotal      3,206,107    3,206,107 
Less accumulated depreciation and amortization      (929,292)   (625,445)
Total property and equipment, net     $2,276,815   $2,580,662 

 

6

 

 

4. Intangible and Other Assets

 

The following table summarizes information related to definite-lived intangible assets:

 

   September 30, 2022   December 31, 2021 
   Gross Carrying Amount   Accumulated Amortization   Net   Gross Carrying Amount   Accumulated Amortization   Net 
                         
Customer relationships  $2,612,649   $(1,220,948)  $1,391,701   $2,612,649   $(796,858)  $1,815,791 
Non-competition agreements   63,176    (36,852)   26,324    63,176    (21,059)   42,117 
Total  $2,675,825   $(1,257,800)  $1,418,025   $2,675,825   $(817,917)  $1,857,908 

 

Other assets included $407,000 at December 31, 2021 for the Company’s option to purchase the 48,000 square foot facility located in Hopkinsville, Kentucky presently leased from Halcyon. Under this agreement, the Company had the option to purchase the facility on or before August 25, 2022, as amended, for a purchase price of $993,000. This agreement was not renewed upon its expiration. Impairment expense totaling $407,000 was recognized in the third quarter of 2022 as a result.

 

5. Notes Payable – Related Parties

 

Notes payable – related parties consisted of the following:

 

   September 30,   December 31, 
   2022   2021 
         
Subordinated Promissory Note to CEO  $523,551   $523,551 
Convertible Promissory Note to CEO   1,107,069    410,000 
Secured Promissory Note to Coventry Asset Management, LTD.   1,000,000    1,000,000 
Subordinated Promissory Note to Investor   200,000    250,000 
Promissory Note to Investment Hunter, LLC   492,000    
-
 
Note payable to Director   35,000    
-
 
Total notes payable – related parties  $3,357,620   $2,183,551 

 

Subordinated Promissory Note to CEO – Our CEO made advances to the Company during 2020 under a subordinated promissory note in the amount of $523,551 initially due September 30, 2021. This note was amended to a new maturity date of January 1, 2023. If the Company raises new equity capital of $3 million or more, then the full amount outstanding under the note is due within five days. The note bears interest at 10% per annum. Accrued interest on this subordinated promissory note totaled $46,761 at September 30, 2022.

 

Convertible Promissory Note to CEO – In 2021, our CEO made advances totaling $410,000 to the Company under a convertible promissory note. Additional advances made in 2022 through September 30 totaled $697,069. The convertible note initially matured on January 1, 2022 but was subsequently amended to extend the maturity date to January 1, 2023. If the Company raises new equity capital of $3 million or more, then the full amount outstanding under the note is due within five days. The note bears interest at 10%. The principal and interest due on the convertible note may be converted, at the option of the holder, into restricted shares of the Company’s common stock at an initial conversion price of $0.50 per share but that was lowered in July 2022 to $0.30 per share. Accrued interest on this convertible promissory note totaled $79,493 at September 30, 2022.

 

Secured Promissory Note and Warrants to Coventry Asset Management, LTD. – On December 30, 2020, the Company received proceeds from issuance of a secured promissory note in principal amount of $1,000,000 to Coventry Asset Management, LTD, a Company stockholder. The promissory note is secured by the property acquired in the acquisition of certain assets of Halcyon. The unpaid balance of the secured promissory note bears interest at a rate of 10% per annum and initially matured on June 30, 2021. The promissory note has been extended six times including the issuance of 20,000 restricted common shares as extension fees each for the first five extensions and the issuance of 50,000 restricted common shares for the sixth extension. The maturity date of the promissory note is December 31, 2022, as amended. If before December 31, 2022, the Company raises new equity capital of $5 million or more, then the full amount outstanding under the promissory note is due within five days. As amended, a payment of 25% of the principal balance of the note is due by October 31, 2022. The Company did not make the principal payment due on October 31, 2022 and, as a result, this note is presently in default. If the promissory note is not paid in full by December 31, 2022, the interest rate increases to 14% per annum. Accrued interest on this secured note totaled $175,069 at September 30, 2022.

 

7

 

 

Subordinated Promissory Note and Warrants to Investor – On December 30, 2020, the Company issued a subordinated promissory note in principal amount of $500,000 to an accredited investor who is also a Company stockholder. The unpaid balance of the Subordinated Note bears interest at a rate of 10% per annum. The Company made a principal payment of $250,000 in April 2021. The subordinated note principal together with accrued and unpaid interest was due, as previously amended, on March 31, 2022 but was subsequently extended. As subsequently amended, a payment of $50,000 was made in April 2022 and the remaining principal of $200,000 together with accrued interest was due on June 30, 2022. The Company did not make the principal payment due on June 30, 2022 and, as a result, this note is presently in default. Accrued interest on this subordinated promissory note totaled $36,990 at September 30, 2022.

 

The holder of the subordinated note received a warrant to purchase 500,000 shares of common stock exercisable for cash at an exercise price of $0.352 per share. As consideration for the April 2022 extension, the term of this warrant was extended by one year to December 30, 2023. The Company recognized $68,756 of interest expense in 2022 for this extension of the warrant term.

 

Promissory Note to Investment Hunter, LLC – In 2022, Investment Hunter, LLC, a Texas LLC controlled by our CEO, made advances totaling $492,000 to the Company under a promissory note due January 1, 2023, as amended. If the Company raises new equity capital of $3 million or more, then the full amount outstanding under the note is due within five days. The note bears interest at 10% per annum. Accrued interest on this subordinated promissory note totaled $30,193 at September 30, 2022.

  

Director NotesIn August 2022, the Company received proceeds totaling $105,000 from unsecured notes payable to three members of our board of directors. The notes bear interest at 10% per annum and matured on September 12, 2022. Two of the notes were repaid in September 2022. The remaining note, having an outstanding principal balance of $35,000 at September 30, 2022, was repaid in October 2022.

 

6. Other Indebtedness

 

The Company is obligated under a mortgage payable dated September 15, 2014 secured by its warehouse property located in Denver, Colorado. The note has been amended a number of times to a maturity date of January 15, 2023. In the latest extension, the Company made a principal payment of $73,190 plus accrued interest in October 2022 and agreed to make two additional principal payments of $50,000 plus accrued interest on November 15, 2022 and December 15, 2022. The interest rate on the mortgage payable is 12%. If before the final maturity of the mortgage payable, the Company raises new equity capital of $5 million or more, then the full amount outstanding is due within ten days.

 

The Company leases the Denver warehouse property to a tenant under an operating lease which was renewed with a new tenant and extended to August 1, 2023 for a monthly rent of $7,500. The lease requires a true-up with the tenant for property taxes and insurance paid by the Company and requires the tenant to maintain the interior and exterior of the warehouse (except for the roof). The lease provides for a rent abatement in the first and last month of the contracted extension. Minimum future rents for the remainder of 2022 are $22,500 and for 2023 are $52,500.

  

7. Leases

 

Office Space – The Company leases office space in Fort Worth, Texas for managerial offices. This lease requires monthly payments of $2,000 and is month-to-month. Lease expense for this facility totaled $6,000 and $18,000 for the three and nine months ended September 30, 2022, respectively. In the three and nine months ended September 30, 2021, lease expense for this facility was $6,000 and $16,000, respectively.

 

Hemp Processing Operating Facility – The Company leases its operating facility in Kentucky from Oz Capital, LLC, a related party, under a lease expiring May 31, 2024. The lease provides for monthly payments of $10,249. Oz Capital, LLC is responsible for all taxes and maintenance under the lease. Lease expense for this facility totaled $30,747 and $92,241 in the three and nine months ended September 30, 2022, respectively. In the three and nine months ended September 30. 2021, lease expense for this facility was $30,747 and $88,604, respectively. A right-of-use asset and lease liability is recorded for this lease. As the lease does not provide an implicit rate, the Company used its estimated incremental borrowing rate of 10% in determining the present value of the lease payments.

 

8

 

 

Future Bitcoin Mining Premises – The Company entered a five-year commercial lease for land and premises in Arkansas. We expect to use these premises as a future Bitcoin mining location because of its favorable power rates and land availability. The lease commences once the Company begins receiving power for its operations conducted at the location. The monthly rent will vary from a minimum of $1,000 per megawatt of power usage monthly up to $4,000 per megawatt monthly depending on the average power usage over a trailing 90-day period. We anticipate commencing operations at the leased premises in the first quarter of 2023.

 

8. Commitments and Contingencies

 

Litigation – From time to time, we are subject to various litigation and other claims in the normal course of business. Below is a discussion of specific matters. We cannot estimate the ultimate outcome of these matters.

 

Generation Hemp, Inc. v. Colorado Mill Equipment, LLC

 

The Defendant sold to the Company a faulty piece of equipment for $16,000 and will not refund to the Company the purchase price after repeated attempts to return their equipment. An original lawsuit filed by the Company against Colorado Mill Equipment in January 2022 in Dallas County was subsequently dismissed due to jurisdiction. A second lawsuit was filed in El Paso County, Colorado and is currently pending.

 

Halcyon Thruput, LLC, Plaintiff v. United National Insurance Company, Defendant, United States District Court for the Northern District of Texas, Dallas Division, Case No. 3:21-CV-3136-K.

 

Halcyon Thruput, LLC (Halcyon) obtained an all-risks commercial insurance policy, including an Equipment Breakdown Endorsement (Policy) from United National Insurance Company (UNIC) to provide substantial coverages for Halcyon Thruput LLC’s (Halcyon) $1,203,735 hemp processing dryer (Dryer) at its facility in Hopkinsville, Kentucky. During the Policy period, the Dryer caught fire due to the Dryer being defectively designed.

 

While UNIC paid a number of Halcyon’s claims, Halcyon’s claim for the cost of the replacement Dryer of $1,498,848 was denied as described below.

  

Buyer, a wholly owned subsidiary of the Company, pursuant to an Asset Purchase Agreement as twice amended, then acquired all the assets of Halcyon, except for the right to the proceeds of UNIC’s insurance policy since the Policy prohibited assignment. Halcyon and Buyer agreed that Buyer’s principal, Gary C. Evans, had the right to control the litigation, engage counsel for Halcyon and make all decisions relating to any proceeds received in the litigation by settlement or otherwise.

 

Halcyon’s suit against UNIC, which was removed to federal court, seeks $796,865.53 (the cost of the replacement dryer of $1,498,848, less a credit for $583,508.47 previously paid by UNIC to Halcyon for the Dryer fire=$915,339.53) plus statutory interest on that sum from August 10, 2020 for violating the Texas Insurance Code’s requirement that claims be promptly paid, additional statutory penalties, and attorneys’ fees. Certain documents have been executed between the Company, Halcyon and legal counsel, which provide for a sharing of costs and expenses and awards, if any, against UNIC. Mediation of the case was held in April 2022 where no agreement was reached by the parties. Depositions of the Company’s expert witnesses were completed in July 2022 and of UNIC’s representatives in September 2022.

 

In August 2022, the Company received a second payment from UNIC of $357,143 as a partial settlement of this claim.

  

JDONE, LLC v. Grand Traverse Holdings, LLC and John Gallegos, Denver District Court Case No. 2019CV33723

 

JDONE, LLC (“JDONE”), a wholly owned subsidiary of the Company and landlord of a commercial warehouse building in Denver, brought suit against Grand Traverse Holdings, LLC for default of its commercial lease of the warehouse from JDONE. This case settled in October 2022 and the Company received $122,500 from the defendant.

 

9

 

 

KBSIII Tower at Lake Carolyn, LLC and Prime US-Tower at Lake Carolyn, LLC (collectively – “KBSIII” v. Energy Hunter Resources, Inc.)

 

Plaintiff/Counterdefendant KBSIII was seeking lost rent on office space for periods after EHR vacated office premises located in Las Colinas, Texas. EHR filed a counter suit alleging specific damages due to uninhabitable premises of the office space due to the intolerable conduct of other tenants located on the same floor. On December 23, 2020, the trial court entered a summary judgment against EHR for $230,712. The judgment provides for post-judgment interest at a rate of 5% per annum until paid and further provides for additional amounts owed should EHR pursue unsuccessful appeals to higher courts. At September 30, 2022, the Company had accrued $252,583 for this judgment, which is exclusively an EHR obligation.

 

9. Income Taxes

 

Income tax provisions for interim quarterly periods are generally based on an estimated annual effective income tax rate calculated separately from the effect of significant, infrequent or unusual items related specifically to interim periods. An income tax benefit for the three or nine months ended September 30, 2022 or 2021 was not recognized because tax losses incurred were fully offset by a valuation allowance against deferred tax assets. There were no uncertain tax positions as of September 30, 2022. The Company is delinquent in filing its 2021 income tax returns.

 

10. Equity

 

Series A Preferred Stock Our Series A Preferred Stock was originally issued in connection with HTF’s acquisition of EHR in 2019. On September 8, 2021, holders of the Company’s Series A Preferred Stock elected to convert such shares into shares of the Company’s common stock. As a result, 6,328,948 shares of Series A Preferred Stock were converted into 75,947,376 shares of common stock, with each share of Series A Preferred Stock converting into 12 shares of restricted common stock pursuant to the applicable Certificate of Designations.

 

Series B Preferred Stock Units – On December 30, 2020, the Company sold to certain accredited investors, including Gary C. Evans, our Chief Executive Officer, an aggregate of 135 preferred stock units comprised of (i) one share of Series B Redeemable Convertible Preferred Stock, no par value, and (ii) one warrant exercisable for 50,000 shares of common stock of the Company until December 30, 2022 at an exercise price of $0.352 per share.

 

The sale of the preferred stock units for $10,000 each resulted in aggregate gross proceeds of approximately $1.35 million, before deducting estimated offering expenses payable by the Company. Substantially all of the proceeds raised in the offering were used to fund the acquisition of assets of Halcyon, expenses related thereto and for general corporate purposes.

 

Each share of Series B Preferred Stock is initially convertible into 25,000 shares of common stock, subject to adjustment. Holders of Series B Preferred Stock are entitled to receive dividends of 6.00% per annum based on the stated value equal to $10,000 per share. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (b) alter or amend the related certificate of designation, (c) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock, (d) repay, repurchase or offer to repay, repurchase or otherwise acquire more than a de minimis number of shares of its common stock, (e) enter into any agreement with respect to any of the foregoing, or (f) pay cash dividends or distributions on any equity securities of the Company other than pursuant to the terms of the outstanding Series B Preferred Stock. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company.

 

Any or all of the Series B Preferred Stock may be converted, at their holder’s option, into 25,000 shares of common stock, as adjusted for any stock dividends, splits, combinations or similar events.

 

10

 

 

At any time after the occurrence of a “Qualifying Event,” the Company, upon 5-day written notice, shall have the right to cause each share of Series B Preferred Stock (and all accrued in-kind dividends with respect thereto) to be converted into common stock. For purposes of this automatic conversion of the Series B Preferred Stock, a “Qualifying Event” shall have occurred if (A) (1) the rolling five-trading day volume-weighted average trading price of shares of the common stock exceeds $1.00, and (2) there shall be an effective registration statement under the Securities Act of 1933, as amended covering all of the shares of common stock which would be issuable upon conversion of all of the outstanding shares of Series B Preferred Stock or (B) the Company closes a firm commitment underwriting of the common stock on a Form S-1 Registration Statement with aggregate gross proceeds of at least $5,000,000 at a price per share equal to or greater than $1.00. In each instance, a conversion may not be made unless the Company has filed an amendment to its Articles of Incorporation effecting an increase in its authorized common stock so that the Company has a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares.

 

The Series B Preferred Stock may be redeemed by the Company for its stated value, plus accrued and unpaid dividends, at any time. Initially, redemption payments of 12.5% each of the total amount of Series B Preferred Stock then outstanding plus accrued dividends were due from the Company to each Holder of Series B Preferred Stock at the end of each calendar quarter of 2021. The first required redemption payments totaling $137,500 were made in April 2021. In May, June and October of 2021, the three holders of the Series B Preferred Stock, including the Company’s chief executive officer, entered into transactions in which they accepted the mandatory redemption payment required pursuant to the Series B Preferred Stock certificate of designation in a number of Series B Units to effectively waive the redemption requirement. All other terms of the Series B Units remain unchanged and the holders’ ownership interest in the Series B Preferred Units remains the same as it was before such transactions.

 

Common Stock – At September 30, 2022, the Company had 113,204,002 common shares outstanding. Following is a discussion of common stock issuances during the periods presented:

 

  Acquisition of Certain Assets of Halcyon – In January 2021, the Company issued 6,250,000 shares of common stock valued at $2.5 million ($0.40 per share; restricted from trading for a period of up to one year) in the acquisition.

 

  2021 First Quarter Issuances of Common Stock Units – In the first quarter of 2021, the Company issued 800,000 common stock units for total proceeds of $400,000. Each common stock unit consisted of one share of common stock and a warrant for the purchase of two shares of common stock for $0.50 each. Each warrant is exercisable any time before its expiration on the second anniversary of its issuance. The Company allocated the total proceeds based on the relative fair values of the common stock and warrants. The fair value of the warrants was determined using an options valuation model with key assumptions including a risk-free interest rate of 0.11% and historical volatility of 272%. A total of $263,293 was allocated to the warrants and reported in additional paid-in capital.  

 

  Warrant Exercises – In the first quarter of 2021, the Company received $2,967,000 for the exercise of 8,428,976 outstanding warrants. In the fourth quarter of 2021, the Company received $375,000 for the exercise of 1,065,340 outstanding warrants.

 

  Issuances for Exchange or Conversion of Debt – The Company issued a total of 1,618,660 common shares for the exchange or conversion of outstanding debt in the first quarter of 2021.
     
  Issuance to Vendor for Services – In the third quarter of 2021, the Company issued 125,000 common shares to a vendor for services performed.
     
  Issuance for Extension of Secured Note – The Company issued 20,000 common shares as consideration to extend the maturity of a senior note in the third quarter of 2021.
     
  Issuance for Conversion of Series A Preferred Stock – As noted above, in the third quarter of 2021, the Company issued 75,947,376 common shares for the conversion of all outstanding shares of its Series A Preferred Stock.
   
  Stock-based Compensation – The Company issued 500,000 restricted common shares valued at $155,000 as incentive compensation to two executives who joined the Company in the first quarter of 2021.
     
  Issuance for Extensions of Secured Note – The Company issued 110,000 common shares as consideration for extensions of the maturity of a senior note in 2022. Refer to Note 5.

11

 

 

Common Stock Warrants Outstanding – Following is a summary of warrants outstanding as of September 30, 2022:

 

   # of
Warrants
   Exercise
Price (each)
   Expiration Date  Method of
Exercise
               
Issued in December 2020 with Series B preferred units (1)   5,500,000   $      0.352   December 30, 2022  Cash
Issued in December 2020 with subordinated note to investor   500,000   $0.352   December 30, 2022  Cash
Issued in Q1 2021 with common stock units (1)   1,600,000   $0.500   January-February, 2023  Cash
Issued in Q4 2021 with common stock units (1)   958,333   $0.600   October-December, 2023  Cash
Total warrants outstanding at September 30, 2022   8,558,333   $0.407       

 

(1) May be redeemed for $0.0001 per warrant at the Company’s option with 30 days advanced notice should the weighted average market price of common stock exceed $1.00 for any five out of seven consecutive trading days with a minimum average daily trading volume for such seven-day period of at least 25,000 shares of common stock.

 

Following is a summary of outstanding stock warrants activity for the periods presented:

 

       Weighted 
       Average 
   # of
Warrants
   Exercise
Price
 
         
Warrants as of December 31, 2021   8,808,333   $0.407 
Canceled   (250,000)  $0.400 
Warrants as of September 30, 2022   8,558,333   $0.407 

 

11. Stock-Based Compensation

 

We award restricted stock or stock options as incentive compensation to employees and compensation to our Board of Directors for services. Generally, these awards include vesting periods of up to three years from the date of grant.

 

The 2021 Omnibus Incentive Plan (“2021 Plan”) was adopted by our Board on July 1, 2021. The 2021 Plan provides for the initial reservation of 15 million shares of common stock for issuance, and provides that the maximum number of shares that may be issued pursuant to the exercise of ISOs is 15 million. On the one-year anniversary date of the 2021 Plan, the number of shares of common stock reserved for issuance automatically increased to 20% of the fully diluted common shares outstanding, including shares issuable upon the conversion of preferred shares, as calculated on an as-converted basis.

 

In the first quarter of 2021, the Company issued 500,000 restricted shares valued at $155,000 as incentive compensation to two executives who joined the Company. Compensation expense related to these awards totaled $38,750 and $81,000 for the three and six months ended June 30, 2021, respectively. These awards became fully vested in January 2022.

 

In the fourth quarter of 2021, the Company awarded options for 13,850,000 shares of the Company’s common stock as incentive compensation to management and the Board of Directors. One-third of the awarded options vested immediately with the remaining options vesting in two equal annual tranches over the next two years. Vested options may be exercised at any time until their expiration after 10 years at an exercise price of $0.76 per share. Unvested options are forfeited upon termination of service. The fair value of the awards at the date of grant was determined using the Black-Scholes option pricing model. Key assumptions included a risk-free interest rate ranging from 1.18% to 1.28%, historical volatility ranging from 331% to 643% and an expected life of the stock options ranging from five to six years.

 

12

 

 

In the third quarter of 2022, the Company awarded options for 1,915,000 shares of the Company’s common stock as incentive compensation to its CEO and board of directors. The awarded options vest over the next three years. Vested options may be exercised at any time until their expiration ranging from eight to 10 years at their exercise prices ranging from $0.30 to $0.33 per share. Unvested options are forfeited upon termination of service. The fair value of the awards at the date of grant was determined using the Black-Scholes option pricing model. Key assumptions included a risk-free interest rate ranging from 2.87% to 3.03%, historical volatility ranging from 251% to 408% and an expected life of the stock options ranging from four to seven years.

 

We recognized $1.3 million of compensation expense for these option awards in each of the quarters ended September 30, 2022. As of September 30, 2022, there was $2.7 million of total unrecognized compensation cost related to options to be recognized over a remaining weighted average period of 21 months.

 

The following table summarizes options outstanding, as well as activity for the periods presented:

 

   Shares   Weighted
Average
Grant Date
Fair Value
   Weighted
Average
Exercise
Price
   Aggregate
Intrinsic
Value
 
                 
Outstanding at December 31, 2021   13,850,000   $0.76   $0.76    
         -
 
Granted   1,915,000   $0.30   $0.31    
-
 
Outstanding at September 30, 2022   15,765,000   $0.70   $0.71    
-
 

 

The remaining weighted average contractual life of exercisable options at September 30, 2022 was nine years.

 

12. Discontinued Operations

 

In 2019, management determined to fully divest of EHR’s oil and gas activities. As such, these activities are presented as discontinued operations for each of the periods presented. The following is a summary of the carrying amounts of major classes of assets and liabilities of the discontinued operations to assets and liabilities held for sale:

 

   September 30,   December 31, 
   2022   2021 
Assets:        
Oil and natural gas properties held for sale, at cost  $1,874,849   $1,874,849 
Accumulated DD&A   (1,874,849)   (1,874,849)
Total assets of discontinued operations held for sale  $
-
   $
-
 
           
Liabilities:          
Accrued liabilities  $39,956   $48,997 
Asset retirement obligations   52,368    52,368 
Revenue payable   52,117    52,117 
Current liabilities of discontinued operations held for sale   144,441    153,482 
Asset retirement obligations -          
Long-term liabilities of discontinued operations held for sale   199,046    162,948 
Total liabilities of discontinued operations held for sale  $343,487   $316,430 

 

The following is a summary of the major classes of line items constituting loss on discontinued operations shown in the consolidated statements of operations:

 

   For the three months ended
September 30,
   For the nine months ended
September 30,
 
   2022   2021   2022   2021 
Revenue -                
Oil and gas sales  $41,077   $55,140   $116,870   $93,248 
                     
Costs and Expenses:                    
Lease operating expense   25,461    53,919    110,649    94,714 
Accretion   5,230    2,851    36,098    9,883 
Total costs and expenses   30,691    56,770    146,747    104,597 
                     
Loss from discontinued operations  $10,386   $(1,630)  $(29,877)  $(11,349)

 

13

 

 

13. Supplemental Cash Flow Information

 

   For the nine months ended
September 30,
 
   2022   2021 
         
Cash paid for interest  $50,690   $127,812 
Cash paid for taxes   
-
    
-
 
           
Noncash investing and financing activities:          
Acquisition of certain assets of Halcyon Thruput, LLC          
- issuance of common shares   
-
    2,500,000 
- issuance of subordinated note   
-
    850,000 
- assumption of Halcyon bank note   
-
    995,614 
Series B preferred stock dividend payable   60,035    39,137 
Issuance of common stock units previously subscribed   
-
    50,000 
Issuances of common shares for exchange or conversion of debt   
-
    2,160,269 

 

14. Earnings (Loss) per Share

 

The following is the computation of earnings (loss) per basic and diluted share:

 

   For the three months ended
September 30,
   For the nine months ended
September 30,
 
   2022   2021   2022   2021 
Amounts attributable to Generation Hemp:                
Numerator                
Loss from continuing operations attributable to common stockholders  $(1,465,404)  $(1,376,030)  $(6,017,867)  $(4,356,315)
Income (loss) from discontinued operations   9,736    (1,528)   (28,007)   (10,639)
Less: preferred stock dividends   (19,668)   (16,125)   (60,035)   (56,625)
Net loss attributable to common stockholders  $(1,475,336)  $(1,393,683)  $(6,105,909)  $(4,423,579)
                     
Denominator                    
Weighted average shares used to compute basic EPS   113,204,002    54,109,797    113,149,973    38,693,679 
Dilutive effect of convertible note   1,164,773    
-
    1,164,773    
-
 
Dilutive effect of preferred stock   2,950,000    59,913,657    2,950,000    72,641,084 
Dilutive effect of common stock options   125,490    
-
    122,052    
-
 
Dilutive effect of common stock warrants   47,560    9,042,419    1,709,576    11,126,327 
Weighted average shares used to compute diluted EPS   117,491,825    123,065,873    119,096,374    122,461,090 
                     
Earnings (loss) per share:                    
Loss from continuing operations                    
Basic  $(0.01)  $(0.03)  $(0.05)  $(0.11)
Diluted  $(0.01)  $(0.03)  $(0.05)  $(0.11)
Loss from discontinued operations                    
Basic  $
-
   $
-
   $
-
   $
-
 
Diluted  $
-
   $
-
   $
-
   $
-
 
Earnings (loss) per share                    
Basic  $(0.01)  $(0.03)  $(0.05)  $(0.11)
Diluted  $(0.01)  $(0.03)  $(0.05)  $(0.11)

 

The computation of diluted earnings per common share excludes the assumed conversion of the Series B Preferred Stock and outstanding convertible notes and exercise of common stock options and warrants in periods when we report a loss. The dilutive effect of the assumed exercise of outstanding options and warrants was calculated using the treasury stock method.

 

* * * * *

  

14

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in our Annual Report on Form 10-K (“Annual Report”) for the year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”), as well as the financial statements and related notes appearing therein and elsewhere in this Quarterly Report. The following discussion contains forward-looking statements that reflect our future plans, estimates, beliefs and expected performance. The forward-looking statements are dependent upon events, risks and uncertainties that may be outside our control. We caution you that our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences are discussed elsewhere in this Quarterly Report, particularly in the “Cautionary Note Regarding Forward-Looking Statements” and in our Annual Report under the heading “Item 1A. Risk Factors,” all of which are difficult to predict. In light of these risks, uncertainties and assumptions, the forward-looking events discussed may not occur. We do not undertake any obligation to publicly update any forward-looking statements except as otherwise required by applicable law.

  

Overview

 

We are a holding company active within the “hemp” space. We were incorporated on August 21, 2021 in the State of Delaware. The Company was originally incorporated on July 28, 2008 in the State of Colorado. On November 27, 2019, we purchased approximately 94% of the common stock of Energy Hunter Resources, Inc. (“EHR”) in a series of transactions accounted for as a reverse merger. Upon closing, we changed our name to Generation Hemp, Inc.

 

There is limited historical financial information about our Company upon which to base an evaluation of our future performance. We cannot guarantee that we will be successful in the hemp business. We are subject to the risks associated with the regulatory environment in the industry in which we operate. In addition, we are subject to risks inherent in a small company, including limited capital resources, delays and cost overruns due to price and cost increases. There is no assurance that future financing will be available to our Company on acceptable terms. Additional equity financing could result in dilution to existing shareholders.

 

We provide post-harvest and midstream services to growers by drying, processing, cleaning and stripping harvested hemp directly from the field and wetbaled at our 48,000 square foot facility located in Hopkinsville, Kentucky. The Company also offers safe storage services for processed hemp, which enables farmers to maximize strategic market timing. We market two retail products, Gas Monkey Spill-Jack, an all-natural, plant-based, sustainable, and biodegradable loose absorbent, and Rowdy Rooster, an animal bedding consumer goods product, each made from the hemp hurd byproduct that is produced from our hemp processing operations.

 

We also generate revenue from rental of our “Cannabis Zoned” (Hemp) warehouse property located in Denver, Colorado currently leased to a hemp seed company.

 

As of September 30, 2022, EHR held an approximate 8% working interest in an oil & gas property located in Cochran County, Texas within the Slaughter-Levelland Field of the San Andres formation in the Northwest Shelf of West Texas. EHR’s oil & gas activities are currently held for sale and are presented in the consolidated financial statements as discontinued operations.

 

Recent Activities

 

New Business Line – During the second quarter of 2022, management and the Board decided to enter a new but related line of business – Bitcoin mining. Management determined after research that hemp biomass can be burned in a biomass boiler to generate heat and steam to drive a turbine for generating electricity. The BTU value of hemp is similar to wood waste generated at saw mills. Hemp plants grow to maturity within six to eight months whereas trees mature in excess of ten years.

 

The Company subsequently formed a new company, GenCrypto, LLC (a Delaware limited liability company) with a 50% partner, Cerberus Digital, LLC, an affiliate of Cryptech Solutions, Inc. Cryptech is one of the largest resellers of Bitcoin mining equipment in North America.

 

15

 

 

GenCrypto now has approximately ten different Bitcoin locations identified and either under contract, under letter of intent, or in final negotiating status, located in two states and in Costa Rica. All of these site locations are deemed “green” based upon the power being provided either from the local utility or co-op. They range in power size from 1.1 megawatts to 50 megawatts. GenCrypto has been contacted by several larger Bitcoin mining operators concerning utilizing some of these mining locations under “hosting” arrangements.

 

The Company anticipates closing its first acquisition which is currently operational in November 2022.

 

Grant Funding Opportunity – The U.S. Department of Agriculture has recently made available a funding opportunity for the Partnerships for Climate-Smart Commodities projects of up to $1 billion in order to build markets and invest in America’s climate-smart farmers, ranchers and forest owners to strengthen U.S. rural and agricultural communities. Within this opportunity is the goal to develop markets and promote the resulting climate-smart commodities. The Company, through its wholly-owned subsidiary GENH Halcyon Acquisition, LLC, is an established floral hemp processor that has provided years of drying, cleaning, stripping and storing hemp, along with acting as a conduit between the supply side of hemp through farmers and the demand side of hemp through extraction labs, buyers and downstream products. Since its inception, the Company has also been a proponent and developer of climate-smart applications of fiber hemp for industry and has helped develop two new U.S. market products to utilize hemp hurd that was previously a waste product.

 

On May 6, 2022, the Company applied for a substantial grant under this funding opportunity that will contractually engage farmers to grow specific hemp genetics, thereby providing them lower risk costs that will be included in grant funding. Under this project, the Company will also build out a hemp supercenter from the nucleus of its current, established operation that will provide the necessary processing capacity for all varieties of hemp at one central location. This will include storage, logistics, testing and tracking capabilities. The Company has obtained a large group of commitments from industry players who have agreed to participate in the program.

 

Liquidity – The Company is dependent upon obtaining additional funding to continue ongoing operations and to pursue its strategy and execute its acquisition plans.

 

In the nine months ended September 30, 2022, the Company used $1.0 million of cash for its operating activities. At September 30, 2022, the Company’s current liabilities, including financing obligations due within one year, totaled $6.1 million as compared with its current assets of $1.0 million.

 

The Company will continue to pursue additional capital raising opportunities in order to fund future acquisitions and meet its obligations as they become due. We may not be successful in obtaining additional financing needed. In the event financing cannot be obtained, the Company may not be able to satisfy these plans and obligations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Results of Operations

 

Three Months Ended September 30, 2022 Compared to Three Months Ended September 30, 2021

 

The net loss attributable to Generation Hemp for the three months ended September 30, 2022 was $1.5 million as compared with a net loss attributable to Generation Hemp of $1.4 million for the same period of 2021. The net loss attributable to Generation Hemp for the three months ended September 30, 2022 includes $1.3 million of stock-based compensation expense, $407 thousand for a non-cash impairment charge and $261 thousand for depreciation and amortization largely due to the Halcyon acquisition. Excluding these non-cash items, the Company had cash income of $561 thousand in the three months ended September 30, 2022 as compared with a cash loss of $1.0 million for the same period of 2021. Our hemp processing operations were fully operational during the third quarter of 2022. We also received $378 thousand for a partial settlement from a lawsuit during the third quarter of 2022.

 

The Company reports its oil & gas activities as discontinued operations. Income from discontinued operations was $10 thousand for the three months ended September 30, 2022 as compared with a loss of $2 thousand in the 2021 period, principally consisting of non-cash items each period.

 

16

 

 

Revenue. Revenue from continuing operations for the third quarter of 2022 totaled $1.2 million as compared with $502 thousand for the same period of 2021. We generate revenue from post-harvest and midstream services in the hemp industry and from rental to a hemp seed company of our warehouse property located in Colorado.

 

Our post-harvest and midstream services revenue totaled $1.2 million in the third quarter of 2022 as compared with $487 thousand in the 2021 period. In June 2022, we commenced hemp processing of six million pounds of hemp biomass from last year’s harvest of our largest customer. We processed 3.2 million pounds of this stored hemp biomass in the third quarter of 2022 and are continuing processing at this time. Hemp processing in 2021 commenced later in the third quarter resulting in lower period over period volumes and revenues.

 

Rental revenue totaled $23 thousand in the 2022 period and $15 thousand in the 2021 period. The lease of the Company’s Denver warehouse expires on August 1, 2023 and provides for a rental of $7.5 thousand per month.

 

Cost of Revenue. Cost of revenue for the third quarter of 2022 was $375 thousand as compared with $280 thousand for the same period of last year. Our gross margin on hemp processing in the third quarter of 2022 was 69%. We expect these stronger margins to continue during processing periods. In periods when we are not processing, we take steps to reduce our operating expenses.

 

Impairment Expense. We recognized $407 thousand of impairment expense in the third quarter of 2022 as a result of the expiration of the Company’s option to purchase its facilities located in Hopkinsville, Kentucky. There was no impairment in the comparable period of 2021.

 

General and Administrative Expense. General and administrative expenses totaled $1.9 million for the three months ended September 30, 2022 as compared with $1.1 million in 2021 period. The increase in general and administrative expense is principally due to non-cash charges for stock-based compensation which totaled $1.3 million in the three months ended September 30, 2022 as compared with $39 thousand in the 2021 period.

 

Depreciation and Amortization. Depreciation and amortization expense totaled $261 thousand in the three months ended September 30, 2022 as compared with $316 thousand for the same period of 2021.

 

Other Income. Total other income was $378 thousand for the three months ended September 30, 2022. We reported no other income in the comparable 2021 period. We received $378 thousand for a partial settlement from a lawsuit during the third quarter of 2022. 

 

Income (loss) from Discontinued Operations. In the three months ended September 30, 2022, we recognized income from discontinued operations of $10 thousand as compared with a loss of $2 thousand in the three months ended September 30, 2021. The major classes of line items constituting the loss on discontinued operations are presented in Item I, “Financial Statements – Note 12 – Discontinued Operations.” Until we fully dispose of our remaining oil & gas property interests, we expect lower future revenues and costs as production activities have declined substantially. We do not anticipate making future investment of growth capital into these properties.

 

Nine Months Ended September 30, 2022 Compared to Nine Months Ended September 30, 2021

 

The net loss attributable to Generation Hemp for the nine months ended September 30, 2022 was $6.0 million as compared with a net loss attributable to Generation Hemp of $4.4 million for the same period of 2021. The net loss attributable to Generation Hemp for the 2022 period includes $4.0 million of stock-based compensation expense, $407 thousand for a non-cash impairment charge and $744 thousand for depreciation and amortization. Excluding these non-cash items, the Company’s cash loss was $916 thousand in the nine months ended September 30, 2022 as compared with a cash loss of $3.2 million in the same period of 2021. The first part of each calendar year is typically a slower period for midstream operations within the hemp industry until the annual harvest begins in late-summer. The Company’s hemp processing facilities were shut-in for much of the first six months of each year to limit operating expenditures. As mentioned above, we commenced processing in June 2022 of hemp biomass harvested last year by our largest customer resulting in higher period over period volumes revenues. We also received $378 thousand for a partial settlement from a lawsuit during the third quarter of 2022.

 

Loss from discontinued operations was $30 thousand for the nine months ended September 30, 2022 as compared with a loss of $11 thousand in the 2021 period, principally consisting of non-cash items each period. Results of operations for the Company’s remaining oil & gas activities have been significantly reduced due to lower field productivity.

 

17

 

 

Revenue. Revenue from continuing operations for the first nine months of 2022 totaled $1.6 million as compared with $595 thousand for the same period of 2021.

 

Our post-harvest and midstream services revenue totaled $1.6 in the 2022 period as compared with $535 thousand in the 2021 period. The Company’s hemp processing facilities were shut-in for much of the first half of each year to limit operating expenditures. As mentioned, we commenced processing of hemp biomass for our largest customer in June 2022. In 2021, our processing was limited until the late-summer harvest.

 

Rental revenue totaled $67 thousand in the 2022 period and $60 thousand in the 2021 period. The lease of the Company’s Denver warehouse expires on August 1, 2023 and provides for a rental of $7.5 thousand per month.

 

Cost of Revenue. Cost of revenue for the first nine months of 2022 was $644 thousand as compared with $550 thousand in the same period of last year. Our gross margin on post-harvest processing and midstream services are expected to be 50% or more during peak operating periods. In the first part of each year, we take steps to reduce operating costs by idling our facilities.

  

Merger and Acquisition Costs. We incurred $16 thousand of costs for acquisition costs in the 2021 period for closing of the Halcyon acquisition. The amount of future expenses of this type that we incur will depend upon our future acquisition activities. The Company incurred no such expenses during the nine months ended September 30, 2022.

 

Impairment Expense. We recognized $407 thousand of impairment expense in the third quarter of 2022 as a result of the expiration of the Company’s option to purchase its facilities located in Hopkinsville, Kentucky. There was no impairment in the comparable period of 2021.

 

General and Administrative Expense. General and administrative expenses totaled $5.8 million for the nine months ended September 30, 2022 as compared with $2.8 million in 2021 period. The increase in general and administrative expense is principally due to non-cash charges for stock-based compensation which totaled $4.0 million in the 2022 period as compared with $120 thousand in the 2021 period. The Company also had lower legal and professional expenses during the 2022 period.

 

Depreciation and Amortization. Depreciation and amortization expense totaled $744 thousand in the nine months ended September 30, 2022 as compared with $1.0 million for the same period of 2021.

 

Other Income. Total other income was $378 thousand for the nine months ended September 30, 2022 as compared with $25 thousand for the comparable 2021 period. We received $378 thousand for a partial settlement from a lawsuit during the third quarter of 2022. 

 

Loss from Discontinued Operations. In the nine months ended September 30, 2022, we recognized a loss from discontinued operations of $30 thousand as compared with a loss of $11 thousand in the same period of 2021. The major classes of line items constituting the loss on discontinued operations are presented in Item I, “Financial Statements – Note 12 – Discontinued Operations.” We revised our estimates of future asset retirement obligations for changes in inflation and interest rates in the second quarter of 2022 period resulting in higher non-cash expense. Until we fully dispose of our remaining oil & gas property interests, we expect lower future revenues and costs as production activities have declined substantially. We do not anticipate making future investment of growth capital into these properties.

 

Liquidity and Capital Resources

 

Our primary source of cash from continuing operations includes post-harvest and midstream services and rental revenue. Our primary uses of cash include our operating costs, general and administrative expenses and merger and acquisition expenses.

 

18

 

 

Cash flow information from continuing operations for the first nine months of 2022 was as follows:

 

Cash used in operating activities was $1.0 million principally due to the net loss adjusted for non-cash items.

 

The Company had no net cash used for investing activities during the period.

 

Net cash from financing activities totaled $1.1 million from advances under notes payable made by our CEO, his related company and other related parties to fund our cash needs.

 

We used $3 thousand of cash for discontinued operations in the first nine months of 2022.

 

Funding Requirements

 

We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses may increase substantially as we grow our hemp business.

 

We expect that we will require additional capital to fund operations, including hiring additional employees, completing acquisitions and funding capital expenditures during the next twelve-month period.

 

Because of the numerous risks and uncertainties associated with the development and commercialization of our business, we are unable to estimate the amounts of increased capital outlays and operating expenses. Our future capital requirements will depend on many factors, including:

 

our success in identifying and making acquisitions of profitable operations;

 

our ability to negotiate operating contracts with growers and others within the hemp industry on favorable terms, if at all;

 

deriving revenue from our assets and operations; and

 

the cost of such operations and costs of being a public company.

 

Until such time, if ever, as we can generate substantial revenues, we expect to finance our cash needs through a combination of equity offerings and debt financings. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common shareholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our growth plans and future commercialization efforts.

 

Indebtedness

 

The Company’s indebtedness at September 30, 2022 is presented in Item I, “Financial Statements – Note 5 – Notes Payable – Related Parties” and in Item I, “Financial Statements—Note 6 – Other Indebtedness.”

 

Subsequently, the Company has received additional advances under new and existing note arrangements. Refer to Item I, “Financial Statements—Note 15 – Subsequent Events.”

 

Off-Balance Sheet Arrangements

 

As of September 30, 2022, we had no material off-balance sheet arrangements.

 

19

 

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Quantitative and qualitative disclosures about market risk are included in Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” of our Annual Report.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

As required by Rule 13a-15(b) of the Exchange Act, we have evaluated, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed by us in reports that we file under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure, and is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Based upon that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were ineffective as of September 30, 2022 due to the material weaknesses previously identified as described below.

 

Previously Reported Material Weaknesses

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements would not be prevented or detected on a timely basis.

 

We previously identified material weaknesses in our internal control over financial reporting. Based on our assessment for the year ended December 31, 2021, management identified a material weakness in internal control over financial reporting related to the accounting for business combination transactions.

 

Management Plans to Remediate Material Weakness. The Company has continued the process of designing and implementing effective internal control measures to improve its internal controls over financial reporting and remediate the reported material weakness. The Company’s efforts include implementing additional reviews of business combination transactions and modifying the Company’s instructions to valuation specialists and reviews of their work product. We will consider the material weakness remediated after the applicable controls operate for a sufficient period of time, and management has concluded, through testing, that the controls are operating effectively.

 

Changes in Internal Control over Financial Reporting

 

We regularly review our system of internal control over financial reporting and make changes to our processes and systems to improve controls and increase efficiency, while ensuring that we maintain an effective internal control environment. Changes may include such activities as implementing new, more efficient systems, consolidating activities and migrating processes.

 

We are taking actions to remediate the material weaknesses relating to our internal control over financial reporting, as described above. Except as otherwise described herein, there have been no changes in our internal control over financial reporting during the quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

20

 

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

Due to the nature of our business, we may become, from time to time, involved in routine litigation or subject to disputes or claims related to our business activities. While the outcome of these proceedings cannot be predicted with certainty, in the opinion of our management, there are no pending litigation, disputes or claims against us which, if decided adversely, individually or in the aggregate, will have a material adverse effect on our financial condition, cash flows or results of operations. For a description of our legal proceedings, see Item I, “Financial Statements – Note 7 – Commitments and Contingencies” in the Condensed Consolidated Financial Statements included in Part I of this Quarterly Report.

 

Item 1A. Risk Factors

 

In addition to the other information set forth in this Quarterly Report, you should carefully consider the risk factors and other cautionary statements described under the heading “Item 1A. Risk Factors” included in our Annual Report and the risk factors and other cautionary statements contained in our other SEC filings, which could materially affect our businesses, financial condition or future results.

 

Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. There have been no material changes in our risk factors from those described in our Annual Report.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

Since July 1, 2022, we have sold or issued securities without registering the securities under the Securities Act as shown below:

 

Issuance for Extension of Secured Note – The Company issued 50,000 common shares as consideration extension of the maturity of a senior note in the third quarter of 2022. Refer to Item I, “Financial Statements – Note 5 – Notes Payable – Related Parties”.

 

Item 4. Mine Safety Disclosures

 

No response required.

 

Item 5. Other Information

 

No response required.

  

Item 6. Exhibits

 

10.1*   Amended and Restated Convertible Promissory Note by Generation Hemp, Inc. with Gary C. Evans as holder, dated September 30, 2022
     
10.2*   Revised and Extended Unsecured Promissory Note, dated September 30, 2022, with Investment Hunter, LLC as holder, dated September 30, 2022
     
10.3*   Secured Promissory Note Amendment and Extension Agreement, dated October 10, 2022, between JDONE LLC, Thomas S. Yang, and Gary C. Evans
     
10.4*   Amended and Restated Subordinated Promissory Note, by Generation Hemp, Inc. with Gary C. Evans as holder, dated September 30, 2022
     
31.1*   Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1**   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Schema Document
101.CAL   Inline XBRL Calculation Linkbase Document
101.DEF   Inline XBRL Definition Linkbase Document
101.LAB   Inline XBRL Label Linkbase Document
101.PRE   Inline XBRL Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

   

* Exhibit filed herewith.

 

** Furnished herewith. Pursuant to SEC Release No. 33-8212, this certification will be treated as “accompanying” this Quarterly Report on Form 10-Q and not “filed” as part of such report for purposes of Section 18 of the Exchange Act or otherwise subject to the liability under Section 18 of the Exchange Act, and this certification will not be deemed to be incorporated by reference into any filing under the Securities Act, except to the extent that the registrant specifically incorporates it by reference.

 

21

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  GENERATION HEMP, INC.
     
November 14, 2022 By: /s/ Gary C. Evans
    Gary C. Evans
    Chairman and Chief Executive Officer

 

 

22

 

false --12-31 Q3 0001527102 0001527102 2022-01-01 2022-09-30 0001527102 2022-11-14 0001527102 2022-09-30 0001527102 2021-12-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2022-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-12-31 0001527102 2022-07-01 2022-09-30 0001527102 2021-07-01 2021-09-30 0001527102 2021-01-01 2021-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2020-12-31 0001527102 us-gaap:PreferredStockMember 2020-12-31 0001527102 us-gaap:CommonStockMember 2020-12-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001527102 us-gaap:RetainedEarningsMember 2020-12-31 0001527102 us-gaap:NoncontrollingInterestMember 2020-12-31 0001527102 2020-12-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-01-01 2021-03-31 0001527102 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001527102 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001527102 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001527102 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001527102 2021-01-01 2021-03-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-03-31 0001527102 us-gaap:PreferredStockMember 2021-03-31 0001527102 us-gaap:CommonStockMember 2021-03-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001527102 us-gaap:RetainedEarningsMember 2021-03-31 0001527102 us-gaap:NoncontrollingInterestMember 2021-03-31 0001527102 2021-03-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-04-01 2021-06-30 0001527102 us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001527102 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001527102 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001527102 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001527102 2021-04-01 2021-06-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-06-30 0001527102 us-gaap:PreferredStockMember 2021-06-30 0001527102 us-gaap:CommonStockMember 2021-06-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001527102 us-gaap:RetainedEarningsMember 2021-06-30 0001527102 us-gaap:NoncontrollingInterestMember 2021-06-30 0001527102 2021-06-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-07-01 2021-09-30 0001527102 us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0001527102 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001527102 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001527102 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-09-30 0001527102 us-gaap:PreferredStockMember 2021-09-30 0001527102 us-gaap:CommonStockMember 2021-09-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001527102 us-gaap:RetainedEarningsMember 2021-09-30 0001527102 us-gaap:NoncontrollingInterestMember 2021-09-30 0001527102 2021-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-12-31 0001527102 us-gaap:PreferredStockMember 2021-12-31 0001527102 us-gaap:CommonStockMember 2021-12-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001527102 us-gaap:RetainedEarningsMember 2021-12-31 0001527102 us-gaap:NoncontrollingInterestMember 2021-12-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2022-01-01 2022-03-31 0001527102 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001527102 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001527102 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001527102 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001527102 2022-01-01 2022-03-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2022-03-31 0001527102 us-gaap:PreferredStockMember 2022-03-31 0001527102 us-gaap:CommonStockMember 2022-03-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001527102 us-gaap:RetainedEarningsMember 2022-03-31 0001527102 us-gaap:NoncontrollingInterestMember 2022-03-31 0001527102 2022-03-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2022-04-01 2022-06-30 0001527102 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001527102 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001527102 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001527102 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001527102 2022-04-01 2022-06-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2022-06-30 0001527102 us-gaap:PreferredStockMember 2022-06-30 0001527102 us-gaap:CommonStockMember 2022-06-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001527102 us-gaap:RetainedEarningsMember 2022-06-30 0001527102 us-gaap:NoncontrollingInterestMember 2022-06-30 0001527102 2022-06-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2022-07-01 2022-09-30 0001527102 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0001527102 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001527102 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001527102 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2022-09-30 0001527102 us-gaap:PreferredStockMember 2022-09-30 0001527102 us-gaap:CommonStockMember 2022-09-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001527102 us-gaap:RetainedEarningsMember 2022-09-30 0001527102 us-gaap:NoncontrollingInterestMember 2022-09-30 0001527102 genh:EnergyHunterResourcesIncMember 2019-11-02 2019-11-27 0001527102 2021-01-01 2021-01-11 0001527102 2022-07-01 2022-07-31 0001527102 2022-07-31 0001527102 us-gaap:LandMember 2022-09-30 0001527102 us-gaap:LandMember 2021-12-31 0001527102 srt:WarehouseMember 2022-01-01 2022-09-30 0001527102 srt:WarehouseMember 2022-09-30 0001527102 srt:WarehouseMember 2021-12-31 0001527102 us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-09-30 0001527102 us-gaap:LeaseholdImprovementsMember 2022-09-30 0001527102 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001527102 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-09-30 0001527102 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-09-30 0001527102 us-gaap:MachineryAndEquipmentMember 2022-09-30 0001527102 us-gaap:MachineryAndEquipmentMember 2021-12-31 0001527102 us-gaap:VehiclesMember 2022-01-01 2022-09-30 0001527102 us-gaap:VehiclesMember 2022-09-30 0001527102 us-gaap:VehiclesMember 2021-12-31 0001527102 us-gaap:ComputerEquipmentMember 2022-01-01 2022-09-30 0001527102 us-gaap:ComputerEquipmentMember 2022-09-30 0001527102 us-gaap:ComputerEquipmentMember 2021-12-31 0001527102 us-gaap:CustomerRelationshipsMember 2022-09-30 0001527102 us-gaap:CustomerRelationshipsMember 2021-12-31 0001527102 genh:NoncompetitionAgreementsMember 2022-09-30 0001527102 genh:NoncompetitionAgreementsMember 2021-12-31 0001527102 genh:SubordinatedPromissoryNoteToCEOMember 2020-01-01 2020-12-31 0001527102 genh:SubordinatedPromissoryNoteToCEOMember 2022-01-01 2022-09-30 0001527102 genh:SubordinatedPromissoryNoteToCEOMember 2022-09-30 0001527102 genh:ConvertiblePromissoryNoteToCEOMember 2021-01-01 2021-12-31 0001527102 genh:ConvertiblePromissoryNoteToCEOMember 2022-01-01 2022-09-30 0001527102 genh:ConvertiblePromissoryNoteToCEOMember 2022-09-30 0001527102 genh:SecuredPromissoryNoteAndWarrantsToCoventryAssetManagementLTDMember 2020-12-30 0001527102 genh:SecuredPromissoryNoteAndWarrantsToCoventryAssetManagementLTDMember 2020-12-01 2020-12-30 0001527102 2020-12-01 2020-12-30 0001527102 genh:PromissoryNoteMember genh:SecuredPromissoryNoteAndWarrantsToCoventryAssetManagementLTDMember 2020-12-01 2020-12-30 0001527102 srt:ScenarioForecastMember genh:SecuredPromissoryNoteAndWarrantsToCoventryAssetManagementLTDMember 2022-12-01 2022-12-30 0001527102 genh:SecuredPromissoryNoteAndWarrantsToCoventryAssetManagementLTDMember 2022-09-30 0001527102 genh:SecuredPromissoryNoteAndWarrantsToCoventryAssetManagementLTDMember 2022-01-01 2022-09-30 0001527102 srt:ScenarioForecastMember genh:SecuredPromissoryNoteAndWarrantsToCoventryAssetManagementLTDMember 2022-12-01 2022-12-31 0001527102 genh:SubordinatedPromissoryNoteAndWarrantsToInvestorMember 2020-12-30 0001527102 genh:SubordinatedPromissoryNoteAndWarrantsToInvestorMember 2020-12-01 2020-12-30 0001527102 genh:SubordinatedPromissoryNoteAndWarrantsToInvestorMember 2021-04-30 0001527102 genh:SubordinatedPromissoryNoteAndWarrantsToInvestorMember 2022-01-01 2022-09-30 0001527102 genh:PromissoryNoteToInvestmentHunterLLCMember 2022-01-01 2022-09-30 0001527102 genh:PromissoryNoteToInvestmentHunterLLCMember 2022-09-30 0001527102 2022-08-01 2022-08-31 0001527102 genh:SubordinatedPromissoryNoteToCEOMember 2021-12-31 0001527102 genh:ConvertiblePromissoryNoteToCEOMember 2021-12-31 0001527102 genh:SecuredPromissoryNoteToCoventryAssetManagementLtdMember 2022-09-30 0001527102 genh:SecuredPromissoryNoteToCoventryAssetManagementLtdMember 2021-12-31 0001527102 genh:SubordinatedPromissoryNoteMember 2022-09-30 0001527102 genh:SubordinatedPromissoryNoteMember 2021-12-31 0001527102 genh:PromissoryNoteToInvestmentHunterLLCMember 2022-09-30 0001527102 genh:PromissoryNoteToInvestmentHunterLLCMember 2021-12-31 0001527102 genh:NotePayableToDirectorMember 2022-09-30 0001527102 genh:NotePayableToDirectorMember 2021-12-31 0001527102 genh:OzCapitalLLCMember 2022-01-01 2022-09-30 0001527102 genh:OzCapitalLLCMember 2022-07-01 2022-09-30 0001527102 genh:OzCapitalLLCMember 2021-07-01 2021-09-30 0001527102 genh:OzCapitalLLCMember 2021-01-01 2021-09-30 0001527102 srt:MinimumMember 2022-01-01 2022-09-30 0001527102 srt:MaximumMember 2022-01-01 2022-09-30 0001527102 genh:HalcyonThruputLLCsMember 2022-01-01 2022-09-30 0001527102 2018-12-31 0001527102 genh:GrandTraverseHoldingsLLCMember us-gaap:SubsequentEventMember 2022-10-31 0001527102 2020-12-01 2020-12-23 0001527102 us-gaap:SeriesAPreferredStockMember 2021-09-08 0001527102 us-gaap:SeriesBPreferredStockMember 2020-12-01 2020-12-30 0001527102 us-gaap:SeriesBPreferredStockMember 2022-09-30 0001527102 us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-09-30 0001527102 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001527102 2021-04-30 0001527102 us-gaap:WarrantMember 2022-09-30 0001527102 genh:DecemberTwoThousandTwentyMember genh:SeriesBPreferredStockUnitsMember 2022-09-30 0001527102 genh:DecemberTwoThousandTwentyMember genh:SeriesBPreferredStockUnitsMember 2022-01-01 2022-09-30 0001527102 genh:DecemberTwoThousandTwentyMember genh:SubordinatedNoteToInvestorMember 2022-09-30 0001527102 genh:DecemberTwoThousandTwentyMember genh:SubordinatedNoteToInvestorMember 2022-01-01 2022-09-30 0001527102 genh:MarchTwoThousandTwentyOneMember genh:CommonStockUnitsMember 2022-09-30 0001527102 genh:MarchTwoThousandTwentyOneMember genh:CommonStockUnitsMember 2022-01-01 2022-09-30 0001527102 genh:DecemberTwoThousandTwentyOneMember genh:CommonStockUnitsMember 2022-09-30 0001527102 genh:DecemberTwoThousandTwentyOneMember genh:CommonStockUnitsMember 2022-01-01 2022-09-30 0001527102 genh:TwoThousandTwentyOnePlanMember 2021-01-01 2021-12-31 0001527102 2021-01-01 2021-12-31 0001527102 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001527102 2021-01-01 2021-06-30 0001527102 2021-10-01 2021-12-31 0001527102 srt:MinimumMember 2021-10-01 2021-12-31 0001527102 srt:MaximumMember 2021-10-01 2021-12-31 0001527102 srt:MinimumMember 2022-07-01 2022-09-30 0001527102 srt:MaximumMember 2022-07-01 2022-09-30 0001527102 srt:MinimumMember 2022-09-30 0001527102 srt:MaximumMember 2022-09-30 0001527102 us-gaap:SegmentDiscontinuedOperationsMember 2022-09-30 0001527102 us-gaap:SegmentDiscontinuedOperationsMember 2021-12-31 0001527102 us-gaap:SegmentDiscontinuedOperationsMember 2022-07-01 2022-09-30 0001527102 us-gaap:SegmentDiscontinuedOperationsMember 2021-07-01 2021-09-30 0001527102 us-gaap:SegmentDiscontinuedOperationsMember 2022-01-01 2022-09-30 0001527102 us-gaap:SegmentDiscontinuedOperationsMember 2021-01-01 2021-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:USD utr:sqft
EX-10.1 2 f10q0922ex10-1_generation.htm AMENDED AND RESTATED CONVERTIBLE PROMISSORY NOTE BY GENERATION HEMP, INC. WITH GARY C. EVANS AS HOLDER, DATED SEPTEMBER 30, 2022

Exhibit 10.1

 

AMENDED AND RESTATED CONVERTIBLE PROMISSORY NOTE

 

$1,107,069.28 September 30, 2022

 

For value received, GENERATION HEMP, INC., a Delaware corporation (the “Borrower”), promises to pay to GARY C. EVANS, an individual, or his assigns (the “Holder”), the principal sum of $1,107,069.28 (U.S. Dollars), together with all accrued and unpaid interest thereon as set forth below. It is expressly understood that the commitment to provide the principal sums set forth on Exhibit A were agreed to on the dates thereon and all provisions of this unsecured promissory note shall be deemed effective as of such dates and all financial obligations shall accrue from such dates with respect to such amounts. All payments of principal and interest hereunder shall be made by check or wire transfer pursuant to wire transfer instructions that may be provided by the Holder to the Borrower from time to time.

 

1.Payments; Conversion. The Borrower shall make the principal payment on January 1, 2023 to the Holder, together with accrued and unpaid interest hereunder. Notwithstanding to the contrary, all outstanding principal and all accrued and unpaid interest hereunder shall be due and payable in full at that time. In addition, the Holder shall have the option to convert the then outstanding balance of principal and interest under this Note into restricted shares of the Borrower’s Common Stock at a conversion price equal to $0.30 per share of Common Stock.

 

2.Alternative Payment. Any time prior to January 1, 2023, if Borrower raises new equity capital in the amount of three million dollars ($3,000,000.00) or greater, then within five (5) business days of closing, repayment of all outstanding principal and interest on this Convertible Promissory Note will be due.
3.Interest Rate. Simple interest on the unpaid principal balance of this Note shall accrue at the lesser of ten percent (10%) per annum and the highest rate permitted by law. If an Event of Default (as defined below) shall occur under this Note, interest shall immediately commence accruing at a default rate of fourteen percent (14%) per annum.

 

4.Default. The occurrence of any of the following events of default (each, an “Event of Default”) shall, at the option of the Holder thereof, make all principal and interest (to the extend accrued) then remaining unpaid hereon and all other amounts payable hereunder immediately due and payable, upon written demand, without presentment, or grace period, all of which hereby are expressly waived, except as set forth below:

 

(a)Failure to Pay Principal or Interest. The Borrower fails to pay any installment of principal or interest due under this Note when due and such failure continues for a period of five (5) days after written notice.

 

PROMISSORY NOTE – Page 1 

 

 

(b)Receiver or Trustee. The Borrower shall make an assignment for the benefit of creditors, or applies for or consents to the appointment of a receiver or trustee for it or for a substantial part of its property or business; or such a receiver of trustee shall otherwise be appointed without the consent of the Borrower, which shall constitute an automatic Event of Default and shall result in all remaining unpaid principal and interest due hereon immediately due and payable without the written demand from the Holder.

 

(c)Bankruptcy. Bankruptcy, insolvency, reorganization, or liquidation proceedings or other proceedings or relief under any bankruptcy law or any law, or the issuance of any notice in relation to such event, for the relief of debtors shall be instituted by or against the Borrower, which shall constitute an automatic Event of Default and shall result in all remaining unpaid principal and interest due hereon immediately due and payable without the written demand from the Holder.

 

5.Termination. Upon payment of all cash amounts due to the Holder as provided in this Note, the Borrower will forever be released from all of its payment obligations and liabilities under this Note and the Holder agrees to promptly return to the Borrower the Note marked “paid in full”. This Note may be prepaid, in whole or in part, without the prior consent of the Holder.

 

6.Miscellaneous

 

(a)Successors and Assigns. This Note shall be binding upon successors and assigns of the Borrower, and shall inure to the benefit of the successors and permitted assigns of the Holder.

 

(b)Severability. The unenforceability or invalidity of any provision or provisions of this Note shall not render any other provision or provisions herein contained unenforceable or invalid.

 

(c)Notice. Any notice or communication required to be given hereunder may be delivered by hand or deposited with an overnight courier (with overnight delivery instructions), if to the Borrower, to the address of the Borrower’s corporate headquarters, and if to the Holder, to the last address of the Holder set forth in the Borrower’s books and records. Notice shall be deemed given and received on the date sent if sent by personal delivery; and one (1) day after the date sent if sent by overnight courier.

 

PROMISSORY NOTE – Page 2 

 

 

(d)Entire Agreement. This Note contains the entire and complete understanding between the parties concerning its subject matter and all representations, agreements, arrangements, and understandings between or among the parties, whether oral or written, have been fully merged herein and are superseded thereby, except for representations, agreements, and understandings between or among the parties made pursuant to the Purchase Agreement and any other agreements entered into in connection therewith and herewith. The Note may be modified only by a writing signed by both parties.

 

(e)Governing Law; Attorneys’ Fees. This Note shall be governed by and construed in accordance with the laws of the State of Texas, without giving effect to its principles regarding conflicts of law. Upon default, the breaching party agrees to pay to the non-breaching party reasonable attorneys’ fees, plus all other reasonable expenses, incurred by the non-breaching party in exercising any of the non-breaching party’s rights and remedies.

 

(f)Jurisdiction. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of the State of Texas, Dallas County, and to the jurisdiction of the United States District Court for the State of Texas, for the purpose of any suit, action, or other proceeding arising out of or based upon this Note; (b) agree not to commence any suit, action, or other proceeding arising out of or based upon this Note except in the state courts of the State of Texas, Dallas County, or the United States District Court for the State of Texas; and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action, or proceeding, any claim that it is not subject personally to the jurisdiction of the above named courts, that its property is exempt or immune from attachment or execution, that the suit, action, or proceeding is brought in an inconvenient forum, that the venue of the suit, action, or proceeding is improper or that this Note or the subject matter hereof may not be enforced in or by such court.

 

(g)FINAL AGREEMENT. THIS NOTE AND ALL OTHER INSTRUMENTS, DOCUMENTS, AND AGREEMENTS EXECUTED AND DELIVERED BY THE BORROWER IN CONNECTION WITH THE INDEBTEDNESS EVIDENCED BY THIS NOTE EMBOTY THE FINAL, ENTIRE AGREEMENT OF THE BORROWER AND THE HOLDER WITH RESPECT TO THE INDEBTEDNESS EVIDENCED BY THIS NOTE AND SUPERSEDE ANY AND ALL PRIOR COMMITMENTS, AGREEMENTS, REPRESENTATIONS, AND UNDERSTANDINGS, WHETHER WRITTEN OR ORAL, RELATING TO THE INDEBTEDNESS EVIDENCED BYT HIS NOTE AND MAY NOT BE CONTRADICTED OR VARIED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS OR SUBSEQUENT ORAL AGREEMENTS OR DISCUSSIONS OF THE BORROWER AND THE HOLDER. THERE ARE NO ORAL AGREEMENTS BETWEEN THE BORROWER AND THE HOLDER.

 

(h)Subordination. By its acceptance hereof, the Holder agrees that the indebtedness evidenced by this Note, including the principal of and interest thereon, shall be subordinate to and subject in right of payment, to the extent hereinafter set forth, to the prior payment in full of all principal, interest, and any other sums then due on all existing or future Senior Indebtedness of the Borrower. The term “Senior Indebtedness” shall mean secured and unsecured indebtedness of the Borrower, or with respect to which the Borrower is a guarantor, for money borrowed by the Borrower from any financial institution or other sources prior to the date of this unsecured promissory note.

 

Signature Page Follows

 

PROMISSORY NOTE – Page 3 

 

 

IN WITNESS WHEREOF, the Borrower has executed this Note as of the date set forth above.

 

  GENERATION HEMP, INC.,    
  a Delaware Corporation    
       
  By:  /s/ Joe McClaugherty   September 30, 2022
    Joe McClaugherty   Date
    Lead Director    

 

PROMISSORY NOTE – Page 4 

 

 

PROMISSORY NOTE

 

Exhibit A

Schedule of Principal Sums Drawn under Promissory Note

 

Principal Sum Draw Date  Principal Sum Drawn 
July 20, 2021  $100,000.00 
August 3, 2021   100,000.00 
August 23, 2021   100,000.00 
September 9, 2021   50,000.00 
September 23, 2021   50,000.00 
September 29, 2021   220,000.00 
October 19, 2021   15,000.00 
November 10, 2021   50,000.00 
November 29, 2021 reduction in principal   (299,999.74)
December 8, 2021   25,000.00 
March 24, 2022   10,000.00 
March 30, 2022   37,069.02 
April 4, 2022   250,000.00 
April 14, 2022   100,000.00 
April 21, 2022   50,000.00 
April 27, 2022   100,000.00 
May 17, 2022   10,000.00 
May 19, 2022   20,000.00 
May 24, 2022   50,000.00 
August 4, 2022   51,000.00 
August 8, 2022   7,000.00 
August 11, 2022   12,000.00 
Total  $1,107,069.28 

 

 

 

PROMISSORY NOTE – Page 5

 

 

EX-10.2 3 f10q0922ex10-2_generation.htm REVISED AND EXTENDED UNSECURED PROMISSORY NOTE, DATED SEPTEMBER 30, 2022, WITH INVESTMENT HUNTER, LLC AS HOLDER, DATED SEPTEMBER 30, 2022

Exhibit 10.2

 

REVISED AND AMENDED UNSECURED PROMISSORY NOTE

 

$492,000.00 September 30, 2022

 

For value received, GENERATION HEMP, INC., a Delaware corporation (the “Borrower”), promises to pay to Investment Hunter, LLC, a Texas LLC, or its assigns (the “Holder”), the principal sum of $492,000.00 (U.S. Dollars), together with all accrued and unpaid interest thereon as set forth below. It is expressly understood that the commitment to provide the individual principal sums which total $492,000.00 was agreed to on the date of each individual loan advance, as presented in Exhibit A, attached hereto, and all provisions of this unsecured promissory note shall be deemed effective as of such date and all financial obligations shall accrue from such date with respect to each amount.

 

All payments of principal and interest hereunder shall be made by check or wire transfer pursuant to wire transfer instructions that may be provided by the Holder to the Borrower from time to time.

 

1.Payments. The Borrower shall make the principal payment on January 1, 2023 to the Holder, together with accrued and unpaid interest hereunder. Notwithstanding to the contrary, all outstanding principal and all accrued and unpaid interest hereunder shall be due and payable in full at that time.

 

2.Alternative Payment. Any time prior to January 1, 2023, if Borrower raises new equity capital in the amount of three million dollars ($3,000,000.00) or greater, then within five (5) business days of closing, repayment of all outstanding principal and interest on this Convertible Promissory Note will be due.

 

3.Interest Rate. Simple interest on the unpaid principal balance of this Note shall accrue at the lesser of ten percent (10%) per annum and the highest rate permitted by law. If an Event of Default (as defined below) shall occur under this Note, interest shall immediately commence accruing at a default rate of fourteen percent (14%) per annum.

 

4.Default. The occurrence of any of the following events of default (each, an “Event of Default”) shall, at the option of the Holder thereof, make all principal and interest (to the extend accrued) then remaining unpaid hereon and all other amounts payable hereunder immediately due and payable, upon written demand, without presentment, or grace period, all of which hereby are expressly waived, except as set forth below:

 

(a)Failure to Pay Principal or Interest. The Borrower fails to pay any installment of principal or interest due under this Note when due and such failure continues for a period of five (5) days after written notice.

 

(b)Receiver or Trustee. The Borrower shall make an assignment for the benefit of creditors, or applies for or consents to the appointment of a receiver or trustee for it or for a substantial part of its property or business; or such a receiver of trustee shall otherwise be appointed without the consent of the Borrower, which shall constitute an automatic Event of Default and shall result in all remaining unpaid principal and interest due hereon immediately due and payable without the written demand from the Holder.

 

INVESTMENT HUNTER, LLC

PROMISSORY NOTE – Page 1

 

 

(c)Bankruptcy. Bankruptcy, insolvency, reorganization, or liquidation proceedings or other proceedings or relief under any bankruptcy law or any law, or the issuance of any notice in relation to such event, for the relief of debtors shall be instituted by or against the Borrower, which shall constitute an automatic Event of Default and shall result in all remaining unpaid principal and interest due hereon immediately due and payable without the written demand from the Holder.

 

5.Termination. Upon payment of all cash amounts due to the Holder as provided in this Note, the Borrower will forever be released from all of its payment obligations and liabilities under this Note and the Holder agrees to promptly return to the Borrower the Note marked “paid in full”. This Note may be prepaid, in whole or in part, without the prior consent of the Holder.

 

6.Miscellaneous

 

(a)Successors and Assigns. This Note shall be binding upon successors and assigns of the Borrower, and shall inure to the benefit of the successors and permitted assigns of the Holder.

 

(b)Severability. The unenforceability or invalidity of any provision or provisions of this Note shall not render any other provision or provisions herein contained unenforceable or invalid.

 

(c)Notice. Any notice or communication required to be given hereunder may be delivered by hand or deposited with an overnight courier (with overnight delivery instructions), if to the Borrower, to the address of the Borrower’s corporate headquarters, and if to the Holder, to the last address of the Holder set forth in the Borrower’s books and records. Notice shall be deemed given and received on the date sent if sent by personal delivery; and one (1) day after the date sent if sent by overnight courier.

  

INVESTMENT HUNTER, LLC

PROMISSORY NOTE – Page 2

 

 

(d)Entire Agreement. This Note contains the entire and complete understanding between the parties concerning its subject matter and all representations, agreements, arrangements, and understandings between or among the parties, whether oral or written, have been fully merged herein and are superseded thereby, except for representations, agreements, and understandings between or among the parties made pursuant to the Purchase Agreement and any other agreements entered into in connection therewith and herewith. The Note may be modified only by a writing signed by both parties.

 

(e)Governing Law; Attorneys’ Fees. This Note shall be governed by and construed in accordance with the laws of the State of Texas, without giving effect to its principles regarding conflicts of law. Upon default, the breaching party agrees to pay to the non-breaching party reasonable attorneys’ fees, plus all other reasonable expenses, incurred by the non-breaching party in exercising any of the non-breaching party’s rights and remedies.

 

(f)Jurisdiction. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of the State of Texas, Dallas County, and to the jurisdiction of the United States District Court for the State of Texas, for the purpose of any suit, action, or other proceeding arising out of or based upon this Note; (b) agree not to commence any suit, action, or other proceeding arising out of or based upon this Note except in the state courts of the State of Texas, Dallas County, or the United States District Court for the State of Texas; and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action, or proceeding, any claim that it is not subject personally to the jurisdiction of the above named courts, that its property is exempt or immune from attachment or execution, that the suit, action, or proceeding is brought in an inconvenient forum, that the venue of the suit, action, or proceeding is improper or that this Note or the subject matter hereof may not be enforced in or by such court.

 

(g)FINAL AGREEMENT. THIS NOTE AND ALL OTHER INSTRUMENTS, DOCUMENTS, AND AGREEMENTS EXECUTED AND DELIVERED BY THE BORROWER IN CONNECTION WITH THE INDEBTEDNESS EVIDENCED BY THIS NOTE EMBOTY THE FINAL, ENTIRE AGREEMENT OF THE BORROWER AND THE HOLDER WITH RESPECT TO THE INDEBTEDNESS EVIDENCED BY THIS NOTE AND SUPERSEDE ANY AND ALL PRIOR COMMITMENTS, AGREEMENTS, REPRESENTATIONS, AND UNDERSTANDINGS, WHETHER WRITTEN OR ORAL, RELATING TO THE INDEBTEDNESS EVIDENCED BYT HIS NOTE AND MAY NOT BE CONTRADICTED OR VARIED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS OR SUBSEQUENT ORAL AGREEMENTS OR DISCUSSIONS OF THE BORROWER AND THE HOLDER. THERE ARE NO ORAL AGREEMENTS BETWEEN THE BORROWER AND THE HOLDER.

 

(h)Subordination. By its acceptance hereof, the Holder agrees that the indebtedness evidenced by this Note, including the principal of and interest thereon, shall be subordinate to and subject in right of payment, to the extent hereinafter set forth, to the prior payment in full of all principal, interest, and any other sums then due on all existing or future Senior Indebtedness of the Borrower. The term “Senior Indebtedness” shall mean secured and unsecured indebtedness of the Borrower, or with respect to which the Borrower is a guarantor, for money borrowed by the Borrower from any financial institution or other sources prior to the date of this unsecured promissory note.

 

Signature Page Follows

 

INVESTMENT HUNTER, LLC

PROMISSORY NOTE – Page 3

 

 

IN WITNESS WHEREOF, the Borrower has executed this Note as of the date set forth above.

 

 

GENERATION HEMP, INC. GENERATION HEMP, INC.
a Delaware Corporation a Delaware Corporation
   
/s/ Gary C. Evans /s/ Joe L. McClaugherty
   
By: Gary C. Evans, CEO By: Joe L. McClaugherty, Lead Director

 

INVESTMENT HUNTER, LLC

PROMISSORY NOTE – Page 4

 

 

PROMISSORY NOTE

 

Exhibit A

Schedule of Principal Sums Drawn under Promissory Note

 

Principal Sum Draw Date  Principal Sum Drawn 
1/4/22  $60,000.00 
1/11/22   25,000.00 
1/20/22   60,000.00 
1/28/22   75,000.00 
2/10/22   25,000.00 
2/14/22   25,000.00 
2/17/22   65,000.00 
3/1/22   40,000.00 
3/3/22   20,000.00 
3/17/22   44,000.00 
3/23/22   1,500.00 
5/11/22   40,000.00 
7/21/22   10,500.00 
8/11/22   1,000.00 
Total  $492,000.00 

 

 

 

INVESTMENT HUNTER, LLC

PROMISSORY NOTE – Page 5

 

EX-10.3 4 f10q0922ex10-3_generation.htm SECURED PROMISSORY NOTE AMENDMENT AND EXTENSION AGREEMENT, DATED OCTOBER 10, 2022, BETWEEN JDONE LLC, THOMAS S. YANG, AND GARY C. EVANS

Exhibit 10.3

 

SECURED PROMISSORY NOTE AMENDMENT AND EXTENSION AGREEMENT

 

This Secured Promissory Note Amendment and Extension Agreement (the “Agreement”) is entered into by JDone LLC, a Colorado limited liability company (the “Borrower”) and Thomas S. Yang (the “Holder”), as of October 10, 2022 and effective as of October 1, 2022.

 

Reference is made to that certain original Secured Promissory Note between the Borrower and the Holder, dated as of September 15, 2014 and amended on October 1, 2019, and most recently April 15, 2022, together with all amendments thereto (the “Note”), together with all associated notes, pledge agreements, guaranties, deeds of trust, security agreements, affidavits and other instruments and documents executed and delivered by the Borrower, the Holder and any Guarantors (the “Loan Documents”). Each of the Loan Documents shall be deemed to be amended in connection with the terms of this Agreement and the terms of this Agreement and the Note, as amended and extended hereby, shall be the controlling document with respect to the Note and the Loan Documents.

 

All capitalized terms used herein, but not otherwise defined, shall have the meaning ascribed to such terms in the Note and the Loan Documents.

 

At the execution of this Agreement, the Borrower shall undertake the following, and the Note shall be amended as follows:

 

(i)The Holder and Borrower agree that the outstanding principal balance under the Note is 423,190.48 after application of the August 2022 payment;

 

(ii)the Borrower shall pay a principal payment in the amount of $73,190.48 plus accrued interest on October 15, 2022;

 

(iii)the Borrower shall pay a principal payment in the amount of $50,000 plus accrued interest on November 15, 2022;

 

(iv)the Borrower shall pay a principal payment in the amount of $50,000 plus accrued interest on December 15, 2022;

 

(v)the Note shall be amended to change the Maturity Date to January 15, 2023;

 

(vi)after the October, November, and December 2022 principal and interest payments, the outstanding principal balance under the note as of January 15, 2023 will be $250,000; and

 

(vii)Borrower may pay off the loan at any time prior to the Maturity Date without penalty.
   
(viii)Any time prior to January 15, 2023, if Borrower raises new equity capital in the amount of five million dollars ($5,000,000.00) or greater, then within ten (10) business days of closing, repayment of all outstanding principal and interest on this Secured Promissory Note will be due to Holder.

 

All other terms contained in the Note and the Loan Documents shall remain unchanged and in full force and effect.

 

 

 

 

IN WITNESS WHEREOF, the Borrower and the Holder have executed this Agreement as of the date first written above and effective as the date stated above.

 

BORROWER:

 

JDone LLC

 

By: Generation Hemp, Inc.

 

/s/ Gary C. Evans

 

By:

 

Gary C. Evans

 

Chairman and Chief Executive Officer

 

 

ACKNOWLEDGED AND AGREED:

 

HOLDER:

 

/s/ Thomas S. Yang

 

By:

 

Thomas S. Yang

 

 

 

 

EX-10.4 5 f10q0922ex10-4_generation.htm AMENDED AND RESTATED SUBORDINATED PROMISSORY NOTE, BY GENERATION HEMP, INC. WITH GARY C. EVANS AS HOLDER, DATED SEPTEMBER 30, 2022

Exhibit 10.4

 

AMENDED AND RESTATED SUBORDINATED PROMISSORY NOTE

 

Dated September 30, 2022

 

Principal Amount $523,550.92

 

FOR VALUE, Generation Hemp, Inc., a Delaware corporation (“Borrower”), whose mailing address is P.O. Box 540308, Dallas, Texas 75354, promises and agrees to pay to the order of Gary C. Evans, a Texas resident (“Lender”), whose address is 8533 Midway Road, Dallas, Texas 75209, or at such other location as the holder of this Amended and Restated Subordinated Promissory Note (the “Note”), originally issued on November 20, 2020 (the “Original Note”), may designate by written notice to Borrower, the sum of five hundred twenty-three thousand five hundred fifty dollars and ninety-two cents ($523,550.92) in the lawful currency of the United States with interest at a rate of 10 % per annum, but in no event higher than the Highest Lawful Rate (as hereinafter defined). This Note amends and restates the Original Note and all amendments, allonges and modifications thereto, in its collective entirety.

 

“Highest Lawful Rate” means the maximum nonusurious rate of interest permitted by applicable federal or Texas law from time to time.

 

Interest on this Note shall be computed for the actual number of days elapsed and on the basis of a year consisting of 360 days, and a month consisting of 30 days, unless the Highest Lawful Rate would thereby be exceeded, in which event, to the extent necessary to avoid exceeding the Highest Lawful Rate, interest shall be computed on the basis of the actual number of days elapsed in the applicable calendar year in which accrued. It is understood that interest will begin to accrue on the date of each principal amount advanced as outlined on Exhibit “A.” If an Event of Default (as defined below) shall occur under this Note, interest shall immediately commence accruing at a default rate of fourteen percent (14%) per annum.

 

The principal amount of this Note and all accrued, unpaid interest thereon is due and payable in full on the 1st day of January, 2023 (the “Payment Date”). This Note may be prepaid in whole or in part at any time prior to the payment date stated in the preceding sentence without penalty as to principal, and any partial payments shall be applied to the principal due on this Note in inverse order of maturity with interest being adjusted accordingly.

 

Any time prior to January 1, 2023, if Borrower raises new equity capital in the amount of three million dollars ($3,000,000.00) or greater, then within five (5) business days of closing, repayment of all outstanding principal and interest on this Subordinated Promissory Note will be due.

 

If one of the following events occurs, Maker shall be in default (“Default”) and this Note shall, at Lender’s option, become immediately due and payable without demand or notice:

 

(i)the failure of Borrower to pay the principal and any accrued interest in full on or before the Payment Date;

 

(ii)the filing of bankruptcy proceedings involving the Borrower as a debtor;

 

(iii)the making of a general assignment for the benefit of the Borrower’s creditors; or the uncured breach by Borrower under any of the security documents executed in conformity with this Note, which remains uncured following any applicable cure period.

 

Promissory Note – Page 1 

 

 

If any payment date falls on a Saturday, Sunday, or a federal holiday, then payment will be due on the next business day and such extension of time shall in such case be included in the computation or payment of interest hereunder. All past due principal and interest on this Note shall bear interest at the Highest Lawful Rate.

 

To the extent that waiver of notice is permitted by applicable law, the Borrower and any and all co-makers, endorsers, guarantors, and sureties jointly and severally waive notice (including, but not limited to, notice of intent to accelerate and notice of acceleration), demand, presentment for payment, protest and the filing of suit for the purpose of fixing liability and consent that the time of payment hereof may be extended and re-extended from time to time without notice to them or any of them, and each agree that his, her, or its liability on or with respect to this Note shall not be affected by any release of or change in any security at any time existing or by any failure to perfect or to maintain perfection of any lien on or security interest in any such security.

 

This Note has been executed and delivered in Dallas, Dallas County, Texas, and shall be governed by and construed in accordance with the laws of the State of Texas and the United States of America from time to time in effect without regard to the choice of law provisions thereof, and shall be enforceable in Dallas County, Texas.

 

Regardless of any provision contained in this Note, the Payee shall never be deemed to have contracted for or be entitled to receive, collect or apply as interest on the Note, any amount in excess of the maximum rate of interest permitted to be charged by applicable law and, in the event Payee ever receives, collects or applies as interest any such excess, such amount which would be excessive interest shall be applied to the reduction of the unpaid principal balance of this Note; and, if the principal balance of this Note is paid in full, any remaining excess shall forthwith be paid to Maker. In determining whether or not the interest paid or payable under any specific contingency exceeds the highest lawful rate, Maker and Payee shall, to the maximum extent permitted under applicable law, (i) exclude voluntary prepayments and the effect thereof, and (ii) spread the total amount of interest throughout the entire contemplated term of this Note so that the interest rate is uniform throughout such term.

 

This Promissory Note is intended to be an obligation of Borrower and, by the execution of this Promissory Note, Borrower agrees that Borrower shall not be entitled to sell, transfer, assign, or convey in any manner whatsoever, this Promissory Note and Borrower shall remain obligated under this Promissory Note until the obligation set forth herein is paid in full.

 

If this Note is placed in the hands of any attorney for collection, or if it is collected through any legal proceedings at law or in equity or in bankruptcy, receivership or other court proceedings, Maker joint and severally agrees to pay all costs of collection, including, but not limited to court costs and reasonable attorney’s fees.

 

IN WITNESS WHEREOF, the undersigned Borrower has duly executed this Note effective as of the date first written above.

 

  By: /s/ Joe McClaugherty   September 30, 2022
  Name:  Joe McClaugherty   DATE
  Title: Generation Hemp, Inc. Lead Director  

 

 

 

Promissory Note – Page 2

 

EX-31.1 6 f10q0922ex31-1_generation.htm CERTIFICATION

Exhibit 31.1

 

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002 

 

I, Gary C. Evans, certify that:

 

1)I have reviewed this Quarterly Report of Generation Hemp, Inc. on Form 10-Q;

 

2)Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3)Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

 

4)I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have;

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure the material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation.

 

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5)I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal controls over financial reporting.

 

DATE: November 14, 2022 By: /s/ Gary C. Evans
   

Gary C. Evans

Chairman

Chief Executive Officer

(Principal Executive Officer and
Principal Accounting and Financial Officer)

 

EX-32.1 7 f10q0922ex32-1_generation.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT 0F 2002

  

In connection with the Quarterly Report of Generation Hemp, Inc. (the Company”) on Form 10-Q for the period ended herein as filed with the Securities and Exchange Commission (the “Report”), I, Gary C. Evans, Chairman and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fully presents, in all material respects, the financial condition and results of operations or the Company.

 

DATE: November 14, 2022 By: /s/ Gary C. Evans
   

Gary C. Evans

Chairman

Chief Executive Officer

(Principal Executive Officer and
Principal Accounting and Financial Officer)

 

EX-101.SCH 8 genh-20220930.xsd XBRL SCHEMA FILE 001 - Statement - Unaudited Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Unaudited Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Unaudited Condensed Consolidated Statements of Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Business link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Intangible and Other Assets link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Notes Payable – Related Parties link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Other Indebtedness link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Equity link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Discontinued Operations link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Earnings (Loss) Per Share link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Intangible and Other Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Notes Payable – Related Parties (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Supplemental Cash Flow Information (Tables) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Earnings (Loss) Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Business (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Intangible and Other Assets (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Intangible and Other Assets (Details) - Schedule of intangible asset link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Notes Payable – Related Parties (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Notes Payable – Related Parties (Details) - Schedule of notes payable – related parties link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Other Indebtedness (Details) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Equity (Details) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Equity (Details) - Schedule of warrants outstanding link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Equity (Details) - Schedule of outstanding stock warrants activity link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Stock-Based Compensation (Details) - Schedule of summarizes options outstanding link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Discontinued Operations (Details) - Schedule of discontinued operations to assets and liabilities held for sale link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Discontinued Operations (Details) - Schedule of discontinued operations shown in the consolidated statements of operations link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - Supplemental Cash Flow Information (Details) - Schedule of supplemental cash flow information link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of earnings (loss) per basic and diluted share link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 genh-20220930_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 genh-20220930_def.xml XBRL DEFINITION FILE EX-101.LAB 11 genh-20220930_lab.xml XBRL LABEL FILE EX-101.PRE 12 genh-20220930_pre.xml XBRL PRESENTATION FILE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document And Entity Information - shares
9 Months Ended
Sep. 30, 2022
Nov. 14, 2022
Document Information Line Items    
Entity Registrant Name GENERATION HEMP, INC.  
Document Type 10-Q  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   113,204,002
Amendment Flag false  
Entity Central Index Key 0001527102  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Sep. 30, 2022  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 000-55019  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 26-3119496  
Entity Address, Address Line One 8533 Midway Road  
Entity Address, City or Town Dallas  
Entity Address, State or Province TX  
Entity Address, Postal Zip Code 75209  
City Area Code (469)  
Local Phone Number 209-6154  
Entity Interactive Data Current Yes  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Unaudited Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current Assets:    
Cash $ 112,538 $ 20,656
Accounts receivable 656,344
Inventories 212,518 212,518
Prepaid expenses 49,078 4,723
Total current assets 1,030,478 237,897
Property and equipment, net 2,276,815 2,580,662
Operating lease right-of-use asset 188,090 263,065
Intangible assets, net 1,418,025 1,857,908
Goodwill 799,888 799,888
Other assets   407,000
Total Assets 5,713,296 6,146,420
Current Liabilities:    
Accounts payable 1,037,275 883,485
Accrued liabilities 402,617 410,990
Deferred revenue 100,311  
Payables to related parties 486,855 204,007
Operating lease liability - related party 109,089 101,238
Notes payable – related parties 3,357,620 2,183,551
Other indebtedness - current 423,192 501,668
Current liabilities of discontinued operations held for sale 144,441 153,482
Total current liabilities 6,061,400 4,438,421
Operating lease liability - related party, net of current portion 79,001 161,827
Long-term liabilities of discontinued operations held for sale 199,046 162,948
Total liabilities 6,339,447 4,763,196
Commitments and contingencies
Series B redeemable preferred stock, no par value, $10,000 stated value, 300 shares authorized, 118 and 135 shares issued and outstanding at September 30, 2022 and December 31, 2021 591,558 591,558
Equity (Deficit):    
Preferred stock, $0.00001 par value; 200,000,000 shares authorized, none outstanding
Common stock, $0.00001 par value; 200,000,000 shares authorized, 113,204,002 and 113,094,002 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively 1,132 1,131
Additional paid-in capital 33,250,858 29,150,258
Accumulated deficit (34,224,154) (28,118,245)
Generation Hemp equity (deficit) (972,164) 1,033,144
Noncontrolling interest (245,545) (241,478)
Total equity (deficit) (1,217,709) 791,666
Total Liabilities and Equity (Deficit) $ 5,713,296 $ 6,146,420
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Preferred stock, par value (in Dollars per share) $ 0.00001 $ 0.00001
Preferred stock, shares authorized 200,000,000 200,000,000
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share) $ 0.00001 $ 0.00001
Common stock, shares authorized 200,000,000 200,000,000
Common stock, shares issued 113,204,002 113,094,002
Common stock, shares outstanding 113,204,002 113,094,002
Series B Redeemable Preferred Stock    
Preferred stock, par value (in Dollars per share)
Preferred stock, stated Value (in Dollars) $ 10,000 $ 10,000
Preferred stock, shares authorized 300 300
Preferred stock, shares issued 118 135
Preferred stock, shares outstanding 118 135
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Unaudited Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:        
Post-harvest and midstream services $ 1,227,123 $ 487,088 $ 1,559,056 $ 535,053
Rental 22,500 15,000 67,500 60,000
Total revenue 1,249,623 502,088 1,626,556 595,053
Costs and Expenses:        
Cost of revenue (exclusive of items shown separately below) 375,269 279,621 644,113 549,881
Depreciation and amortization 261,490 315,729 743,730 1,006,804
Merger and acquisition costs 16,115
Impairment expense 407,000 407,000
General and administrative 1,933,281 1,128,298 5,825,809 2,763,529
Total costs and expenses 2,977,040 1,723,648 7,620,652 4,336,329
Operating loss (1,727,417) (1,221,560) (5,994,096) (3,741,276)
Other expense (income):        
Other income (378,304) (378,304) (25,424)
Change in fair value of marketable security (11,770)
Interest expense 116,999 155,505 404,272 651,807
Total other expense (income) (261,305) 155,505 25,968 614,613
Loss from continuing operations (1,466,112) (1,377,065) (6,020,064) (4,355,889)
Income (loss) from discontinued operations 10,386 (1,630) (29,877) (11,349)
Net loss (1,455,726) (1,378,695) (6,049,941) (4,367,238)
Less: net income (loss) attributable to noncontrolling interests (58) (1,137) (4,067) (284)
Net loss attributable to Generation Hemp $ (1,455,668) $ (1,377,558) $ (6,045,874) $ (4,366,954)
Loss from continuing operations        
Basic (in Dollars per share) $ (0.01) $ (0.03) $ (0.05) $ (0.11)
Diluted (in Dollars per share) (0.01) (0.03) (0.05) (0.11)
Loss from discontinued operations        
Basic (in Dollars per share)
Diluted (in Dollars per share)
Earnings (loss) per share        
Basic (in Dollars per share) (0.01) (0.03) (0.05) (0.11)
Diluted (in Dollars per share) $ (0.01) $ (0.03) $ (0.05) $ (0.11)
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Unaudited Condensed Consolidated Statements of Equity (Deficit) - USD ($)
Total
Series B Redeemable Preferred Stock
Series A Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Noncontrolling Interest
Balance at Dec. 31, 2020 $ (2,964,935) $ 729,058 $ 4,975,503 $ 6,083,480 $ 4,436,018 $ (18,220,705) $ (239,231)
Balance (in Shares) at Dec. 31, 2020   135 6,328,948 17,380,317      
Acquisition of Certain Assets of Halcyon Thruput, LLC 2,500,000 $ 2,500,000
Acquisition of Certain Assets of Halcyon Thruput, LLC (in Shares)   6,250,000      
Issuances of common stock units 400,000 $ 136,707 263,293
Issuances of common stock units (in Shares)   800,000      
Warrant exercises 2,967,000 $ 4,771,669 (1,804,669)
Warrant exercises (in Shares)   8,428,976      
Issuance of common shares for Convertible Promissory Note 217,769 $ 217,769
Issuance of common shares for Convertible Promissory Note (in Shares)   618,660      
Issuance of common shares for Senior Secured Promissory Note 1,942,500 $ 1,942,500
Issuance of common shares for Senior Secured Promissory Note (in Shares)   1,000,000      
Series B preferred stock dividend (20,250) (20,250)
Stock-based compensation 42,250 $ 42,250
Stock-based compensation (in Shares)   500,000      
Net loss (1,833,214) (1,836,882) 3,668
Balance at Mar. 31, 2021 3,251,120 $ 729,058 $ 4,975,503 $ 15,694,375 2,894,642 (20,077,837) (235,563)
Balance (in Shares) at Mar. 31, 2021   135 6,328,948 34,977,953      
Balance at Dec. 31, 2020 (2,964,935) $ 729,058 $ 4,975,503 $ 6,083,480 4,436,018 (18,220,705) (239,231)
Balance (in Shares) at Dec. 31, 2020   135 6,328,948 17,380,317      
Net loss (4,367,238)            
Balance at Sep. 30, 2021 893,721 $ 591,558 $ 1,111 23,776,409 (22,644,284) (239,515)
Balance (in Shares) at Sep. 30, 2021   118 111,070,329      
Balance at Mar. 31, 2021 3,251,120 $ 729,058 $ 4,975,503 $ 15,694,375 2,894,642 (20,077,837) (235,563)
Balance (in Shares) at Mar. 31, 2021   135 6,328,948 34,977,953      
Series B preferred stock redemptions $ (137,500)
Series B preferred stock redemptions (in Shares)   (17)      
Series B preferred stock dividend (20,250) (20,250)
Stock-based compensation 38,750 38,750
Net loss (1,155,329) (1,152,514) (2,815)
Balance at Jun. 30, 2021 2,114,291 $ 591,558 $ 4,975,503 $ 15,733,125 2,894,642 (21,250,601) (238,378)
Balance (in Shares) at Jun. 30, 2021   118 6,328,948 34,977,953      
Common shares issued to vendor for services 117,500 $ 117,500
Common shares issued to vendor for services (in Shares)   125,000      
Issuance of common shares for extension of secured note 18,000 $ 18,000
Issuance of common shares for extension of secured note (in Shares)   20,000      
Change in common stock par value due to change in corporate domicile $ (15,868,273) 15,868,273
Conversion of Series A preferred stock $ (4,975,503) $ 759 4,974,744
Conversion of Series A preferred stock (in Shares)   (6,328,948) 75,947,376      
Series B preferred stock dividend (16,125) (16,125)
Stock-based compensation 38,750 38,750
Stock-based compensation (in Shares)        
Net loss (1,378,695) (1,377,558) (1,137)
Balance at Sep. 30, 2021 893,721 $ 591,558 $ 1,111 23,776,409 (22,644,284) (239,515)
Balance (in Shares) at Sep. 30, 2021   118 111,070,329      
Balance at Dec. 31, 2021 791,666 $ 591,558 $ 1,131 29,150,258 (28,118,245) (241,478)
Balance (in Shares) at Dec. 31, 2021   118 113,094,002      
Issuance of common shares for extension of secured note 11,480 11,480
Issuance of common shares for extension of secured note (in Shares)   20,000      
Modification of warrants for extension of promissory note to investor 68,756 68,756
Series B preferred stock dividend (20,992) (20,992)
Stock-based compensation 1,315,750 1,315,750
Net loss (2,456,671) (2,455,084) (1,587)
Balance at Mar. 31, 2022 (290,011) $ 591,558 $ 1,131 30,546,244 (30,594,321) (243,065)
Balance (in Shares) at Mar. 31, 2022   118 113,114,002      
Balance at Dec. 31, 2021 791,666 $ 591,558 $ 1,131 29,150,258 (28,118,245) (241,478)
Balance (in Shares) at Dec. 31, 2021   118 113,094,002      
Net loss (6,049,941)            
Balance at Sep. 30, 2022 (1,217,709) $ 591,558 $ 1,132 33,250,858 (34,224,154) (245,545)
Balance (in Shares) at Sep. 30, 2022   118 113,204,002      
Balance at Mar. 31, 2022 (290,011) $ 591,558 $ 1,131 30,546,244 (30,594,321) (243,065)
Balance (in Shares) at Mar. 31, 2022   118 113,114,002      
Issuance of common shares for extension of secured note 26,001 $ 1 26,000
Issuance of common shares for extension of secured note (in Shares)   40,000      
Series B preferred stock dividend (19,375) (19,375)
Stock-based compensation 1,315,750 1,315,750
Net loss (2,137,544) (2,135,122) (2,422)
Balance at Jun. 30, 2022 (1,105,179) $ 591,558 $ 1,132 31,887,994 (32,748,818) (245,487)
Balance (in Shares) at Jun. 30, 2022   118 113,154,002      
Issuance of common shares for extension of secured note 15,100 15,100
Issuance of common shares for extension of secured note (in Shares)   50,000      
Series B preferred stock dividend (19,668) (19,668)
Stock-based compensation 1,347,764 1,347,764
Net loss (1,455,726) (1,455,668) (58)
Balance at Sep. 30, 2022 $ (1,217,709) $ 591,558 $ 1,132 $ 33,250,858 $ (34,224,154) $ (245,545)
Balance (in Shares) at Sep. 30, 2022   118 113,204,002      
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash Flows From Operating Activities    
Net loss $ (6,049,941) $ (4,367,238)
Loss from discontinued operations (29,877) (11,349)
Net loss from continuing operations (6,020,064) (4,355,889)
Adjustments to reconcile net loss from continuing operations to net cash from operating activities:    
Depreciation and amortization 743,730 1,006,804
Impairment expense 407,000
Amortization of debt discount 52,581 380,282
Stock-based compensation 3,979,264 119,750
Common shares issued to vendor for services 117,500
Modification of warrants for extension of promissory note to investor 68,756
Other income - PPP Loan forgiveness (25,424)
Change in fair value of marketable securities (11,770)
Changes in operating assets and liabilities:    
Accounts receivable (656,344) (52,195)
Prepaid expenses (44,355) (14,232)
Accounts payable and accrued liabilities 368,230 176,969
Deferred revenue 100,311
Net cash from operating activities – continuing operations (1,000,891) (2,658,205)
Net cash from operating activities – discontinued operations (2,820)
Net cash from operating activities (1,003,711) (2,658,205)
Cash Flows From Investing Activities    
Capital expenditures (77,716)
Acquisition of certain assets of Halcyon Thruput, LLC, net of acquired cash of $224,530 (1,525,470)
Proceeds from sale of investment in common stock 34,847
Net cash from investing activities – continuing operations (1,568,339)
Net cash from investing activities – discontinued operations
Net cash from investing activities (1,568,339)
Cash Flows From Financing Activities    
Issuance of common stock units 350,000
Redemptions of Series B preferred stock (137,500)
Series B preferred stock dividends paid (16,500)
Proceeds from warrant exercises 2,967,000
Repayment of Halcyon bank note (995,614)
Proceeds from notes payable - related parties 1,294,069
Repayments of notes payable - related parties (70,000)
Proceeds from subordinated notes 620,000
Repayment of subordinated notes (50,000) (1,100,000)
Payment of mortgage payable (78,476) (103,102)
Net cash from financing activities – continuing operations 1,095,593 1,584,284
Net cash from financing activities – discontinued operations
Net cash from financing activities 1,095,593 1,584,284
Net change in cash 91,882 (2,642,260)
Cash, beginning of period 20,656 2,776,425
Cash, end of period $ 112,538 $ 134,165
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Unaudited Condensed Consolidated Statements of Cash Flows (Parentheticals) - USD ($)
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Statement of Cash Flows [Abstract]    
Net of acquired cash $ 224,530 $ 224,530
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business
9 Months Ended
Sep. 30, 2022
Business [Abstract]  
Business

1. Business

 

Generation Hemp, Inc. (the “Company”) was incorporated on August 21, 2021 in the State of Delaware. The Company was originally incorporated as Home Treasure Finders, Inc. (“HTF”) on July 28, 2008 in the State of Colorado. On November 27, 2019, HTF purchased approximately 94% of the common stock of Energy Hunter Resources, Inc. (“EHR”) in a series of transactions accounted for as a reverse merger. Upon closing, HTF changed its name to Generation Hemp, Inc.

 

On January 11, 2021, we completed the acquisition of certain assets of Halcyon Thruput, LLC (“Halcyon”). With this acquisition, we commenced providing post-harvest and midstream services to hemp growers by drying, processing, cleaning and stripping harvested hemp directly from the field and wetbaled at our 48,000 square foot leased facility located in Hopkinsville, Kentucky. The Company also offers safe storage services for processed hemp, which enables farmers to maximize strategic market timing. We market two retail products, Gas Monkey Spill-Jack, an all-natural, plant-based, sustainable, and biodegradable loose absorbent, and Rowdy Rooster, an animal bedding consumer goods product, each made from the hemp hurd byproduct that is produced from our hemp processing operations.

 

We also generate revenue from rental of our “Cannabis Zoned” (Hemp) warehouse property located in Denver, Colorado currently leased to an unaffiliated hemp seed company.

 

As of September 30, 2022, EHR held an approximate 8% working interest in an oil & gas property located in Cochran County, Texas within the Slaughter-Levelland Field of the San Andres formation in the Northwest Shelf of West Texas. EHR’s oil & gas activities are currently held for sale and are presented in these consolidated financial statements as discontinued operations for each of the periods presented.

 

Our management team has been and continues to actively review acquisition candidates involved in the hemp industry that operate within a number of vertical businesses, predominantly within the midstream sector that are attractive to us and are within the hemp supply chain. Additionally, the Company has been studying the Bitcoin mining space and anticipates future activity in this business sector.

 

Liquidity and Going Concern – The Company is dependent upon obtaining additional funding to continue ongoing operations and to pursue its strategy and execute its acquisition plans.

 

In the nine months ended September 30, 2022, the Company used $1.0 million of cash for its operating activities. At September 30, 2022, the Company’s current liabilities, including financing obligations due within one year, totaled $6.1 million as compared with its current assets of $1.0 million.

 

The Company will continue to pursue additional capital raising opportunities in order to fund future acquisitions and meet its obligations as they become due. We may not be successful in obtaining additional financing needed. In the event financing cannot be obtained, the Company may not be able to satisfy these plans and obligations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

 

Basis of Presentation – These interim financial statements are unaudited and have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain disclosures have been condensed or omitted from these financial statements. Accordingly, they do not include all the information and notes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements, and should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021.

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, necessary to fairly present the financial position as of, and the results of operations for, all periods presented. In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the condensed consolidated financial statements and disclosures of contingencies. Actual results may differ from those estimates. The results for interim periods are not necessarily indicative of annual results. Certain reclassifications have been made to the prior period’s consolidated financial statements and related footnotes to conform them to the current period presentation. Intercompany balances and transactions between consolidated entities are eliminated.

 

Fair Value Measurement – Our financial assets and liabilities consist of cash, accounts receivable, accounts payable and indebtedness. The fair values of these instruments approximate their carrying amounts at each reporting date.

 

Deferred Revenue – In July 2022, the Company entered into an agreement for the sale of 66,782 pounds of dried hemp biomass from its inventories on-hand for a sales price of $1.50 per pound. Deliveries and payment of the $100,173 sales proceeds are scheduled monthly through December 2022 and are reported as deferred revenue in the consolidated balance sheets. We expect to recognize revenue for these amounts when the contract is completed and product is shipped in the fourth quarter of 2022.

 

Major Customer and Concentration of Credit Risk – We estimate an allowance for doubtful accounts based on an analysis of specific customers, taking into consideration the age of past due accounts and an assessment of the customer’s ability to pay. An allowance for doubtful accounts was not needed as of September 30, 2022 or December 31, 2021.

 

During the three and nine months ended September 30, 2022, one customer accounted for all of our post-harvest and midstream services revenue. A total of $656,344 was outstanding from this customer as a receivable at September 30, 2022.

 

Our rental revenue is derived from a single lessee on a commercial warehouse owned by the Company. There were no amounts due from this customer at September 30, 2022 or December 31, 2021.

 

Recent Accounting Pronouncements – There are no other new accounting pronouncements that are expected to have a material impact on the consolidated financial statements.

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment
9 Months Ended
Sep. 30, 2022
Property and Equipment [Abstract]  
Property and Equipment

3. Property and Equipment

 

Property and equipment consisted of the following:

 

   Useful  September 30,   December 31, 
   Life (yrs)  2022   2021 
            
Land     $96,000   $96,000 
Warehouse  30   916,500    916,500 
Leasehold Improvements  3   473,601    473,601 
Machinery and equipment   5-7   1,506,447    1,506,447 
Vehicles  4   149,440    149,440 
Computer equipment and software  3   46,825    46,825 
Office furniture and equipment   3-5   17,294    17,294 
Subtotal      3,206,107    3,206,107 
Less accumulated depreciation and amortization      (929,292)   (625,445)
Total property and equipment, net     $2,276,815   $2,580,662 
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible and Other Assets
9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible and Other Assets

4. Intangible and Other Assets

 

The following table summarizes information related to definite-lived intangible assets:

 

   September 30, 2022   December 31, 2021 
   Gross Carrying Amount   Accumulated Amortization   Net   Gross Carrying Amount   Accumulated Amortization   Net 
                         
Customer relationships  $2,612,649   $(1,220,948)  $1,391,701   $2,612,649   $(796,858)  $1,815,791 
Non-competition agreements   63,176    (36,852)   26,324    63,176    (21,059)   42,117 
Total  $2,675,825   $(1,257,800)  $1,418,025   $2,675,825   $(817,917)  $1,857,908 

 

Other assets included $407,000 at December 31, 2021 for the Company’s option to purchase the 48,000 square foot facility located in Hopkinsville, Kentucky presently leased from Halcyon. Under this agreement, the Company had the option to purchase the facility on or before August 25, 2022, as amended, for a purchase price of $993,000. This agreement was not renewed upon its expiration. Impairment expense totaling $407,000 was recognized in the third quarter of 2022 as a result.

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes Payable – Related Parties
9 Months Ended
Sep. 30, 2022
Notes Payable – Related Parties [Abstract]  
Notes Payable – Related Parties

5. Notes Payable – Related Parties

 

Notes payable – related parties consisted of the following:

 

   September 30,   December 31, 
   2022   2021 
         
Subordinated Promissory Note to CEO  $523,551   $523,551 
Convertible Promissory Note to CEO   1,107,069    410,000 
Secured Promissory Note to Coventry Asset Management, LTD.   1,000,000    1,000,000 
Subordinated Promissory Note to Investor   200,000    250,000 
Promissory Note to Investment Hunter, LLC   492,000    
-
 
Note payable to Director   35,000    
-
 
Total notes payable – related parties  $3,357,620   $2,183,551 

 

Subordinated Promissory Note to CEO – Our CEO made advances to the Company during 2020 under a subordinated promissory note in the amount of $523,551 initially due September 30, 2021. This note was amended to a new maturity date of January 1, 2023. If the Company raises new equity capital of $3 million or more, then the full amount outstanding under the note is due within five days. The note bears interest at 10% per annum. Accrued interest on this subordinated promissory note totaled $46,761 at September 30, 2022.

 

Convertible Promissory Note to CEO – In 2021, our CEO made advances totaling $410,000 to the Company under a convertible promissory note. Additional advances made in 2022 through September 30 totaled $697,069. The convertible note initially matured on January 1, 2022 but was subsequently amended to extend the maturity date to January 1, 2023. If the Company raises new equity capital of $3 million or more, then the full amount outstanding under the note is due within five days. The note bears interest at 10%. The principal and interest due on the convertible note may be converted, at the option of the holder, into restricted shares of the Company’s common stock at an initial conversion price of $0.50 per share but that was lowered in July 2022 to $0.30 per share. Accrued interest on this convertible promissory note totaled $79,493 at September 30, 2022.

 

Secured Promissory Note and Warrants to Coventry Asset Management, LTD. – On December 30, 2020, the Company received proceeds from issuance of a secured promissory note in principal amount of $1,000,000 to Coventry Asset Management, LTD, a Company stockholder. The promissory note is secured by the property acquired in the acquisition of certain assets of Halcyon. The unpaid balance of the secured promissory note bears interest at a rate of 10% per annum and initially matured on June 30, 2021. The promissory note has been extended six times including the issuance of 20,000 restricted common shares as extension fees each for the first five extensions and the issuance of 50,000 restricted common shares for the sixth extension. The maturity date of the promissory note is December 31, 2022, as amended. If before December 31, 2022, the Company raises new equity capital of $5 million or more, then the full amount outstanding under the promissory note is due within five days. As amended, a payment of 25% of the principal balance of the note is due by October 31, 2022. The Company did not make the principal payment due on October 31, 2022 and, as a result, this note is presently in default. If the promissory note is not paid in full by December 31, 2022, the interest rate increases to 14% per annum. Accrued interest on this secured note totaled $175,069 at September 30, 2022.

 

Subordinated Promissory Note and Warrants to Investor – On December 30, 2020, the Company issued a subordinated promissory note in principal amount of $500,000 to an accredited investor who is also a Company stockholder. The unpaid balance of the Subordinated Note bears interest at a rate of 10% per annum. The Company made a principal payment of $250,000 in April 2021. The subordinated note principal together with accrued and unpaid interest was due, as previously amended, on March 31, 2022 but was subsequently extended. As subsequently amended, a payment of $50,000 was made in April 2022 and the remaining principal of $200,000 together with accrued interest was due on June 30, 2022. The Company did not make the principal payment due on June 30, 2022 and, as a result, this note is presently in default. Accrued interest on this subordinated promissory note totaled $36,990 at September 30, 2022.

 

The holder of the subordinated note received a warrant to purchase 500,000 shares of common stock exercisable for cash at an exercise price of $0.352 per share. As consideration for the April 2022 extension, the term of this warrant was extended by one year to December 30, 2023. The Company recognized $68,756 of interest expense in 2022 for this extension of the warrant term.

 

Promissory Note to Investment Hunter, LLC – In 2022, Investment Hunter, LLC, a Texas LLC controlled by our CEO, made advances totaling $492,000 to the Company under a promissory note due January 1, 2023, as amended. If the Company raises new equity capital of $3 million or more, then the full amount outstanding under the note is due within five days. The note bears interest at 10% per annum. Accrued interest on this subordinated promissory note totaled $30,193 at September 30, 2022.

  

Director Notes – In August 2022, the Company received proceeds totaling $105,000 from unsecured notes payable to three members of our board of directors. The notes bear interest at 10% per annum and matured on September 12, 2022. Two of the notes were repaid in September 2022. The remaining note, having an outstanding principal balance of $35,000 at September 30, 2022, was repaid in October 2022.

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other Indebtedness
9 Months Ended
Sep. 30, 2022
Other Indebtedness [Abstract]  
Other Indebtedness

6. Other Indebtedness

 

The Company is obligated under a mortgage payable dated September 15, 2014 secured by its warehouse property located in Denver, Colorado. The note has been amended a number of times to a maturity date of January 15, 2023. In the latest extension, the Company made a principal payment of $73,190 plus accrued interest in October 2022 and agreed to make two additional principal payments of $50,000 plus accrued interest on November 15, 2022 and December 15, 2022. The interest rate on the mortgage payable is 12%. If before the final maturity of the mortgage payable, the Company raises new equity capital of $5 million or more, then the full amount outstanding is due within ten days.

 

The Company leases the Denver warehouse property to a tenant under an operating lease which was renewed with a new tenant and extended to August 1, 2023 for a monthly rent of $7,500. The lease requires a true-up with the tenant for property taxes and insurance paid by the Company and requires the tenant to maintain the interior and exterior of the warehouse (except for the roof). The lease provides for a rent abatement in the first and last month of the contracted extension. Minimum future rents for the remainder of 2022 are $22,500 and for 2023 are $52,500.

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases
9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Leases

7. Leases

 

Office Space – The Company leases office space in Fort Worth, Texas for managerial offices. This lease requires monthly payments of $2,000 and is month-to-month. Lease expense for this facility totaled $6,000 and $18,000 for the three and nine months ended September 30, 2022, respectively. In the three and nine months ended September 30, 2021, lease expense for this facility was $6,000 and $16,000, respectively.

 

Hemp Processing Operating Facility – The Company leases its operating facility in Kentucky from Oz Capital, LLC, a related party, under a lease expiring May 31, 2024. The lease provides for monthly payments of $10,249. Oz Capital, LLC is responsible for all taxes and maintenance under the lease. Lease expense for this facility totaled $30,747 and $92,241 in the three and nine months ended September 30, 2022, respectively. In the three and nine months ended September 30. 2021, lease expense for this facility was $30,747 and $88,604, respectively. A right-of-use asset and lease liability is recorded for this lease. As the lease does not provide an implicit rate, the Company used its estimated incremental borrowing rate of 10% in determining the present value of the lease payments.

 

Future Bitcoin Mining Premises – The Company entered a five-year commercial lease for land and premises in Arkansas. We expect to use these premises as a future Bitcoin mining location because of its favorable power rates and land availability. The lease commences once the Company begins receiving power for its operations conducted at the location. The monthly rent will vary from a minimum of $1,000 per megawatt of power usage monthly up to $4,000 per megawatt monthly depending on the average power usage over a trailing 90-day period. We anticipate commencing operations at the leased premises in the first quarter of 2023.

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies
9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

8. Commitments and Contingencies

 

Litigation – From time to time, we are subject to various litigation and other claims in the normal course of business. Below is a discussion of specific matters. We cannot estimate the ultimate outcome of these matters.

 

Generation Hemp, Inc. v. Colorado Mill Equipment, LLC

 

The Defendant sold to the Company a faulty piece of equipment for $16,000 and will not refund to the Company the purchase price after repeated attempts to return their equipment. An original lawsuit filed by the Company against Colorado Mill Equipment in January 2022 in Dallas County was subsequently dismissed due to jurisdiction. A second lawsuit was filed in El Paso County, Colorado and is currently pending.

 

Halcyon Thruput, LLC, Plaintiff v. United National Insurance Company, Defendant, United States District Court for the Northern District of Texas, Dallas Division, Case No. 3:21-CV-3136-K.

 

Halcyon Thruput, LLC (Halcyon) obtained an all-risks commercial insurance policy, including an Equipment Breakdown Endorsement (Policy) from United National Insurance Company (UNIC) to provide substantial coverages for Halcyon Thruput LLC’s (Halcyon) $1,203,735 hemp processing dryer (Dryer) at its facility in Hopkinsville, Kentucky. During the Policy period, the Dryer caught fire due to the Dryer being defectively designed.

 

While UNIC paid a number of Halcyon’s claims, Halcyon’s claim for the cost of the replacement Dryer of $1,498,848 was denied as described below.

  

Buyer, a wholly owned subsidiary of the Company, pursuant to an Asset Purchase Agreement as twice amended, then acquired all the assets of Halcyon, except for the right to the proceeds of UNIC’s insurance policy since the Policy prohibited assignment. Halcyon and Buyer agreed that Buyer’s principal, Gary C. Evans, had the right to control the litigation, engage counsel for Halcyon and make all decisions relating to any proceeds received in the litigation by settlement or otherwise.

 

Halcyon’s suit against UNIC, which was removed to federal court, seeks $796,865.53 (the cost of the replacement dryer of $1,498,848, less a credit for $583,508.47 previously paid by UNIC to Halcyon for the Dryer fire=$915,339.53) plus statutory interest on that sum from August 10, 2020 for violating the Texas Insurance Code’s requirement that claims be promptly paid, additional statutory penalties, and attorneys’ fees. Certain documents have been executed between the Company, Halcyon and legal counsel, which provide for a sharing of costs and expenses and awards, if any, against UNIC. Mediation of the case was held in April 2022 where no agreement was reached by the parties. Depositions of the Company’s expert witnesses were completed in July 2022 and of UNIC’s representatives in September 2022.

 

In August 2022, the Company received a second payment from UNIC of $357,143 as a partial settlement of this claim.

  

JDONE, LLC v. Grand Traverse Holdings, LLC and John Gallegos, Denver District Court Case No. 2019CV33723

 

JDONE, LLC (“JDONE”), a wholly owned subsidiary of the Company and landlord of a commercial warehouse building in Denver, brought suit against Grand Traverse Holdings, LLC for default of its commercial lease of the warehouse from JDONE. This case settled in October 2022 and the Company received $122,500 from the defendant.

 

KBSIII Tower at Lake Carolyn, LLC and Prime US-Tower at Lake Carolyn, LLC (collectively – “KBSIII” v. Energy Hunter Resources, Inc.)

 

Plaintiff/Counterdefendant KBSIII was seeking lost rent on office space for periods after EHR vacated office premises located in Las Colinas, Texas. EHR filed a counter suit alleging specific damages due to uninhabitable premises of the office space due to the intolerable conduct of other tenants located on the same floor. On December 23, 2020, the trial court entered a summary judgment against EHR for $230,712. The judgment provides for post-judgment interest at a rate of 5% per annum until paid and further provides for additional amounts owed should EHR pursue unsuccessful appeals to higher courts. At September 30, 2022, the Company had accrued $252,583 for this judgment, which is exclusively an EHR obligation.

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes
9 Months Ended
Sep. 30, 2022
Income Taxes [Abstract]  
Income Taxes

9. Income Taxes

 

Income tax provisions for interim quarterly periods are generally based on an estimated annual effective income tax rate calculated separately from the effect of significant, infrequent or unusual items related specifically to interim periods. An income tax benefit for the three or nine months ended September 30, 2022 or 2021 was not recognized because tax losses incurred were fully offset by a valuation allowance against deferred tax assets. There were no uncertain tax positions as of September 30, 2022. The Company is delinquent in filing its 2021 income tax returns.

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity
9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Equity

10. Equity

 

Series A Preferred Stock Our Series A Preferred Stock was originally issued in connection with HTF’s acquisition of EHR in 2019. On September 8, 2021, holders of the Company’s Series A Preferred Stock elected to convert such shares into shares of the Company’s common stock. As a result, 6,328,948 shares of Series A Preferred Stock were converted into 75,947,376 shares of common stock, with each share of Series A Preferred Stock converting into 12 shares of restricted common stock pursuant to the applicable Certificate of Designations.

 

Series B Preferred Stock Units – On December 30, 2020, the Company sold to certain accredited investors, including Gary C. Evans, our Chief Executive Officer, an aggregate of 135 preferred stock units comprised of (i) one share of Series B Redeemable Convertible Preferred Stock, no par value, and (ii) one warrant exercisable for 50,000 shares of common stock of the Company until December 30, 2022 at an exercise price of $0.352 per share.

 

The sale of the preferred stock units for $10,000 each resulted in aggregate gross proceeds of approximately $1.35 million, before deducting estimated offering expenses payable by the Company. Substantially all of the proceeds raised in the offering were used to fund the acquisition of assets of Halcyon, expenses related thereto and for general corporate purposes.

 

Each share of Series B Preferred Stock is initially convertible into 25,000 shares of common stock, subject to adjustment. Holders of Series B Preferred Stock are entitled to receive dividends of 6.00% per annum based on the stated value equal to $10,000 per share. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (b) alter or amend the related certificate of designation, (c) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock, (d) repay, repurchase or offer to repay, repurchase or otherwise acquire more than a de minimis number of shares of its common stock, (e) enter into any agreement with respect to any of the foregoing, or (f) pay cash dividends or distributions on any equity securities of the Company other than pursuant to the terms of the outstanding Series B Preferred Stock. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company.

 

Any or all of the Series B Preferred Stock may be converted, at their holder’s option, into 25,000 shares of common stock, as adjusted for any stock dividends, splits, combinations or similar events.

 

At any time after the occurrence of a “Qualifying Event,” the Company, upon 5-day written notice, shall have the right to cause each share of Series B Preferred Stock (and all accrued in-kind dividends with respect thereto) to be converted into common stock. For purposes of this automatic conversion of the Series B Preferred Stock, a “Qualifying Event” shall have occurred if (A) (1) the rolling five-trading day volume-weighted average trading price of shares of the common stock exceeds $1.00, and (2) there shall be an effective registration statement under the Securities Act of 1933, as amended covering all of the shares of common stock which would be issuable upon conversion of all of the outstanding shares of Series B Preferred Stock or (B) the Company closes a firm commitment underwriting of the common stock on a Form S-1 Registration Statement with aggregate gross proceeds of at least $5,000,000 at a price per share equal to or greater than $1.00. In each instance, a conversion may not be made unless the Company has filed an amendment to its Articles of Incorporation effecting an increase in its authorized common stock so that the Company has a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares.

 

The Series B Preferred Stock may be redeemed by the Company for its stated value, plus accrued and unpaid dividends, at any time. Initially, redemption payments of 12.5% each of the total amount of Series B Preferred Stock then outstanding plus accrued dividends were due from the Company to each Holder of Series B Preferred Stock at the end of each calendar quarter of 2021. The first required redemption payments totaling $137,500 were made in April 2021. In May, June and October of 2021, the three holders of the Series B Preferred Stock, including the Company’s chief executive officer, entered into transactions in which they accepted the mandatory redemption payment required pursuant to the Series B Preferred Stock certificate of designation in a number of Series B Units to effectively waive the redemption requirement. All other terms of the Series B Units remain unchanged and the holders’ ownership interest in the Series B Preferred Units remains the same as it was before such transactions.

 

Common Stock – At September 30, 2022, the Company had 113,204,002 common shares outstanding. Following is a discussion of common stock issuances during the periods presented:

 

  Acquisition of Certain Assets of Halcyon – In January 2021, the Company issued 6,250,000 shares of common stock valued at $2.5 million ($0.40 per share; restricted from trading for a period of up to one year) in the acquisition.

 

  2021 First Quarter Issuances of Common Stock Units – In the first quarter of 2021, the Company issued 800,000 common stock units for total proceeds of $400,000. Each common stock unit consisted of one share of common stock and a warrant for the purchase of two shares of common stock for $0.50 each. Each warrant is exercisable any time before its expiration on the second anniversary of its issuance. The Company allocated the total proceeds based on the relative fair values of the common stock and warrants. The fair value of the warrants was determined using an options valuation model with key assumptions including a risk-free interest rate of 0.11% and historical volatility of 272%. A total of $263,293 was allocated to the warrants and reported in additional paid-in capital.  

 

  Warrant Exercises – In the first quarter of 2021, the Company received $2,967,000 for the exercise of 8,428,976 outstanding warrants. In the fourth quarter of 2021, the Company received $375,000 for the exercise of 1,065,340 outstanding warrants.

 

  Issuances for Exchange or Conversion of Debt – The Company issued a total of 1,618,660 common shares for the exchange or conversion of outstanding debt in the first quarter of 2021.
     
  Issuance to Vendor for Services – In the third quarter of 2021, the Company issued 125,000 common shares to a vendor for services performed.
     
  Issuance for Extension of Secured Note – The Company issued 20,000 common shares as consideration to extend the maturity of a senior note in the third quarter of 2021.
     
  Issuance for Conversion of Series A Preferred Stock – As noted above, in the third quarter of 2021, the Company issued 75,947,376 common shares for the conversion of all outstanding shares of its Series A Preferred Stock.
   
  Stock-based Compensation – The Company issued 500,000 restricted common shares valued at $155,000 as incentive compensation to two executives who joined the Company in the first quarter of 2021.
     
  Issuance for Extensions of Secured Note – The Company issued 110,000 common shares as consideration for extensions of the maturity of a senior note in 2022. Refer to Note 5.

Common Stock Warrants Outstanding – Following is a summary of warrants outstanding as of September 30, 2022:

 

   # of
Warrants
   Exercise
Price (each)
   Expiration Date  Method of
Exercise
               
Issued in December 2020 with Series B preferred units (1)   5,500,000   $      0.352   December 30, 2022  Cash
Issued in December 2020 with subordinated note to investor   500,000   $0.352   December 30, 2022  Cash
Issued in Q1 2021 with common stock units (1)   1,600,000   $0.500   January-February, 2023  Cash
Issued in Q4 2021 with common stock units (1)   958,333   $0.600   October-December, 2023  Cash
Total warrants outstanding at September 30, 2022   8,558,333   $0.407       

 

(1) May be redeemed for $0.0001 per warrant at the Company’s option with 30 days advanced notice should the weighted average market price of common stock exceed $1.00 for any five out of seven consecutive trading days with a minimum average daily trading volume for such seven-day period of at least 25,000 shares of common stock.

 

Following is a summary of outstanding stock warrants activity for the periods presented:

 

       Weighted 
       Average 
   # of
Warrants
   Exercise
Price
 
         
Warrants as of December 31, 2021   8,808,333   $0.407 
Canceled   (250,000)  $0.400 
Warrants as of September 30, 2022   8,558,333   $0.407 
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation
9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

11. Stock-Based Compensation

 

We award restricted stock or stock options as incentive compensation to employees and compensation to our Board of Directors for services. Generally, these awards include vesting periods of up to three years from the date of grant.

 

The 2021 Omnibus Incentive Plan (“2021 Plan”) was adopted by our Board on July 1, 2021. The 2021 Plan provides for the initial reservation of 15 million shares of common stock for issuance, and provides that the maximum number of shares that may be issued pursuant to the exercise of ISOs is 15 million. On the one-year anniversary date of the 2021 Plan, the number of shares of common stock reserved for issuance automatically increased to 20% of the fully diluted common shares outstanding, including shares issuable upon the conversion of preferred shares, as calculated on an as-converted basis.

 

In the first quarter of 2021, the Company issued 500,000 restricted shares valued at $155,000 as incentive compensation to two executives who joined the Company. Compensation expense related to these awards totaled $38,750 and $81,000 for the three and six months ended June 30, 2021, respectively. These awards became fully vested in January 2022.

 

In the fourth quarter of 2021, the Company awarded options for 13,850,000 shares of the Company’s common stock as incentive compensation to management and the Board of Directors. One-third of the awarded options vested immediately with the remaining options vesting in two equal annual tranches over the next two years. Vested options may be exercised at any time until their expiration after 10 years at an exercise price of $0.76 per share. Unvested options are forfeited upon termination of service. The fair value of the awards at the date of grant was determined using the Black-Scholes option pricing model. Key assumptions included a risk-free interest rate ranging from 1.18% to 1.28%, historical volatility ranging from 331% to 643% and an expected life of the stock options ranging from five to six years.

 

In the third quarter of 2022, the Company awarded options for 1,915,000 shares of the Company’s common stock as incentive compensation to its CEO and board of directors. The awarded options vest over the next three years. Vested options may be exercised at any time until their expiration ranging from eight to 10 years at their exercise prices ranging from $0.30 to $0.33 per share. Unvested options are forfeited upon termination of service. The fair value of the awards at the date of grant was determined using the Black-Scholes option pricing model. Key assumptions included a risk-free interest rate ranging from 2.87% to 3.03%, historical volatility ranging from 251% to 408% and an expected life of the stock options ranging from four to seven years.

 

We recognized $1.3 million of compensation expense for these option awards in each of the quarters ended September 30, 2022. As of September 30, 2022, there was $2.7 million of total unrecognized compensation cost related to options to be recognized over a remaining weighted average period of 21 months.

 

The following table summarizes options outstanding, as well as activity for the periods presented:

 

   Shares   Weighted
Average
Grant Date
Fair Value
   Weighted
Average
Exercise
Price
   Aggregate
Intrinsic
Value
 
                 
Outstanding at December 31, 2021   13,850,000   $0.76   $0.76    
         -
 
Granted   1,915,000   $0.30   $0.31    
-
 
Outstanding at September 30, 2022   15,765,000   $0.70   $0.71    
-
 

 

The remaining weighted average contractual life of exercisable options at September 30, 2022 was nine years.

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Discontinued Operations
9 Months Ended
Sep. 30, 2022
Discontinued Operations [Abstract]  
Discontinued Operations

12. Discontinued Operations

 

In 2019, management determined to fully divest of EHR’s oil and gas activities. As such, these activities are presented as discontinued operations for each of the periods presented. The following is a summary of the carrying amounts of major classes of assets and liabilities of the discontinued operations to assets and liabilities held for sale:

 

   September 30,   December 31, 
   2022   2021 
Assets:        
Oil and natural gas properties held for sale, at cost  $1,874,849   $1,874,849 
Accumulated DD&A   (1,874,849)   (1,874,849)
Total assets of discontinued operations held for sale  $
-
   $
-
 
           
Liabilities:          
Accrued liabilities  $39,956   $48,997 
Asset retirement obligations   52,368    52,368 
Revenue payable   52,117    52,117 
Current liabilities of discontinued operations held for sale   144,441    153,482 
Asset retirement obligations -          
Long-term liabilities of discontinued operations held for sale   199,046    162,948 
Total liabilities of discontinued operations held for sale  $343,487   $316,430 

 

The following is a summary of the major classes of line items constituting loss on discontinued operations shown in the consolidated statements of operations:

 

   For the three months ended
September 30,
   For the nine months ended
September 30,
 
   2022   2021   2022   2021 
Revenue -                
Oil and gas sales  $41,077   $55,140   $116,870   $93,248 
                     
Costs and Expenses:                    
Lease operating expense   25,461    53,919    110,649    94,714 
Accretion   5,230    2,851    36,098    9,883 
Total costs and expenses   30,691    56,770    146,747    104,597 
                     
Loss from discontinued operations  $10,386   $(1,630)  $(29,877)  $(11,349)
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Supplemental Cash Flow Information
9 Months Ended
Sep. 30, 2022
Supplemental Cash Flow Information [Abstract]  
Supplemental Cash Flow Information

13. Supplemental Cash Flow Information

 

   For the nine months ended
September 30,
 
   2022   2021 
         
Cash paid for interest  $50,690   $127,812 
Cash paid for taxes   
-
    
-
 
           
Noncash investing and financing activities:          
Acquisition of certain assets of Halcyon Thruput, LLC          
- issuance of common shares   
-
    2,500,000 
- issuance of subordinated note   
-
    850,000 
- assumption of Halcyon bank note   
-
    995,614 
Series B preferred stock dividend payable   60,035    39,137 
Issuance of common stock units previously subscribed   
-
    50,000 
Issuances of common shares for exchange or conversion of debt   
-
    2,160,269 
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings (Loss) Per Share
9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Earnings (Loss) per Share

14. Earnings (Loss) per Share

 

The following is the computation of earnings (loss) per basic and diluted share:

 

   For the three months ended
September 30,
   For the nine months ended
September 30,
 
   2022   2021   2022   2021 
Amounts attributable to Generation Hemp:                
Numerator                
Loss from continuing operations attributable to common stockholders  $(1,465,404)  $(1,376,030)  $(6,017,867)  $(4,356,315)
Income (loss) from discontinued operations   9,736    (1,528)   (28,007)   (10,639)
Less: preferred stock dividends   (19,668)   (16,125)   (60,035)   (56,625)
Net loss attributable to common stockholders  $(1,475,336)  $(1,393,683)  $(6,105,909)  $(4,423,579)
                     
Denominator                    
Weighted average shares used to compute basic EPS   113,204,002    54,109,797    113,149,973    38,693,679 
Dilutive effect of convertible note   1,164,773    
-
    1,164,773    
-
 
Dilutive effect of preferred stock   2,950,000    59,913,657    2,950,000    72,641,084 
Dilutive effect of common stock options   125,490    
-
    122,052    
-
 
Dilutive effect of common stock warrants   47,560    9,042,419    1,709,576    11,126,327 
Weighted average shares used to compute diluted EPS   117,491,825    123,065,873    119,096,374    122,461,090 
                     
Earnings (loss) per share:                    
Loss from continuing operations                    
Basic  $(0.01)  $(0.03)  $(0.05)  $(0.11)
Diluted  $(0.01)  $(0.03)  $(0.05)  $(0.11)
Loss from discontinued operations                    
Basic  $
-
   $
-
   $
-
   $
-
 
Diluted  $
-
   $
-
   $
-
   $
-
 
Earnings (loss) per share                    
Basic  $(0.01)  $(0.03)  $(0.05)  $(0.11)
Diluted  $(0.01)  $(0.03)  $(0.05)  $(0.11)

 

The computation of diluted earnings per common share excludes the assumed conversion of the Series B Preferred Stock and outstanding convertible notes and exercise of common stock options and warrants in periods when we report a loss. The dilutive effect of the assumed exercise of outstanding options and warrants was calculated using the treasury stock method.

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accounting Policies, by Policy (Policies)
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation – These interim financial statements are unaudited and have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain disclosures have been condensed or omitted from these financial statements. Accordingly, they do not include all the information and notes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements, and should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021.

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, necessary to fairly present the financial position as of, and the results of operations for, all periods presented. In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the condensed consolidated financial statements and disclosures of contingencies. Actual results may differ from those estimates. The results for interim periods are not necessarily indicative of annual results. Certain reclassifications have been made to the prior period’s consolidated financial statements and related footnotes to conform them to the current period presentation. Intercompany balances and transactions between consolidated entities are eliminated.

 

Fair Value Measurement

Fair Value Measurement – Our financial assets and liabilities consist of cash, accounts receivable, accounts payable and indebtedness. The fair values of these instruments approximate their carrying amounts at each reporting date.

 

Deferred Revenue

Deferred Revenue – In July 2022, the Company entered into an agreement for the sale of 66,782 pounds of dried hemp biomass from its inventories on-hand for a sales price of $1.50 per pound. Deliveries and payment of the $100,173 sales proceeds are scheduled monthly through December 2022 and are reported as deferred revenue in the consolidated balance sheets. We expect to recognize revenue for these amounts when the contract is completed and product is shipped in the fourth quarter of 2022.

 

Major Customer and Concentration of Credit Risk

Major Customer and Concentration of Credit Risk – We estimate an allowance for doubtful accounts based on an analysis of specific customers, taking into consideration the age of past due accounts and an assessment of the customer’s ability to pay. An allowance for doubtful accounts was not needed as of September 30, 2022 or December 31, 2021.

 

During the three and nine months ended September 30, 2022, one customer accounted for all of our post-harvest and midstream services revenue. A total of $656,344 was outstanding from this customer as a receivable at September 30, 2022.

 

Our rental revenue is derived from a single lessee on a commercial warehouse owned by the Company. There were no amounts due from this customer at September 30, 2022 or December 31, 2021.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements – There are no other new accounting pronouncements that are expected to have a material impact on the consolidated financial statements.

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment (Tables)
9 Months Ended
Sep. 30, 2022
Property and Equipment [Abstract]  
Schedule of property and equipment
   Useful  September 30,   December 31, 
   Life (yrs)  2022   2021 
            
Land     $96,000   $96,000 
Warehouse  30   916,500    916,500 
Leasehold Improvements  3   473,601    473,601 
Machinery and equipment   5-7   1,506,447    1,506,447 
Vehicles  4   149,440    149,440 
Computer equipment and software  3   46,825    46,825 
Office furniture and equipment   3-5   17,294    17,294 
Subtotal      3,206,107    3,206,107 
Less accumulated depreciation and amortization      (929,292)   (625,445)
Total property and equipment, net     $2,276,815   $2,580,662 
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible and Other Assets (Tables)
9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangible asset
   September 30, 2022   December 31, 2021 
   Gross Carrying Amount   Accumulated Amortization   Net   Gross Carrying Amount   Accumulated Amortization   Net 
                         
Customer relationships  $2,612,649   $(1,220,948)  $1,391,701   $2,612,649   $(796,858)  $1,815,791 
Non-competition agreements   63,176    (36,852)   26,324    63,176    (21,059)   42,117 
Total  $2,675,825   $(1,257,800)  $1,418,025   $2,675,825   $(817,917)  $1,857,908 

 

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes Payable – Related Parties (Tables)
9 Months Ended
Sep. 30, 2022
Notes Payable – Related Parties [Abstract]  
Schedule of notes payable – related parties
   September 30,   December 31, 
   2022   2021 
         
Subordinated Promissory Note to CEO  $523,551   $523,551 
Convertible Promissory Note to CEO   1,107,069    410,000 
Secured Promissory Note to Coventry Asset Management, LTD.   1,000,000    1,000,000 
Subordinated Promissory Note to Investor   200,000    250,000 
Promissory Note to Investment Hunter, LLC   492,000    
-
 
Note payable to Director   35,000    
-
 
Total notes payable – related parties  $3,357,620   $2,183,551 

 

XML 38 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity (Tables)
9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Schedule of warrants outstanding
   # of
Warrants
   Exercise
Price (each)
   Expiration Date  Method of
Exercise
               
Issued in December 2020 with Series B preferred units (1)   5,500,000   $      0.352   December 30, 2022  Cash
Issued in December 2020 with subordinated note to investor   500,000   $0.352   December 30, 2022  Cash
Issued in Q1 2021 with common stock units (1)   1,600,000   $0.500   January-February, 2023  Cash
Issued in Q4 2021 with common stock units (1)   958,333   $0.600   October-December, 2023  Cash
Total warrants outstanding at September 30, 2022   8,558,333   $0.407       

 

(1) May be redeemed for $0.0001 per warrant at the Company’s option with 30 days advanced notice should the weighted average market price of common stock exceed $1.00 for any five out of seven consecutive trading days with a minimum average daily trading volume for such seven-day period of at least 25,000 shares of common stock.

 

Schedule of outstanding stock warrants activity
       Weighted 
       Average 
   # of
Warrants
   Exercise
Price
 
         
Warrants as of December 31, 2021   8,808,333   $0.407 
Canceled   (250,000)  $0.400 
Warrants as of September 30, 2022   8,558,333   $0.407 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of summarizes options outstanding
   Shares   Weighted
Average
Grant Date
Fair Value
   Weighted
Average
Exercise
Price
   Aggregate
Intrinsic
Value
 
                 
Outstanding at December 31, 2021   13,850,000   $0.76   $0.76    
         -
 
Granted   1,915,000   $0.30   $0.31    
-
 
Outstanding at September 30, 2022   15,765,000   $0.70   $0.71    
-
 

 

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Discontinued Operations (Tables)
9 Months Ended
Sep. 30, 2022
Discontinued Operations [Abstract]  
Schedule of discontinued operations to assets and liabilities held for sale
   September 30,   December 31, 
   2022   2021 
Assets:        
Oil and natural gas properties held for sale, at cost  $1,874,849   $1,874,849 
Accumulated DD&A   (1,874,849)   (1,874,849)
Total assets of discontinued operations held for sale  $
-
   $
-
 
           
Liabilities:          
Accrued liabilities  $39,956   $48,997 
Asset retirement obligations   52,368    52,368 
Revenue payable   52,117    52,117 
Current liabilities of discontinued operations held for sale   144,441    153,482 
Asset retirement obligations -          
Long-term liabilities of discontinued operations held for sale   199,046    162,948 
Total liabilities of discontinued operations held for sale  $343,487   $316,430 

 

Schedule of discontinued operations shown in the consolidated statements of operations
   For the three months ended
September 30,
   For the nine months ended
September 30,
 
   2022   2021   2022   2021 
Revenue -                
Oil and gas sales  $41,077   $55,140   $116,870   $93,248 
                     
Costs and Expenses:                    
Lease operating expense   25,461    53,919    110,649    94,714 
Accretion   5,230    2,851    36,098    9,883 
Total costs and expenses   30,691    56,770    146,747    104,597 
                     
Loss from discontinued operations  $10,386   $(1,630)  $(29,877)  $(11,349)
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Supplemental Cash Flow Information (Tables)
9 Months Ended
Sep. 30, 2022
Supplemental Cash Flow Information [Abstract]  
Schedule of supplemental cash flow information
   For the nine months ended
September 30,
 
   2022   2021 
         
Cash paid for interest  $50,690   $127,812 
Cash paid for taxes   
-
    
-
 
           
Noncash investing and financing activities:          
Acquisition of certain assets of Halcyon Thruput, LLC          
- issuance of common shares   
-
    2,500,000 
- issuance of subordinated note   
-
    850,000 
- assumption of Halcyon bank note   
-
    995,614 
Series B preferred stock dividend payable   60,035    39,137 
Issuance of common stock units previously subscribed   
-
    50,000 
Issuances of common shares for exchange or conversion of debt   
-
    2,160,269 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings (Loss) Per Share (Tables)
9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Schedule of earnings (loss) per basic and diluted share
   For the three months ended
September 30,
   For the nine months ended
September 30,
 
   2022   2021   2022   2021 
Amounts attributable to Generation Hemp:                
Numerator                
Loss from continuing operations attributable to common stockholders  $(1,465,404)  $(1,376,030)  $(6,017,867)  $(4,356,315)
Income (loss) from discontinued operations   9,736    (1,528)   (28,007)   (10,639)
Less: preferred stock dividends   (19,668)   (16,125)   (60,035)   (56,625)
Net loss attributable to common stockholders  $(1,475,336)  $(1,393,683)  $(6,105,909)  $(4,423,579)
                     
Denominator                    
Weighted average shares used to compute basic EPS   113,204,002    54,109,797    113,149,973    38,693,679 
Dilutive effect of convertible note   1,164,773    
-
    1,164,773    
-
 
Dilutive effect of preferred stock   2,950,000    59,913,657    2,950,000    72,641,084 
Dilutive effect of common stock options   125,490    
-
    122,052    
-
 
Dilutive effect of common stock warrants   47,560    9,042,419    1,709,576    11,126,327 
Weighted average shares used to compute diluted EPS   117,491,825    123,065,873    119,096,374    122,461,090 
                     
Earnings (loss) per share:                    
Loss from continuing operations                    
Basic  $(0.01)  $(0.03)  $(0.05)  $(0.11)
Diluted  $(0.01)  $(0.03)  $(0.05)  $(0.11)
Loss from discontinued operations                    
Basic  $
-
   $
-
   $
-
   $
-
 
Diluted  $
-
   $
-
   $
-
   $
-
 
Earnings (loss) per share                    
Basic  $(0.01)  $(0.03)  $(0.05)  $(0.11)
Diluted  $(0.01)  $(0.03)  $(0.05)  $(0.11)

 

XML 43 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business (Details)
$ in Millions
1 Months Ended 9 Months Ended
Jan. 11, 2021
$ / ft²
Nov. 27, 2019
Sep. 30, 2022
USD ($)
Business (Details) [Line Items]      
Square Foot Facility (in Dollars per Square Foot) | $ / ft² 48,000    
Cash for its operating activities     $ 1.0
Financing obligations     6.1
Current Assets     $ 1.0
Description of business, description     As of September 30, 2022, EHR held an approximate 8% working interest in an oil & gas property located in Cochran County, Texas within the Slaughter-Levelland Field of the San Andres formation in the Northwest Shelf of West Texas. EHR’s oil & gas activities are currently held for sale and are presented in these consolidated financial statements as discontinued operations for each of the periods presented. 
Financing obligations terms     1 year
Energy Hunter Resources, Inc. [Member]      
Business (Details) [Line Items]      
Percentage of common stock   94.00%  
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Details) - USD ($)
1 Months Ended 9 Months Ended
Jul. 31, 2022
Sep. 30, 2022
Accounting Policies [Abstract]    
Sale of pounds $ 66,782  
Sale price per pound (in Dollars per share) $ 1.5  
Deliveries and payment amount $ 100,173  
Outstanding amount   $ 656,344
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment (Details) - Schedule of property and equipment - USD ($)
9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Subtotal $ 3,206,107 $ 3,206,107
Total property and equipment, net 2,276,815 2,580,662
Land [Member]    
Property, Plant and Equipment [Line Items]    
Subtotal $ 96,000 96,000
Warehouse [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, useful Life (years) 30 years  
Subtotal $ 916,500 916,500
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, useful Life (years) 3 years  
Subtotal $ 473,601 473,601
Machinery and equipment [Member]    
Property, Plant and Equipment [Line Items]    
Subtotal $ 1,506,447 1,506,447
Machinery and equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, useful Life (years) 5 years  
Machinery and equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, useful Life (years) 7 years  
Vehicles [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, useful Life (years) 4 years  
Subtotal $ 149,440 149,440
Computer equipment and software [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, useful Life (years) 3 years  
Subtotal $ 46,825 $ 46,825
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible and Other Assets (Details) - USD ($)
9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
Other assets   $ 407,000
Option to purchase, description the Company’s option to purchase the 48,000 square foot facility located in Hopkinsville, Kentucky presently leased from Halcyon. Under this agreement, the Company had the option to purchase the facility on or before August 25, 2022, as amended, for a purchase price of $993,000.  
Impairment expense $ 407,000  
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible and Other Assets (Details) - Schedule of intangible asset - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 2,675,825 $ 2,675,825
Accumulated Amortization (1,257,800) (817,917)
Net 1,418,025 1,857,908
Customer relationships [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 2,612,649 2,612,649
Accumulated Amortization (1,220,948) (796,858)
Net 1,391,701 1,815,791
Non-competition agreements [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 63,176 63,176
Accumulated Amortization (36,852) (21,059)
Net $ 26,324 $ 42,117
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes Payable – Related Parties (Details) - USD ($)
1 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 30, 2022
Aug. 31, 2022
Dec. 30, 2020
Sep. 30, 2022
Dec. 31, 2021
Dec. 31, 2020
Jul. 31, 2022
Apr. 30, 2021
Notes Payable – Related Parties (Details) [Line Items]                  
Convertible note matured, description         The convertible note initially matured on January 1, 2022 but was subsequently amended to extend the maturity date to January 1, 2023.        
Conversion price per share (in Dollars per share)               $ 0.3  
Restricted common shares (in Shares)       50,000          
Accrued interest         $ 36,990        
Warrant to purchase shares of common stock (in Shares)         500,000        
Exercise price per share (in Dollars per share)         $ 0.352        
Warrant term         1 year        
Extension date         Dec. 30, 2023        
Interest expense         $ 68,756        
Description of director notes     In August 2022, the Company received proceeds totaling $105,000 from unsecured notes payable to three members of our board of directors. The notes bear interest at 10% per annum and matured on September 12, 2022. Two of the notes were repaid in September 2022. The remaining note, having an outstanding principal balance of $35,000 at September 30, 2022, was repaid in October 2022.            
Subordinated Promissory Note to CEO [Member]                  
Notes Payable – Related Parties (Details) [Line Items]                  
Subordinated promissory note amount             $ 523,551    
Subordinated promissory note due date         Sep. 30, 2021        
New maturity date         Jan. 01, 2023        
New equity capital         $ 3,000,000        
Bears interest rate         10.00%        
Accrued interest         $ 46,761        
Convertible Promissory Note to CEO [Member]                  
Notes Payable – Related Parties (Details) [Line Items]                  
New equity capital         $ 3,000,000        
Bears interest rate         10.00%        
Accrued interest         $ 79,493        
Advances totaling           $ 410,000      
Additional advances         $ 697,069        
Conversion price per share (in Dollars per share)         $ 0.5        
Secured Promissory Note and Warrants to Coventry Asset Management, LTD. [Member]                  
Notes Payable – Related Parties (Details) [Line Items]                  
Bears interest rate       10.00%          
Principal amount       $ 1,000,000          
Maturity date       Jun. 30, 2021          
Restricted common shares (in Shares)       20,000          
Interest rate percentage         25.00%        
Due date         Oct. 31, 2022        
Accrued interest         $ 175,069        
Secured Promissory Note and Warrants to Coventry Asset Management, LTD. [Member] | Forecast [Member]                  
Notes Payable – Related Parties (Details) [Line Items]                  
New equity capital   $ 5,000,000              
Interest rate increases 14%                
Secured Promissory Note and Warrants to Coventry Asset Management, LTD. [Member] | Promissory Note [Member]                  
Notes Payable – Related Parties (Details) [Line Items]                  
Maturity date       Dec. 31, 2022          
Subordinated Promissory Note and Warrants to Investor [Member]                  
Notes Payable – Related Parties (Details) [Line Items]                  
Convertible note matured, description         As subsequently amended, a payment of $50,000 was made in April 2022 and the remaining principal of $200,000 together with accrued interest was due on June 30, 2022.        
Principal amount       $ 500,000         $ 250,000
Interest rate, percentage       10.00%          
Promissory Note to Investment Hunter, LLC [Member]                  
Notes Payable – Related Parties (Details) [Line Items]                  
Bears interest rate         10.00%        
Advances totaling         $ 492,000        
New equity capital         $ 3,000,000        
Due date         Jan. 01, 2023        
Accrued interest         $ 30,193        
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes Payable – Related Parties (Details) - Schedule of notes payable – related parties - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Notes Payable – Related Parties (Details) - Schedule of notes payable – related parties [Line Items]    
Total notes payable – related parties $ 3,357,620 $ 2,183,551
Subordinated Promissory Note to CEO [Member]    
Notes Payable – Related Parties (Details) - Schedule of notes payable – related parties [Line Items]    
Total 523,551 523,551
Convertible Promissory Note to CEO [Member]    
Notes Payable – Related Parties (Details) - Schedule of notes payable – related parties [Line Items]    
Total 1,107,069 410,000
Secured Promissory Note to Coventry Asset Management, LTD. [Member]    
Notes Payable – Related Parties (Details) - Schedule of notes payable – related parties [Line Items]    
Total 1,000,000 1,000,000
Subordinated Promissory Note to Investor [Member]    
Notes Payable – Related Parties (Details) - Schedule of notes payable – related parties [Line Items]    
Total 200,000 250,000
Promissory Note to Investment Hunter, LLC [Member]    
Notes Payable – Related Parties (Details) - Schedule of notes payable – related parties [Line Items]    
Total 492,000
Note payable to Director [Member]    
Notes Payable – Related Parties (Details) - Schedule of notes payable – related parties [Line Items]    
Total $ 35,000
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other Indebtedness (Details)
9 Months Ended
Sep. 30, 2022
USD ($)
Other Indebtedness [Abstract]  
Mortgage payable, description The note has been amended a number of times to a maturity date of January 15, 2023. In the latest extension, the Company made a principal payment of $73,190 plus accrued interest in October 2022 and agreed to make two additional principal payments of $50,000 plus accrued interest on November 15, 2022 and December 15, 2022.
Interest rate 12.00%
Interest expenses $ 5,000,000
Lease and rental expense 7,500
Minimum future of remainder of 2022 22,500
Minimum future of remainder of 2023 $ 52,500
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Leases (Details) [Line Items]        
Lease payment     $ 2,000  
Lease expense $ 6,000 $ 6,000 $ 18,000 $ 16,000
Borrowing rate percentage     10.00%  
Minimum [Member]        
Leases (Details) [Line Items]        
Monthly rent     $ 1,000  
Maximum [Member]        
Leases (Details) [Line Items]        
Monthly rent     4,000  
Oz Capital, LLC [Member]        
Leases (Details) [Line Items]        
Lease payment     10,249  
Lease expense $ 30,747 $ 30,747 $ 92,241 $ 88,604
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies (Details) - USD ($)
1 Months Ended 9 Months Ended
Dec. 23, 2020
Sep. 30, 2022
Oct. 31, 2022
Dec. 31, 2018
Commitments and Contingencies (Details) [Line Items]        
Purchase price of equipment   $ 16,000    
Insurance claim for replacement   $ 1,498,848    
Description of suit against UNIC   Halcyon’s suit against UNIC, which was removed to federal court, seeks $796,865.53 (the cost of the replacement dryer of $1,498,848, less a credit for $583,508.47 previously paid by UNIC to Halcyon for the Dryer fire=$915,339.53) plus statutory interest on that sum from August 10, 2020 for violating the Texas Insurance Code’s requirement that claims be promptly paid, additional statutory penalties, and attorneys’ fees. Certain documents have been executed between the Company, Halcyon and legal counsel, which provide for a sharing of costs and expenses and awards, if any, against UNIC.    
Partial settlement claim       $ 357,143
Amount of summary judgment $ 230,712      
Litigation settlement interest percentage 5.00%      
Amount accrued for judgment   $ 252,583    
Halcyon Thruput LLC’s [Member]        
Commitments and Contingencies (Details) [Line Items]        
Substantial coverages   $ 1,203,735    
Grand Traverse Holdings, LLC [Member] | Subsequent Event [Member]        
Commitments and Contingencies (Details) [Line Items]        
Amount received from defendant     $ 122,500  
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity (Details) - USD ($)
1 Months Ended 9 Months Ended
Dec. 30, 2020
Sep. 30, 2022
Jul. 31, 2022
Sep. 08, 2021
Apr. 30, 2021
Equity (Details) [Line Items]          
Converted into shares of common stock   25,000      
Sale of preferred stock units (in Dollars)   $ 10,000      
Aggregate gross proceeds (in Dollars)   $ 1,350,000      
Price per share (in Dollars per share)   $ 1      
Redemption payments percentage   12.50%      
Redemption payments total (in Dollars)         $ 137,500
Warrant per share (in Dollars per share)     $ 1.5    
Weighted average market price of common stock exceed (in Dollars per share)   $ 1      
Shares of Common stock   25,000      
Common Stock [Member]          
Equity (Details) [Line Items]          
Equity, description   At September 30, 2022, the Company had 113,204,002 common shares outstanding. Following is a discussion of common stock issuances during the periods presented:   ● Acquisition of Certain Assets of Halcyon – In January 2021, the Company issued 6,250,000 shares of common stock valued at $2.5 million ($0.40 per share; restricted from trading for a period of up to one year) in the acquisition.     ● 2021 First Quarter Issuances of Common Stock Units – In the first quarter of 2021, the Company issued 800,000 common stock units for total proceeds of $400,000. Each common stock unit consisted of one share of common stock and a warrant for the purchase of two shares of common stock for $0.50 each. Each warrant is exercisable any time before its expiration on the second anniversary of its issuance. The Company allocated the total proceeds based on the relative fair values of the common stock and warrants. The fair value of the warrants was determined using an options valuation model with key assumptions including a risk-free interest rate of 0.11% and historical volatility of 272%. A total of $263,293 was allocated to the warrants and reported in additional paid-in capital.       ● Warrant Exercises – In the first quarter of 2021, the Company received $2,967,000 for the exercise of 8,428,976 outstanding warrants. In the fourth quarter of 2021, the Company received $375,000 for the exercise of 1,065,340 outstanding warrants.     ● Issuances for Exchange or Conversion of Debt – The Company issued a total of 1,618,660 common shares for the exchange or conversion of outstanding debt in the first quarter of 2021.         ● Issuance to Vendor for Services – In the third quarter of 2021, the Company issued 125,000 common shares to a vendor for services performed.         ● Issuance for Extension of Secured Note – The Company issued 20,000 common shares as consideration to extend the maturity of a senior note in the third quarter of 2021.         ● Issuance for Conversion of Series A Preferred Stock – As noted above, in the third quarter of 2021, the Company issued 75,947,376 common shares for the conversion of all outstanding shares of its Series A Preferred Stock.       ● Stock-based Compensation – The Company issued 500,000 restricted common shares valued at $155,000 as incentive compensation to two executives who joined the Company in the first quarter of 2021.         ● Issuance for Extensions of Secured Note – The Company issued 110,000 common shares as consideration for extensions of the maturity of a senior note in 2022. Refer to Note 5.      
Aggregate gross proceeds (in Dollars)   $ 5,000,000      
Price per share (in Dollars per share)   $ 1      
Warrant [Member]          
Equity (Details) [Line Items]          
Warrant per share (in Dollars per share)   $ 0.0001      
Series A Preferred Stock [Member]          
Equity (Details) [Line Items]          
Shares of preferred stock       6,328,948  
Converted into shares of common stock       75,947,376  
Converting into shares of restricted common stock       12  
Series B Preferred Stock [Member]          
Equity (Details) [Line Items]          
Converted into shares of common stock   25,000      
Equity, description On December 30, 2020, the Company sold to certain accredited investors, including Gary C. Evans, our Chief Executive Officer, an aggregate of 135 preferred stock units comprised of (i) one share of Series B Redeemable Convertible Preferred Stock, no par value, and (ii) one warrant exercisable for 50,000 shares of common stock of the Company until December 30, 2022 at an exercise price of $0.352 per share.        
Dividends percentage   6.00%      
Stated value per share (in Dollars)   $ 10,000      
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity (Details) - Schedule of warrants outstanding
9 Months Ended
Sep. 30, 2022
$ / shares
shares
Equity (Details) - Schedule of warrants outstanding [Line Items]  
Number of Warrants | shares 8,558,333
Exercise Price (each) | $ / shares $ 0.407
Issued in December 2020 [Member] | Series B preferred units [Member]  
Equity (Details) - Schedule of warrants outstanding [Line Items]  
Number of Warrants | shares 5,500,000 [1]
Exercise Price (each) | $ / shares $ 0.352 [1]
Expiration Date December 30, 2022 [1]
Method of Exercise Cash [1]
Issued in December 2020 [Member] | Subordinated note to investor [Member]  
Equity (Details) - Schedule of warrants outstanding [Line Items]  
Number of Warrants | shares 500,000
Exercise Price (each) | $ / shares $ 0.352
Expiration Date December 30, 2022
Method of Exercise Cash
Issued in Q1 2021 [Member] | Common stock units [Member]  
Equity (Details) - Schedule of warrants outstanding [Line Items]  
Number of Warrants | shares 1,600,000 [1]
Exercise Price (each) | $ / shares $ 0.5 [1]
Expiration Date January-February, 2023 [1]
Method of Exercise Cash [1]
Issued in Q4 2021 [Member] | Common stock units [Member]  
Equity (Details) - Schedule of warrants outstanding [Line Items]  
Number of Warrants | shares 958,333 [1]
Exercise Price (each) | $ / shares $ 0.6 [1]
Expiration Date October-December, 2023 [1]
Method of Exercise Cash [1]
[1] May be redeemed for $0.0001 per warrant at the Company’s option with 30 days advanced notice should the weighted average market price of common stock exceed $1.00 for any five out of seven consecutive trading days with a minimum average daily trading volume for such seven-day period of at least 25,000 shares of common stock.
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity (Details) - Schedule of outstanding stock warrants activity
9 Months Ended
Sep. 30, 2022
$ / shares
shares
Schedule Of Outstanding Stock Warrants Activity Abstract  
Number of Warrants, Warrants beginning | shares 8,808,333
Weighted Average Exercise Price, Warrants beginning | $ / shares $ 0.407
Number of Warrants, Warrants cancelled | shares (250,000)
Weighted Average Exercise Price, Cancelled | $ / shares $ 0.4
Number of Warrants, Warrants ending | shares 8,558,333
Weighted Average Exercise Price, Warrants ending | $ / shares $ 0.407
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation (Details) - USD ($)
3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2021
Sep. 30, 2022
Dec. 31, 2021
Stock-Based Compensation (Details) [Line Items]              
Diluted common shares outstanding percentage             20.00%
Compensation expense related to awards     $ 38,750   $ 81,000    
Common stock incentive compensation 1,915,000 13,850,000          
Weighted average contractual life   10 years       9 years  
Exercise price per share   0.76         0.76
Compensation expense           1,300,000  
Total unrecognized compensation cost           $ 2,700,000  
Awarded options vest over year 3 years            
Minimum [Member]              
Stock-Based Compensation (Details) [Line Items]              
Weighted average contractual life 8 years            
Exercise price per share 0.3         0.3  
Risk free interest rate 2.87% 1.18%          
Volatility ranging 251.00% 331.00%          
Stock options range 4 years 5 years          
Maximum [Member]              
Stock-Based Compensation (Details) [Line Items]              
Weighted average contractual life 10 years            
Exercise price per share 0.33         0.33  
Risk free interest rate 3.03%            
Risk free interest rate   1.28%          
Volatility ranging 408.00% 643.00%          
Stock options range 7 years 6 years          
2021 Plan [Member]              
Stock-Based Compensation (Details) [Line Items]              
common stock for issuance             15,000,000
Number of shares             15,000,000
Restricted Stock [Member]              
Stock-Based Compensation (Details) [Line Items]              
Restricted shares, issued       500,000      
Restricted shares, value       $ 155,000      
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation (Details) - Schedule of summarizes options outstanding
9 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Schedule Of Summarizes Options Outstanding Abstract  
Shares Beginning (in Shares) | shares 13,850,000
Weighted Average Grant Date Fair Value Beginning $ 0.76
Weighted Average Exercise Price Beginning $ 0.76
Aggregate Intrinsic Value Beginning (in Dollars) | $
Shares Granted (in Shares) | shares 1,915,000
Weighted Average Grant Date Fair Value Granted $ 0.3
Weighted Average Exercise Price Granted $ 0.31
Aggregate Intrinsic Value Granted (in Dollars) | $
Shares Ending (in Shares) | shares 15,765,000
Weighted Average Grant Date Fair Value Ending $ 0.7
Weighted Average Exercise Price Ending $ 0.71
Aggregate Intrinsic Value Ending (in Dollars) | $
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Discontinued Operations (Details) - Schedule of discontinued operations to assets and liabilities held for sale - Discontinued Operations [Member] - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Assets:    
Oil and natural gas properties held for sale, at cost $ 1,874,849 $ 1,874,849
Accumulated DD&A (1,874,849) (1,874,849)
Total assets of discontinued operations held for sale
Liabilities:    
Accrued liabilities 39,956 48,997
Asset retirement obligations 52,368 52,368
Revenue payable 52,117 52,117
Current liabilities of discontinued operations held for sale 144,441 153,482
Long-term liabilities of discontinued operations held for sale 199,046 162,948
Total liabilities of discontinued operations held for sale $ 343,487 $ 316,430
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Discontinued Operations (Details) - Schedule of discontinued operations shown in the consolidated statements of operations - Discontinued Operations [Member] - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue -        
Oil and gas sales $ 41,077 $ 55,140 $ 116,870 $ 93,248
Costs and Expenses:        
Lease operating expense 25,461 53,919 110,649 94,714
Accretion 5,230 2,851 36,098 9,883
Total costs and expenses 30,691 56,770 146,747 104,597
Loss from discontinued operations $ 10,386 $ (1,630) $ (29,877) $ (11,349)
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Supplemental Cash Flow Information (Details) - Schedule of supplemental cash flow information - USD ($)
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Schedule Of Supplemental Cash Flow Information Abstract    
Cash paid for interest $ 50,690 $ 127,812
Cash paid for taxes
Acquisition of certain assets of Halcyon Thruput, LLC    
- issuance of common shares 2,500,000
- issuance of subordinated note 850,000
- assumption of Halcyon bank note 995,614
Series B preferred stock dividend payable 60,035 39,137
Issuance of common stock units previously subscribed 50,000
Issuances of common shares for exchange or conversion of debt $ 2,160,269
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings (Loss) Per Share (Details) - Schedule of earnings (loss) per basic and diluted share - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Numerator        
Loss from continuing operations attributable to common stockholders $ (1,465,404) $ (1,376,030) $ (6,017,867) $ (4,356,315)
Income (loss) from discontinued operations 9,736 (1,528) (28,007) (10,639)
Less: preferred stock dividends (19,668) (16,125) (60,035) (56,625)
Net loss attributable to common stockholders $ (1,475,336) $ (1,393,683) $ (6,105,909) $ (4,423,579)
Denominator        
Weighted average shares used to compute basic EPS 113,204,002 54,109,797 113,149,973 38,693,679
Dilutive effect of convertible note 1,164,773 1,164,773
Dilutive effect of preferred stock 2,950,000 59,913,657 2,950,000 72,641,084
Dilutive effect of common stock options 125,490 122,052
Dilutive effect of common stock warrants 47,560 9,042,419 1,709,576 11,126,327
Weighted average shares used to compute diluted EPS 117,491,825 123,065,873 119,096,374 122,461,090
Loss from continuing operations        
Basic $ (0.01) $ (0.03) $ (0.05) $ (0.11)
Diluted (0.01) (0.03) (0.05) (0.11)
Loss from discontinued operations        
Basic
Diluted
Earnings (loss) per share        
Basic (0.01) (0.03) (0.05) (0.11)
Diluted $ (0.01) $ (0.03) $ (0.05) $ (0.11)
XML 62 f10q0922_generation_htm.xml IDEA: XBRL DOCUMENT 0001527102 2022-01-01 2022-09-30 0001527102 2022-11-14 0001527102 2022-09-30 0001527102 2021-12-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2022-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-12-31 0001527102 2022-07-01 2022-09-30 0001527102 2021-07-01 2021-09-30 0001527102 2021-01-01 2021-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2020-12-31 0001527102 us-gaap:PreferredStockMember 2020-12-31 0001527102 us-gaap:CommonStockMember 2020-12-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001527102 us-gaap:RetainedEarningsMember 2020-12-31 0001527102 us-gaap:NoncontrollingInterestMember 2020-12-31 0001527102 2020-12-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-01-01 2021-03-31 0001527102 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001527102 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001527102 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001527102 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001527102 2021-01-01 2021-03-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-03-31 0001527102 us-gaap:PreferredStockMember 2021-03-31 0001527102 us-gaap:CommonStockMember 2021-03-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001527102 us-gaap:RetainedEarningsMember 2021-03-31 0001527102 us-gaap:NoncontrollingInterestMember 2021-03-31 0001527102 2021-03-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-04-01 2021-06-30 0001527102 us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001527102 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001527102 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001527102 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001527102 2021-04-01 2021-06-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-06-30 0001527102 us-gaap:PreferredStockMember 2021-06-30 0001527102 us-gaap:CommonStockMember 2021-06-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001527102 us-gaap:RetainedEarningsMember 2021-06-30 0001527102 us-gaap:NoncontrollingInterestMember 2021-06-30 0001527102 2021-06-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-07-01 2021-09-30 0001527102 us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0001527102 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001527102 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001527102 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-09-30 0001527102 us-gaap:PreferredStockMember 2021-09-30 0001527102 us-gaap:CommonStockMember 2021-09-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001527102 us-gaap:RetainedEarningsMember 2021-09-30 0001527102 us-gaap:NoncontrollingInterestMember 2021-09-30 0001527102 2021-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-12-31 0001527102 us-gaap:PreferredStockMember 2021-12-31 0001527102 us-gaap:CommonStockMember 2021-12-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001527102 us-gaap:RetainedEarningsMember 2021-12-31 0001527102 us-gaap:NoncontrollingInterestMember 2021-12-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2022-01-01 2022-03-31 0001527102 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001527102 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001527102 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001527102 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001527102 2022-01-01 2022-03-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2022-03-31 0001527102 us-gaap:PreferredStockMember 2022-03-31 0001527102 us-gaap:CommonStockMember 2022-03-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001527102 us-gaap:RetainedEarningsMember 2022-03-31 0001527102 us-gaap:NoncontrollingInterestMember 2022-03-31 0001527102 2022-03-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2022-04-01 2022-06-30 0001527102 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001527102 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001527102 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001527102 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001527102 2022-04-01 2022-06-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2022-06-30 0001527102 us-gaap:PreferredStockMember 2022-06-30 0001527102 us-gaap:CommonStockMember 2022-06-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001527102 us-gaap:RetainedEarningsMember 2022-06-30 0001527102 us-gaap:NoncontrollingInterestMember 2022-06-30 0001527102 2022-06-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2022-07-01 2022-09-30 0001527102 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0001527102 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001527102 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001527102 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2022-09-30 0001527102 us-gaap:PreferredStockMember 2022-09-30 0001527102 us-gaap:CommonStockMember 2022-09-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001527102 us-gaap:RetainedEarningsMember 2022-09-30 0001527102 us-gaap:NoncontrollingInterestMember 2022-09-30 0001527102 genh:EnergyHunterResourcesIncMember 2019-11-02 2019-11-27 0001527102 2021-01-01 2021-01-11 0001527102 2022-07-01 2022-07-31 0001527102 2022-07-31 0001527102 us-gaap:LandMember 2022-09-30 0001527102 us-gaap:LandMember 2021-12-31 0001527102 srt:WarehouseMember 2022-01-01 2022-09-30 0001527102 srt:WarehouseMember 2022-09-30 0001527102 srt:WarehouseMember 2021-12-31 0001527102 us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-09-30 0001527102 us-gaap:LeaseholdImprovementsMember 2022-09-30 0001527102 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001527102 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-09-30 0001527102 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-09-30 0001527102 us-gaap:MachineryAndEquipmentMember 2022-09-30 0001527102 us-gaap:MachineryAndEquipmentMember 2021-12-31 0001527102 us-gaap:VehiclesMember 2022-01-01 2022-09-30 0001527102 us-gaap:VehiclesMember 2022-09-30 0001527102 us-gaap:VehiclesMember 2021-12-31 0001527102 us-gaap:ComputerEquipmentMember 2022-01-01 2022-09-30 0001527102 us-gaap:ComputerEquipmentMember 2022-09-30 0001527102 us-gaap:ComputerEquipmentMember 2021-12-31 0001527102 us-gaap:CustomerRelationshipsMember 2022-09-30 0001527102 us-gaap:CustomerRelationshipsMember 2021-12-31 0001527102 genh:NoncompetitionAgreementsMember 2022-09-30 0001527102 genh:NoncompetitionAgreementsMember 2021-12-31 0001527102 genh:SubordinatedPromissoryNoteToCEOMember 2020-01-01 2020-12-31 0001527102 genh:SubordinatedPromissoryNoteToCEOMember 2022-01-01 2022-09-30 0001527102 genh:SubordinatedPromissoryNoteToCEOMember 2022-09-30 0001527102 genh:ConvertiblePromissoryNoteToCEOMember 2021-01-01 2021-12-31 0001527102 genh:ConvertiblePromissoryNoteToCEOMember 2022-01-01 2022-09-30 0001527102 genh:ConvertiblePromissoryNoteToCEOMember 2022-09-30 0001527102 genh:SecuredPromissoryNoteAndWarrantsToCoventryAssetManagementLTDMember 2020-12-30 0001527102 genh:SecuredPromissoryNoteAndWarrantsToCoventryAssetManagementLTDMember 2020-12-01 2020-12-30 0001527102 2020-12-01 2020-12-30 0001527102 genh:PromissoryNoteMember genh:SecuredPromissoryNoteAndWarrantsToCoventryAssetManagementLTDMember 2020-12-01 2020-12-30 0001527102 srt:ScenarioForecastMember genh:SecuredPromissoryNoteAndWarrantsToCoventryAssetManagementLTDMember 2022-12-01 2022-12-30 0001527102 genh:SecuredPromissoryNoteAndWarrantsToCoventryAssetManagementLTDMember 2022-09-30 0001527102 genh:SecuredPromissoryNoteAndWarrantsToCoventryAssetManagementLTDMember 2022-01-01 2022-09-30 0001527102 srt:ScenarioForecastMember genh:SecuredPromissoryNoteAndWarrantsToCoventryAssetManagementLTDMember 2022-12-01 2022-12-31 0001527102 genh:SubordinatedPromissoryNoteAndWarrantsToInvestorMember 2020-12-30 0001527102 genh:SubordinatedPromissoryNoteAndWarrantsToInvestorMember 2020-12-01 2020-12-30 0001527102 genh:SubordinatedPromissoryNoteAndWarrantsToInvestorMember 2021-04-30 0001527102 genh:SubordinatedPromissoryNoteAndWarrantsToInvestorMember 2022-01-01 2022-09-30 0001527102 genh:PromissoryNoteToInvestmentHunterLLCMember 2022-01-01 2022-09-30 0001527102 genh:PromissoryNoteToInvestmentHunterLLCMember 2022-09-30 0001527102 2022-08-01 2022-08-31 0001527102 genh:SubordinatedPromissoryNoteToCEOMember 2021-12-31 0001527102 genh:ConvertiblePromissoryNoteToCEOMember 2021-12-31 0001527102 genh:SecuredPromissoryNoteToCoventryAssetManagementLtdMember 2022-09-30 0001527102 genh:SecuredPromissoryNoteToCoventryAssetManagementLtdMember 2021-12-31 0001527102 genh:SubordinatedPromissoryNoteMember 2022-09-30 0001527102 genh:SubordinatedPromissoryNoteMember 2021-12-31 0001527102 genh:PromissoryNoteToInvestmentHunterLLCMember 2022-09-30 0001527102 genh:PromissoryNoteToInvestmentHunterLLCMember 2021-12-31 0001527102 genh:NotePayableToDirectorMember 2022-09-30 0001527102 genh:NotePayableToDirectorMember 2021-12-31 0001527102 genh:OzCapitalLLCMember 2022-01-01 2022-09-30 0001527102 genh:OzCapitalLLCMember 2022-07-01 2022-09-30 0001527102 genh:OzCapitalLLCMember 2021-07-01 2021-09-30 0001527102 genh:OzCapitalLLCMember 2021-01-01 2021-09-30 0001527102 srt:MinimumMember 2022-01-01 2022-09-30 0001527102 srt:MaximumMember 2022-01-01 2022-09-30 0001527102 genh:HalcyonThruputLLCsMember 2022-01-01 2022-09-30 0001527102 2018-12-31 0001527102 genh:GrandTraverseHoldingsLLCMember us-gaap:SubsequentEventMember 2022-10-31 0001527102 2020-12-01 2020-12-23 0001527102 us-gaap:SeriesAPreferredStockMember 2021-09-08 0001527102 us-gaap:SeriesBPreferredStockMember 2020-12-01 2020-12-30 0001527102 us-gaap:SeriesBPreferredStockMember 2022-09-30 0001527102 us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-09-30 0001527102 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001527102 2021-04-30 0001527102 us-gaap:WarrantMember 2022-09-30 0001527102 genh:DecemberTwoThousandTwentyMember genh:SeriesBPreferredStockUnitsMember 2022-09-30 0001527102 genh:DecemberTwoThousandTwentyMember genh:SeriesBPreferredStockUnitsMember 2022-01-01 2022-09-30 0001527102 genh:DecemberTwoThousandTwentyMember genh:SubordinatedNoteToInvestorMember 2022-09-30 0001527102 genh:DecemberTwoThousandTwentyMember genh:SubordinatedNoteToInvestorMember 2022-01-01 2022-09-30 0001527102 genh:MarchTwoThousandTwentyOneMember genh:CommonStockUnitsMember 2022-09-30 0001527102 genh:MarchTwoThousandTwentyOneMember genh:CommonStockUnitsMember 2022-01-01 2022-09-30 0001527102 genh:DecemberTwoThousandTwentyOneMember genh:CommonStockUnitsMember 2022-09-30 0001527102 genh:DecemberTwoThousandTwentyOneMember genh:CommonStockUnitsMember 2022-01-01 2022-09-30 0001527102 genh:TwoThousandTwentyOnePlanMember 2021-01-01 2021-12-31 0001527102 2021-01-01 2021-12-31 0001527102 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001527102 2021-01-01 2021-06-30 0001527102 2021-10-01 2021-12-31 0001527102 srt:MinimumMember 2021-10-01 2021-12-31 0001527102 srt:MaximumMember 2021-10-01 2021-12-31 0001527102 srt:MinimumMember 2022-07-01 2022-09-30 0001527102 srt:MaximumMember 2022-07-01 2022-09-30 0001527102 srt:MinimumMember 2022-09-30 0001527102 srt:MaximumMember 2022-09-30 0001527102 us-gaap:SegmentDiscontinuedOperationsMember 2022-09-30 0001527102 us-gaap:SegmentDiscontinuedOperationsMember 2021-12-31 0001527102 us-gaap:SegmentDiscontinuedOperationsMember 2022-07-01 2022-09-30 0001527102 us-gaap:SegmentDiscontinuedOperationsMember 2021-07-01 2021-09-30 0001527102 us-gaap:SegmentDiscontinuedOperationsMember 2022-01-01 2022-09-30 0001527102 us-gaap:SegmentDiscontinuedOperationsMember 2021-01-01 2021-09-30 shares iso4217:USD iso4217:USD shares pure iso4217:USD utr:sqft 10-Q true 2022-09-30 2022 false 000-55019 GENERATION HEMP, INC. DE 26-3119496 8533 Midway Road Dallas TX 75209 (469) 209-6154 Yes Yes Non-accelerated Filer true false false 113204002 112538 20656 656344 212518 212518 49078 4723 1030478 237897 2276815 2580662 188090 263065 1418025 1857908 799888 799888 407000 5713296 6146420 1037275 883485 402617 410990 100311 486855 204007 109089 101238 3357620 2183551 423192 501668 144441 153482 6061400 4438421 79001 161827 199046 162948 6339447 4763196 10000 10000 300 300 118 118 135 135 591558 591558 0.00001 0.00001 200000000 200000000 0.00001 0.00001 200000000 200000000 113204002 113204002 113094002 113094002 1132 1131 33250858 29150258 -34224154 -28118245 -972164 1033144 -245545 -241478 -1217709 791666 5713296 6146420 1227123 487088 1559056 535053 22500 15000 67500 60000 1249623 502088 1626556 595053 375269 279621 644113 549881 261490 315729 743730 1006804 16115 407000 407000 1933281 1128298 5825809 2763529 2977040 1723648 7620652 4336329 -1727417 -1221560 -5994096 -3741276 -378304 -378304 -25424 11770 116999 155505 404272 651807 -261305 155505 25968 614613 -1466112 -1377065 -6020064 -4355889 10386 -1630 -29877 -11349 -1455726 -1378695 -6049941 -4367238 -58 -1137 -4067 -284 -1455668 -1377558 -6045874 -4366954 -0.01 -0.03 -0.05 -0.11 -0.01 -0.03 -0.05 -0.11 -0.01 -0.03 -0.05 -0.11 -0.01 -0.03 -0.05 -0.11 135 729058 6328948 4975503 17380317 6083480 4436018 -18220705 -239231 -2964935 6250000 2500000 2500000 800000 136707 263293 400000 8428976 4771669 -1804669 2967000 618660 217769 217769 1000000 1942500 1942500 20250 20250 500000 42250 42250 -1836882 3668 -1833214 135 729058 6328948 4975503 34977953 15694375 2894642 -20077837 -235563 3251120 -17 -137500 20250 20250 38750 38750 -1152514 -2815 -1155329 118 591558 6328948 4975503 34977953 15733125 2894642 -21250601 -238378 2114291 125000 117500 117500 20000 18000 18000 -15868273 15868273 38750 38750 -6328948 -4975503 75947376 759 4974744 16125 16125 -1377558 -1137 -1378695 118 591558 111070329 1111 23776409 -22644284 -239515 893721 118 591558 113094002 1131 29150258 -28118245 -241478 791666 20000 11480 11480 68756 68756 20992 20992 1315750 1315750 -2455084 -1587 -2456671 118 591558 113114002 1131 30546244 -30594321 -243065 -290011 40000 1 26000 26001 19375 19375 1315750 1315750 -2135122 -2422 -2137544 118 591558 113154002 1132 31887994 -32748818 -245487 -1105179 50000 15100 15100 19668 19668 1347764 1347764 -1455668 -58 -1455726 118 591558 113204002 1132 33250858 -34224154 -245545 -1217709 -6049941 -4367238 29877 11349 -6020064 -4355889 743730 1006804 407000 52581 380282 3979264 119750 117500 68756 -25424 11770 656344 52195 44355 14232 368230 176969 100311 -1000891 -2658205 -2820 -1003711 -2658205 77716 224530 224530 -1525470 34847 -1568339 -1568339 350000 137500 16500 2967000 995614 1294069 70000 620000 50000 1100000 78476 103102 1095593 1584284 1095593 1584284 91882 -2642260 20656 2776425 112538 134165 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>1. Business</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">Generation Hemp, Inc. (the “Company”) was incorporated on August 21, 2021 in the State of Delaware. The Company was originally incorporated as Home Treasure Finders, Inc. (“HTF”) on July 28, 2008 in the State of Colorado. On November 27, 2019, HTF purchased approximately 94% of the common stock of Energy Hunter Resources, Inc. (“EHR”) in a series of transactions accounted for as a reverse merger. Upon closing, HTF changed its name to Generation Hemp, Inc.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">On January 11, 2021, we completed the acquisition of certain assets of Halcyon Thruput, LLC (“Halcyon”). With this acquisition, we commenced providing post-harvest and midstream services to hemp growers by drying, processing, cleaning and stripping harvested hemp directly from the field and wetbaled at our 48,000 square foot leased facility located in Hopkinsville, Kentucky. The Company also offers safe storage services for processed hemp, which enables farmers to maximize strategic market timing. We market two retail products, <i>Gas Monkey Spill-Jack</i>, an all-natural, plant-based, sustainable, and biodegradable loose absorbent, and <i>Rowdy Rooster</i>, an animal bedding consumer goods product, each made from the hemp hurd byproduct that is produced from our hemp processing operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">We also generate revenue from rental of our “Cannabis Zoned” (Hemp) warehouse property located in Denver, Colorado currently leased to an unaffiliated hemp seed company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">As of September 30, 2022, EHR held an approximate 8% working interest in an oil &amp; gas property located in Cochran County, Texas within the Slaughter-Levelland Field of the San Andres formation in the Northwest Shelf of West Texas. EHR’s oil &amp; gas activities are currently held for sale and are presented in these consolidated financial statements as discontinued operations for each of the periods presented.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">Our management team has been and continues to actively review acquisition candidates involved in the hemp industry that operate within a number of vertical businesses, predominantly within the midstream sector that are attractive to us and are within the hemp supply chain. Additionally, the Company has been studying the Bitcoin mining space and anticipates future activity in this business sector.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"><i>Liquidity and Going Concern – </i>The Company is dependent upon obtaining additional funding to continue ongoing operations and to pursue its strategy and execute its acquisition plans.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">In the nine months ended September 30, 2022, the Company used $1.0 million of cash for its operating activities. At September 30, 2022, the Company’s current liabilities, including financing obligations due within one year, totaled $6.1 million as compared with its current assets of $1.0 million.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">The Company will continue to pursue additional capital raising opportunities in order to fund future acquisitions and meet its obligations as they become due. We may not be successful in obtaining additional financing needed. In the event financing cannot be obtained, the Company may not be able to satisfy these plans and obligations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> 0.94 48000 As of September 30, 2022, EHR held an approximate 8% working interest in an oil & gas property located in Cochran County, Texas within the Slaughter-Levelland Field of the San Andres formation in the Northwest Shelf of West Texas. EHR’s oil & gas activities are currently held for sale and are presented in these consolidated financial statements as discontinued operations for each of the periods presented.  1000000 P1Y 6100000 1000000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>2. Summary of Significant Accounting Policies</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Basis of Presentation</i> – These interim financial statements are unaudited and have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain disclosures have been condensed or omitted from these financial statements. Accordingly, they do not include all the information and notes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements, and should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, necessary to fairly present the financial position as of, and the results of operations for, all periods presented. In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the condensed consolidated financial statements and disclosures of contingencies. Actual results may differ from those estimates. The results for interim periods are not necessarily indicative of annual results. Certain reclassifications have been made to the prior period’s consolidated financial statements and related footnotes to conform them to the current period presentation. Intercompany balances and transactions between consolidated entities are eliminated.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Fair Value Measurement</i> – Our financial assets and liabilities consist of cash, accounts receivable, accounts payable and indebtedness. The fair values of these instruments approximate their carrying amounts at each reporting date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Deferred Revenue</i> – In July 2022, the Company entered into an agreement for the sale of 66,782 pounds of dried hemp biomass from its inventories on-hand for a sales price of $1.50 per pound. Deliveries and payment of the $100,173 sales proceeds are scheduled monthly through December 2022 and are reported as deferred revenue in the consolidated balance sheets. We expect to recognize revenue for these amounts when the contract is completed and product is shipped in the fourth quarter of 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Major Customer and Concentration of Credit Risk</i> – We estimate an allowance for doubtful accounts based on an analysis of specific customers, taking into consideration the age of past due accounts and an assessment of the customer’s ability to pay. An allowance for doubtful accounts was not needed as of September 30, 2022 or December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During the three and nine months ended September 30, 2022, one customer accounted for all of our post-harvest and midstream services revenue. A total of $656,344 was outstanding from this customer as a receivable at September 30, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our rental revenue is derived from a single lessee on a commercial warehouse owned by the Company. There were no amounts due from this customer at September 30, 2022 or December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Recent Accounting Pronouncements – </i>There are no other new accounting pronouncements that are expected to have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Basis of Presentation</i> – These interim financial statements are unaudited and have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain disclosures have been condensed or omitted from these financial statements. Accordingly, they do not include all the information and notes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements, and should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, necessary to fairly present the financial position as of, and the results of operations for, all periods presented. In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the condensed consolidated financial statements and disclosures of contingencies. Actual results may differ from those estimates. The results for interim periods are not necessarily indicative of annual results. Certain reclassifications have been made to the prior period’s consolidated financial statements and related footnotes to conform them to the current period presentation. Intercompany balances and transactions between consolidated entities are eliminated.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Fair Value Measurement</i> – Our financial assets and liabilities consist of cash, accounts receivable, accounts payable and indebtedness. The fair values of these instruments approximate their carrying amounts at each reporting date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Deferred Revenue</i> – In July 2022, the Company entered into an agreement for the sale of 66,782 pounds of dried hemp biomass from its inventories on-hand for a sales price of $1.50 per pound. Deliveries and payment of the $100,173 sales proceeds are scheduled monthly through December 2022 and are reported as deferred revenue in the consolidated balance sheets. We expect to recognize revenue for these amounts when the contract is completed and product is shipped in the fourth quarter of 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 66782 1.5 100173 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Major Customer and Concentration of Credit Risk</i> – We estimate an allowance for doubtful accounts based on an analysis of specific customers, taking into consideration the age of past due accounts and an assessment of the customer’s ability to pay. An allowance for doubtful accounts was not needed as of September 30, 2022 or December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During the three and nine months ended September 30, 2022, one customer accounted for all of our post-harvest and midstream services revenue. A total of $656,344 was outstanding from this customer as a receivable at September 30, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our rental revenue is derived from a single lessee on a commercial warehouse owned by the Company. There were no amounts due from this customer at September 30, 2022 or December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 656344 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Recent Accounting Pronouncements – </i>There are no other new accounting pronouncements that are expected to have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>3. Property and Equipment</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">Property and equipment consisted of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Useful</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Life (yrs)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Land</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">96,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">96,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Warehouse</td><td> </td> <td style="text-align: center">30</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">916,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">916,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold Improvements</td><td> </td> <td style="text-align: center">3</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">473,601</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">473,601</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Machinery and equipment</td><td> </td> <td style="text-align: center"> 5-7</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,506,447</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,506,447</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vehicles</td><td> </td> <td style="text-align: center">4</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">149,440</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">149,440</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Computer equipment and software</td><td> </td> <td style="text-align: center">3</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,825</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,825</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Office furniture and equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> 3-5</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,294</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,294</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Subtotal</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,206,107</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,206,107</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(929,292</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(625,445</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total property and equipment, net</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,276,815</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,580,662</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Useful</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Life (yrs)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Land</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">96,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">96,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Warehouse</td><td> </td> <td style="text-align: center">30</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">916,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">916,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold Improvements</td><td> </td> <td style="text-align: center">3</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">473,601</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">473,601</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Machinery and equipment</td><td> </td> <td style="text-align: center"> 5-7</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,506,447</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,506,447</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vehicles</td><td> </td> <td style="text-align: center">4</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">149,440</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">149,440</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Computer equipment and software</td><td> </td> <td style="text-align: center">3</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,825</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,825</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Office furniture and equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> 3-5</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,294</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,294</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Subtotal</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,206,107</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,206,107</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(929,292</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(625,445</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total property and equipment, net</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,276,815</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,580,662</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 96000 96000 P30Y 916500 916500 P3Y 473601 473601 P5Y P7Y 1506447 1506447 P4Y 149440 149440 P3Y 46825 46825 3206107 3206107 2276815 2580662 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>4. Intangible and Other Assets</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">The following table summarizes information related to definite-lived intangible assets:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Gross Carrying Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Gross Carrying Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: left">Customer relationships</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,612,649</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,220,948</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,391,701</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,612,649</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(796,858</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,815,791</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Non-competition agreements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">63,176</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(36,852</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,324</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">63,176</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,059</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,675,825</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,257,800</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,418,025</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,675,825</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(817,917</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,857,908</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">Other assets included $407,000 at December 31, 2021 for the Company’s option to purchase the 48,000 square foot facility located in Hopkinsville, Kentucky presently leased from Halcyon. Under this agreement, the Company had the option to purchase the facility on or before August 25, 2022, as amended, for a purchase price of $993,000. This agreement was not renewed upon its expiration. Impairment expense totaling $407,000 was recognized in the third quarter of 2022 as a result.</span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Gross Carrying Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Gross Carrying Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: left">Customer relationships</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,612,649</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,220,948</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,391,701</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,612,649</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(796,858</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,815,791</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Non-competition agreements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">63,176</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(36,852</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,324</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">63,176</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,059</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,675,825</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,257,800</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,418,025</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,675,825</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(817,917</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,857,908</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p> 2612649 -1220948 1391701 2612649 -796858 1815791 63176 -36852 26324 63176 -21059 42117 2675825 -1257800 1418025 2675825 -817917 1857908 407000 the Company’s option to purchase the 48,000 square foot facility located in Hopkinsville, Kentucky presently leased from Halcyon. Under this agreement, the Company had the option to purchase the facility on or before August 25, 2022, as amended, for a purchase price of $993,000. 407000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>5. Notes Payable – Related Parties</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Notes payable – related parties consisted of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Subordinated Promissory Note to CEO</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">523,551</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">523,551</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Convertible Promissory Note to CEO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,107,069</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">410,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Secured Promissory Note to Coventry Asset Management, LTD.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Subordinated Promissory Note to Investor</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">250,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Promissory Note to Investment Hunter, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">492,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Note payable to Director</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total notes payable – related parties</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,357,620</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,183,551</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Subordinated Promissory Note to CEO – </i>Our CEO made advances to the Company during 2020 under a subordinated promissory note in the amount of $523,551 initially due September 30, 2021. This note was amended to a new maturity date of January 1, 2023. If the Company raises new equity capital of $3 million or more, then the full amount outstanding under the note is due within five days. The note bears interest at 10% per annum. Accrued interest on this subordinated promissory note totaled $46,761 at September 30, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Convertible Promissory Note to CEO</i> – In 2021, our CEO made advances totaling $410,000 to the Company under a convertible promissory note. Additional advances made in 2022 through September 30 totaled $697,069. The convertible note initially matured on January 1, 2022 but was subsequently amended to extend the maturity date to January 1, 2023. If the Company raises new equity capital of $3 million or more, then the full amount outstanding under the note is due within five days. The note bears interest at 10%. The principal and interest due on the convertible note may be converted, at the option of the holder, into restricted shares of the Company’s common stock at an initial conversion price of $0.50 per share but that was lowered in July 2022 to $0.30 per share. Accrued interest on this convertible promissory note totaled $79,493 at September 30, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"><i>Secured Promissory Note and Warrants to Coventry Asset Management, LTD. – </i>On December 30, 2020, the Company received proceeds from issuance of a secured promissory note in principal amount of $1,000,000 to Coventry Asset Management, LTD, a Company stockholder. The promissory note is secured by the property acquired in the acquisition of certain assets of Halcyon. The unpaid balance of the secured promissory note bears interest at a rate of 10% per annum and initially matured on June 30, 2021. The promissory note has been extended six times including the issuance of 20,000 restricted common shares as extension fees each for the first five extensions and the issuance of 50,000 restricted common shares for the sixth extension. The maturity date of the promissory note is December 31, 2022, as amended. If before December 31, 2022, the Company raises new equity capital of $5 million or more, then the full amount outstanding under the promissory note is due within five days. As amended, a payment of 25% of the principal balance of the note is due by October 31, 2022. The Company did not make the principal payment due on October 31, 2022 and, as a result, this note is presently in default. If the promissory note is not paid in full by December 31, 2022, the interest rate increases to 14% per annum. Accrued interest on this secured note totaled $175,069 at September 30, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"><i>Subordinated Promissory Note and Warrants to Investor – </i>On December 30, 2020, the Company issued a subordinated promissory note in principal amount of $500,000 to an accredited investor who is also a Company stockholder. The unpaid balance of the Subordinated Note bears interest at a rate of 10% per annum. The Company made a principal payment of $250,000 in April 2021. The subordinated note principal together with accrued and unpaid interest was due, as previously amended, on March 31, 2022 but was subsequently extended. As subsequently amended, a payment of $50,000 was made in April 2022 and the remaining principal of $200,000 together with accrued interest was due on June 30, 2022. The Company did not make the principal payment due on June 30, 2022 and, as a result, this note is presently in default. Accrued interest on this subordinated promissory note totaled $36,990 at September 30, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The holder of the subordinated note received a warrant to purchase 500,000 shares of common stock exercisable for cash at an exercise price of $0.352 per share. As consideration for the April 2022 extension, the term of this warrant was extended by one year to December 30, 2023. The Company recognized $68,756 of interest expense in 2022 for this extension of the warrant term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"><i>Promissory Note to Investment Hunter, LLC</i> – In 2022, Investment Hunter, LLC, a Texas LLC controlled by our CEO, made advances totaling $492,000 to the Company under a promissory note due January 1, 2023, as amended. If the Company raises new equity capital of $3 million or more, then the full amount outstanding under the note is due within five days. The note bears interest at 10% per annum. Accrued interest on this subordinated promissory note totaled $30,193 at September 30, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Director Notes</i> – In August 2022, the Company received proceeds totaling $105,000 from unsecured notes payable to three members of our board of directors. The notes bear interest at 10% per annum and matured on September 12, 2022. Two of the notes were repaid in September 2022. The remaining note, having an outstanding principal balance of $35,000 at September 30, 2022, was repaid in October 2022.</span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Subordinated Promissory Note to CEO</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">523,551</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">523,551</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Convertible Promissory Note to CEO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,107,069</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">410,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Secured Promissory Note to Coventry Asset Management, LTD.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Subordinated Promissory Note to Investor</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">250,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Promissory Note to Investment Hunter, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">492,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Note payable to Director</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total notes payable – related parties</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,357,620</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,183,551</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 523551 523551 1107069 410000 1000000 1000000 200000 250000 492000 35000 3357620 2183551 523551 2021-09-30 2023-01-01 3000000 0.10 46761 410000 697069 The convertible note initially matured on January 1, 2022 but was subsequently amended to extend the maturity date to January 1, 2023. 3000000 0.10 0.5 0.3 79493 1000000 0.10 2021-06-30 20000 50000 2022-12-31 5000000 0.25 2022-10-31 14% 175069 500000 0.10 250000 As subsequently amended, a payment of $50,000 was made in April 2022 and the remaining principal of $200,000 together with accrued interest was due on June 30, 2022. 36990 500000 0.352 P1Y 2023-12-30 68756 492000 2023-01-01 3000000 0.10 30193 In August 2022, the Company received proceeds totaling $105,000 from unsecured notes payable to three members of our board of directors. The notes bear interest at 10% per annum and matured on September 12, 2022. Two of the notes were repaid in September 2022. The remaining note, having an outstanding principal balance of $35,000 at September 30, 2022, was repaid in October 2022. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>6. Other Indebtedness</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">The Company is obligated under a mortgage payable dated September 15, 2014 secured by its warehouse property located in Denver, Colorado. The note has been amended a number of times to a maturity date of January 15, 2023. In the latest extension, the Company made a principal payment of $73,190 plus accrued interest in October 2022 and agreed to make two additional principal payments of $50,000 plus accrued interest on November 15, 2022 and December 15, 2022. The interest rate on the mortgage payable is 12%. If before the final maturity of the mortgage payable, the Company raises new equity capital of $5 million or more, then the full amount outstanding is due within ten days.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">The Company leases the Denver warehouse property to a tenant under an operating lease which was renewed with a new tenant and extended to August 1, 2023 for a monthly rent of $7,500. The lease requires a true-up with the tenant for property taxes and insurance paid by the Company and requires the tenant to maintain the interior and exterior of the warehouse (except for the roof). The lease provides for a rent abatement in the first and last month of the contracted extension. Minimum future rents for the remainder of 2022 are $22,500 and for 2023 are $52,500.</span></p> The note has been amended a number of times to a maturity date of January 15, 2023. In the latest extension, the Company made a principal payment of $73,190 plus accrued interest in October 2022 and agreed to make two additional principal payments of $50,000 plus accrued interest on November 15, 2022 and December 15, 2022. 0.12 5000000 7500 22500 52500 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>7. Leases</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"><i>Office Space – </i>The Company leases office space in Fort Worth, Texas for managerial offices. This lease requires monthly payments of $2,000 and is month-to-month. Lease expense for this facility totaled $6,000 and $18,000 for the three and nine months ended September 30, 2022, respectively. In the three and nine months ended September 30, 2021, lease expense for this facility was $6,000 and $16,000, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Hemp Processing Operating Facility</i> – The Company leases its operating facility in Kentucky from Oz Capital, LLC, a related party, under a lease expiring May 31, 2024. The lease provides for monthly payments of $10,249. Oz Capital, LLC is responsible for all taxes and maintenance under the lease. Lease expense for this facility totaled $30,747 and $92,241 in the three and nine months ended September 30, 2022, respectively. In the three and nine months ended September 30. 2021, lease expense for this facility was $30,747 and $88,604, respectively. A right-of-use asset and lease liability is recorded for this lease. As the lease does not provide an implicit rate, the Company used its estimated incremental borrowing rate of 10% in determining the present value of the lease payments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Future Bitcoin Mining Premises</i> – The Company entered a five-year commercial lease for land and premises in Arkansas. We expect to use these premises as a future Bitcoin mining location because of its favorable power rates and land availability. The lease commences once the Company begins receiving power for its operations conducted at the location. The monthly rent will vary from a minimum of $1,000 per megawatt of power usage monthly up to $4,000 per megawatt monthly depending on the average power usage over a trailing 90-day period. We anticipate commencing operations at the leased premises in the first quarter of 2023.</span></p> 2000 6000 18000 6000 16000 10249 30747 92241 30747 88604 0.10 1000 4000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>8. Commitments and Contingencies</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Litigation – </i>From time to time, we are subject to various litigation and other claims in the normal course of business. Below is a discussion of specific matters. We cannot estimate the ultimate outcome of these matters.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Generation Hemp, Inc. v. Colorado Mill Equipment, LLC</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">The Defendant sold to the Company a faulty piece of equipment for $16,000 and will not refund to the Company the purchase price after repeated attempts to return their equipment. An original lawsuit filed by the Company against Colorado Mill Equipment in January 2022 in Dallas County was subsequently dismissed due to jurisdiction. A second lawsuit was filed in El Paso County, Colorado and is currently pending.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Halcyon Thruput, LLC, Plaintiff v. United National Insurance Company, Defendant, United States District Court for the Northern District of Texas, Dallas Division, Case No. 3:21-CV-3136-K.</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">Halcyon Thruput, LLC (Halcyon) obtained an all-risks commercial insurance policy, including an Equipment Breakdown Endorsement (Policy) from United National Insurance Company (UNIC) to provide substantial coverages for Halcyon Thruput LLC’s (Halcyon) $1,203,735 hemp processing dryer (Dryer) at its facility in Hopkinsville, Kentucky. During the Policy period, the Dryer caught fire due to the Dryer being defectively designed.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">While UNIC paid a number of Halcyon’s claims, Halcyon’s claim for the cost of the replacement Dryer of $1,498,848 was denied as described below.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">Buyer, a wholly owned subsidiary of the Company, pursuant to an Asset Purchase Agreement as twice amended, then acquired all the assets of Halcyon, except for the right to the proceeds of UNIC’s insurance policy since the Policy prohibited assignment. Halcyon and Buyer agreed that Buyer’s principal, Gary C. Evans, had the right to control the litigation, engage counsel for Halcyon and make all decisions relating to any proceeds received in the litigation by settlement or otherwise.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">Halcyon’s suit against UNIC, which was removed to federal court, seeks $796,865.53 (the cost of the replacement dryer of $1,498,848, less a credit for $583,508.47 previously paid by UNIC to Halcyon for the Dryer fire=$915,339.53) plus statutory interest on that sum from August 10, 2020 for violating the Texas Insurance Code’s requirement that claims be promptly paid, additional statutory penalties, and attorneys’ fees. Certain documents have been executed between the Company, Halcyon and legal counsel, which provide for a sharing of costs and expenses and awards, if any, against UNIC. Mediation of the case was held in April 2022 where no agreement was reached by the parties. Depositions of the Company’s expert witnesses were completed in July 2022 and of UNIC’s representatives in September 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">In August 2022, the Company received a second payment from UNIC of $357,143 as a partial settlement of this claim.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">JDONE, LLC v. Grand Traverse Holdings, LLC and John Gallegos, Denver District Court Case No. 2019CV33723</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><span style="font-family: Times New Roman, Times, Serif">JDONE, LLC (“JDONE”), a wholly owned subsidiary of the Company and landlord of a commercial warehouse building in Denver, brought suit against Grand Traverse Holdings, LLC for default of its commercial lease of the warehouse from JDONE. This case settled in October 2022 and the Company received $122,500 from the defendant.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">KBSIII Tower at Lake Carolyn, LLC and Prime US-Tower at Lake Carolyn, LLC (collectively – “KBSIII” v. Energy Hunter Resources, Inc.)</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><span style="font-family: Times New Roman, Times, Serif">Plaintiff/Counterdefendant KBSIII was seeking lost rent on office space for periods after EHR vacated office premises located in Las Colinas, Texas. EHR filed a counter suit alleging specific damages due to uninhabitable premises of the office space due to the intolerable conduct of other tenants located on the same floor. On December 23, 2020, the trial court entered a summary judgment against EHR for $230,712. The judgment provides for post-judgment interest at a rate of 5% per annum until paid and further provides for additional amounts owed should EHR pursue unsuccessful appeals to higher courts. At September 30, 2022, the Company had accrued $252,583 for this judgment, which is exclusively an EHR obligation.</span></p> 16000 1203735 1498848 Halcyon’s suit against UNIC, which was removed to federal court, seeks $796,865.53 (the cost of the replacement dryer of $1,498,848, less a credit for $583,508.47 previously paid by UNIC to Halcyon for the Dryer fire=$915,339.53) plus statutory interest on that sum from August 10, 2020 for violating the Texas Insurance Code’s requirement that claims be promptly paid, additional statutory penalties, and attorneys’ fees. Certain documents have been executed between the Company, Halcyon and legal counsel, which provide for a sharing of costs and expenses and awards, if any, against UNIC. 357143 122500 230712 0.05 252583 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>9. Income Taxes</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Income tax provisions for interim quarterly periods are generally based on an estimated annual effective income tax rate calculated separately from the effect of significant, infrequent or unusual items related specifically to interim periods. An income tax benefit for the three or nine months ended September 30, 2022 or 2021 was not recognized because tax losses incurred were fully offset by a valuation allowance against deferred tax assets. There were no uncertain tax positions as of September 30, 2022. The Company is delinquent in filing its 2021 income tax returns.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>10. Equity</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Series A Preferred Stock <b>– </b></i>Our Series A Preferred Stock was originally issued in connection with HTF’s acquisition of EHR in 2019. On September 8, 2021, holders of the Company’s Series A Preferred Stock elected to convert such shares into shares of the Company’s common stock. As a result, 6,328,948 shares of Series A Preferred Stock were converted into 75,947,376 shares of common stock, with each share of Series A Preferred Stock converting into 12 shares of restricted common stock pursuant to the applicable Certificate of Designations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"><i>Series B Preferred Stock Units – </i>On December 30, 2020, the Company sold to certain accredited investors, including Gary C. Evans, our Chief Executive Officer, an aggregate of 135 preferred stock units comprised of (i) one share of Series B Redeemable Convertible Preferred Stock, no par value, and (ii) one warrant exercisable for 50,000 shares of common stock of the Company until December 30, 2022 at an exercise price of $0.352 per share.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">The sale of the preferred stock units for $10,000 each resulted in aggregate gross proceeds of approximately $1.35 million, before deducting estimated offering expenses payable by the Company. Substantially all of the proceeds raised in the offering were used to fund the acquisition of assets of Halcyon, expenses related thereto and for general corporate purposes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">Each share of Series B Preferred Stock is initially convertible into 25,000 shares of common stock, subject to adjustment. Holders of Series B Preferred Stock are entitled to receive dividends of 6.00% per annum based on the stated value equal to $10,000 per share. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (b) alter or amend the related certificate of designation, (c) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock, (d) repay, repurchase or offer to repay, repurchase or otherwise acquire more than a de minimis number of shares of its common stock, (e) enter into any agreement with respect to any of the foregoing, or (f) pay cash dividends or distributions on any equity securities of the Company other than pursuant to the terms of the outstanding Series B Preferred Stock. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">Any or all of the Series B Preferred Stock may be converted, at their holder’s option, into 25,000 shares of common stock, as adjusted for any stock dividends, splits, combinations or similar events.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">At any time after the occurrence of a “Qualifying Event,” the Company, upon 5-day written notice, shall have the right to cause each share of Series B Preferred Stock (and all accrued in-kind dividends with respect thereto) to be converted into common stock. For purposes of this automatic conversion of the Series B Preferred Stock, a “Qualifying Event” shall have occurred if (A) (1) the rolling five-trading day volume-weighted average trading price of shares of the common stock exceeds $1.00, and (2) there shall be an effective registration statement under the Securities Act of 1933, as amended covering all of the shares of common stock which would be issuable upon conversion of all of the outstanding shares of Series B Preferred Stock or (B) the Company closes a firm commitment underwriting of the common stock on a Form S-1 Registration Statement with aggregate gross proceeds of at least $5,000,000 at a price per share equal to or greater than $1.00. In each instance, a conversion may not be made unless the Company has filed an amendment to its Articles of Incorporation effecting an increase in its authorized common stock so that the Company has a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">The Series B Preferred Stock may be redeemed by the Company for its stated value, plus accrued and unpaid dividends, at any time. Initially, redemption payments of 12.5% each of the total amount of Series B Preferred Stock then outstanding plus accrued dividends were due from the Company to each Holder of Series B Preferred Stock at the end of each calendar quarter of 2021. The first required redemption payments totaling $137,500 were made in April 2021. In May, June and October of 2021, the three holders of the Series B Preferred Stock, including the Company’s chief executive officer, entered into transactions in which they accepted the mandatory redemption payment required pursuant to the Series B Preferred Stock certificate of designation in a number of Series B Units to effectively waive the redemption requirement. All other terms of the Series B Units remain unchanged and the holders’ ownership interest in the Series B Preferred Units remains the same as it was before such transactions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"><i>Common Stock – </i>At September 30, 2022, the Company had 113,204,002 common shares outstanding. Following is a discussion of common stock issuances during the periods presented:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Acquisition of Certain Assets of Halcyon </i>– In January 2021, the Company issued 6,250,000 shares of common stock valued at $2.5 million ($0.40 per share; restricted from trading for a period of up to one year) in the acquisition. </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021 First Quarter Issuances of Common Stock Units</i> – In the first quarter of 2021, the Company issued 800,000 common stock units for total proceeds of $400,000. Each common stock unit consisted of one share of common stock and a warrant for the purchase of two shares of common stock for $0.50 each. Each warrant is exercisable any time before its expiration on the second anniversary of its issuance. The Company allocated the total proceeds based on the relative fair values of the common stock and warrants. The fair value of the warrants was determined using an options valuation model with key assumptions including a risk-free interest rate of 0.11% and historical volatility of 272%. A total of $263,293 was allocated to the warrants and reported in additional paid-in capital.  </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant Exercises </i>– In the first quarter of 2021, the Company received $2,967,000 for the exercise of 8,428,976 outstanding warrants. In the fourth quarter of 2021, the Company received $375,000 for the exercise of 1,065,340 outstanding warrants.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>●</i></span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuances for Exchange or Conversion of Debt </i>– The Company issued a total of 1,618,660 common shares for the exchange or conversion of outstanding debt in the first quarter of 2021. </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance to Vendor for Services </i>– In the third quarter of 2021, the Company issued 125,000 common shares to a vendor for services performed.</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance for Extension of Secured Note </i>– The Company issued 20,000 common shares as consideration to extend the maturity of a senior note in the third quarter of 2021.</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance for Conversion of Series A Preferred Stock </i>– As noted above, in the third quarter of 2021, the Company issued 75,947,376 common shares for the conversion of all outstanding shares of its Series A Preferred Stock.</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based Compensation </i>– The Company issued 500,000 restricted common shares valued at $155,000 as incentive compensation to two executives who joined the Company in the first quarter of 2021.</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance for Extensions of Secured Note – </i>The Company issued 110,000 common shares as consideration for extensions of the maturity of a senior note in 2022. Refer to Note 5.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Common Stock Warrants Outstanding – </i>Following is a summary of warrants outstanding as of September 30, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"># of <br/> Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise<br/> Price (each)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Expiration Date</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Method of<br/> Exercise</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; width: 45%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued in December 2020 with Series B preferred units <sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,500,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">      0.352</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif">December 30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cash</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued in December 2020 with subordinated note to investor</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">500,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.352</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">December 30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cash</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued in Q1 2021 with common stock units <sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,600,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.500</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">January-February, 2023</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cash</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued in Q4 2021 with common stock units <sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">958,333</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.600</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">October-December, 2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total warrants outstanding at September 30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,558,333</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right">0.407</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May be redeemed for $0.0001 per warrant at the Company’s option with 30 days advanced notice should the weighted average market price of common stock exceed $1.00 for any five out of seven consecutive trading days with a minimum average daily trading volume for such seven-day period of at least 25,000 shares of common stock.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">Following is a summary of outstanding stock warrants activity for the periods presented:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"># of <br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-indent: -0.25in; padding-left: 0.25in">Warrants as of December 31, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8,808,333</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.407</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.375in">Canceled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(250,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.400</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Warrants as of September 30, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">8,558,333</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.407</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 6328948 75947376 12 On December 30, 2020, the Company sold to certain accredited investors, including Gary C. Evans, our Chief Executive Officer, an aggregate of 135 preferred stock units comprised of (i) one share of Series B Redeemable Convertible Preferred Stock, no par value, and (ii) one warrant exercisable for 50,000 shares of common stock of the Company until December 30, 2022 at an exercise price of $0.352 per share. 10000 1350000 25000 0.06 10000 25000 1 5000000 1 0.125 137500 At September 30, 2022, the Company had 113,204,002 common shares outstanding. Following is a discussion of common stock issuances during the periods presented:   ● Acquisition of Certain Assets of Halcyon – In January 2021, the Company issued 6,250,000 shares of common stock valued at $2.5 million ($0.40 per share; restricted from trading for a period of up to one year) in the acquisition.     ● 2021 First Quarter Issuances of Common Stock Units – In the first quarter of 2021, the Company issued 800,000 common stock units for total proceeds of $400,000. Each common stock unit consisted of one share of common stock and a warrant for the purchase of two shares of common stock for $0.50 each. Each warrant is exercisable any time before its expiration on the second anniversary of its issuance. The Company allocated the total proceeds based on the relative fair values of the common stock and warrants. The fair value of the warrants was determined using an options valuation model with key assumptions including a risk-free interest rate of 0.11% and historical volatility of 272%. A total of $263,293 was allocated to the warrants and reported in additional paid-in capital.       ● Warrant Exercises – In the first quarter of 2021, the Company received $2,967,000 for the exercise of 8,428,976 outstanding warrants. In the fourth quarter of 2021, the Company received $375,000 for the exercise of 1,065,340 outstanding warrants.     ● Issuances for Exchange or Conversion of Debt – The Company issued a total of 1,618,660 common shares for the exchange or conversion of outstanding debt in the first quarter of 2021.         ● Issuance to Vendor for Services – In the third quarter of 2021, the Company issued 125,000 common shares to a vendor for services performed.         ● Issuance for Extension of Secured Note – The Company issued 20,000 common shares as consideration to extend the maturity of a senior note in the third quarter of 2021.         ● Issuance for Conversion of Series A Preferred Stock – As noted above, in the third quarter of 2021, the Company issued 75,947,376 common shares for the conversion of all outstanding shares of its Series A Preferred Stock.       ● Stock-based Compensation – The Company issued 500,000 restricted common shares valued at $155,000 as incentive compensation to two executives who joined the Company in the first quarter of 2021.         ● Issuance for Extensions of Secured Note – The Company issued 110,000 common shares as consideration for extensions of the maturity of a senior note in 2022. Refer to Note 5. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"># of <br/> Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise<br/> Price (each)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Expiration Date</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Method of<br/> Exercise</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; width: 45%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued in December 2020 with Series B preferred units <sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,500,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">      0.352</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif">December 30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cash</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued in December 2020 with subordinated note to investor</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">500,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.352</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">December 30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cash</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued in Q1 2021 with common stock units <sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,600,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.500</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">January-February, 2023</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cash</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued in Q4 2021 with common stock units <sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">958,333</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.600</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">October-December, 2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total warrants outstanding at September 30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,558,333</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right">0.407</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May be redeemed for $0.0001 per warrant at the Company’s option with 30 days advanced notice should the weighted average market price of common stock exceed $1.00 for any five out of seven consecutive trading days with a minimum average daily trading volume for such seven-day period of at least 25,000 shares of common stock.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 5500000 0.352 December 30, 2022 Cash 500000 0.352 December 30, 2022 Cash 1600000 0.5 January-February, 2023 Cash 958333 0.6 October-December, 2023 Cash 8558333 0.407 0.0001 1 25000 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"># of <br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-indent: -0.25in; padding-left: 0.25in">Warrants as of December 31, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8,808,333</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.407</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.375in">Canceled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(250,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.400</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Warrants as of September 30, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">8,558,333</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.407</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 8808333 0.407 -250000 0.4 8558333 0.407 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>11. Stock-Based Compensation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">We award restricted stock or stock options as incentive compensation to employees and compensation to our Board of Directors for services. Generally, these awards include vesting periods of up to three years from the date of grant.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">The 2021 Omnibus Incentive Plan (“2021 Plan”) was adopted by our Board on July 1, 2021. The 2021 Plan provides for the initial reservation of 15 million shares of common stock for issuance, and provides that the maximum number of shares that may be issued pursuant to the exercise of ISOs is 15 million. On the one-year anniversary date of the 2021 Plan, the number of shares of common stock reserved for issuance automatically increased to 20% of the fully diluted common shares outstanding, including shares issuable upon the conversion of preferred shares, as calculated on an as-converted basis.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">In the first quarter of 2021, the Company issued 500,000 restricted shares valued at $155,000 as incentive compensation to two executives who joined the Company. Compensation expense related to these awards totaled $38,750 and $81,000 for the three and six months ended June 30, 2021, respectively. These awards became fully vested in January 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">In the fourth quarter of 2021, the Company awarded options for 13,850,000 shares of the Company’s common stock as incentive compensation to management and the Board of Directors. One-third of the awarded options vested immediately with the remaining options vesting in two equal annual tranches over the next two years. Vested options may be exercised at any time until their expiration after 10 years at an exercise price of $0.76 per share. Unvested options are forfeited upon termination of service. The fair value of the awards at the date of grant was determined using the Black-Scholes option pricing model. Key assumptions included a risk-free interest rate ranging from 1.18% to 1.28%, historical volatility ranging from 331% to 643% and an expected life of the stock options ranging from five to six years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">In the third quarter of 2022, the Company awarded options for 1,915,000 shares of the Company’s common stock as incentive compensation to its CEO and board of directors. The awarded options vest over the next three years. Vested options may be exercised at any time until their expiration ranging from eight to 10 years at their exercise prices ranging from $0.30 to $0.33 per share. Unvested options are forfeited upon termination of service. The fair value of the awards at the date of grant was determined using the Black-Scholes option pricing model. Key assumptions included a risk-free interest rate ranging from 2.87% to 3.03%, historical volatility ranging from 251% to 408% and an expected life of the stock options ranging from four to seven years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">We recognized $1.3 million of compensation expense for these option awards in each of the quarters ended September 30, 2022. As of September 30, 2022, there was $2.7 million of total unrecognized compensation cost related to options to be recognized over a remaining weighted average period of 21 months.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">The following table summarizes options outstanding, as well as activity for the periods presented:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant Date <br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding at December 31, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">13,850,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.76</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.76</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">         -</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; padding-left: 0.125in">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,915,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.30</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.31</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at September 30, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,765,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.70</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.71</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The remaining weighted average contractual life of exercisable options at September 30, 2022 was nine years.</span></p> 15000000 15000000 0.20 500000 155000 38750 81000 13850000 P10Y 0.76 0.0118 0.0128 3.31 6.43 P5Y P6Y 1915000 P3Y P8Y P10Y 0.3 0.33 0.0287 0.0303 2.51 4.08 P4Y P7Y 1300000 2700000 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant Date <br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding at December 31, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">13,850,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.76</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.76</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">         -</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; padding-left: 0.125in">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,915,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.30</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.31</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at September 30, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,765,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.70</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.71</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p> 13850000 0.76 0.76 1915000 0.3 0.31 15765000 0.7 0.71 P9Y <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>12. Discontinued Operations</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In 2019, management determined to fully divest of EHR’s oil and gas activities. As such, these activities are presented as discontinued operations for each of the periods presented. The following is a summary of the carrying amounts of major classes of assets and liabilities of the discontinued operations to assets and liabilities held for sale:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: 0in; padding-left: 0.125in">Oil and natural gas properties held for sale, at cost</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,874,849</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,874,849</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0.125in">Accumulated DD&amp;A</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,874,849</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,874,849</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: 0in; padding-left: 0.125in">Total assets of discontinued operations held for sale</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0in; padding-left: 0.125in">Accrued liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">39,956</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">48,997</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in; padding-left: 0.125in">Asset retirement obligations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,368</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0.125in">Revenue payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in; padding-left: 0.25in">Current liabilities of discontinued operations held for sale</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">144,441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">153,482</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0in; padding-left: 0.125in">Asset retirement obligations -</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0.25in">Long-term liabilities of discontinued operations held for sale</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">199,046</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">162,948</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: 0in; padding-left: 0.125in">Total liabilities of discontinued operations held for sale</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">343,487</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">316,430</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The following is a summary of the major classes of line items constituting loss on discontinued operations shown in the consolidated statements of operations:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Revenue -</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-left: 0.125in">Oil and gas sales</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">41,077</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">55,140</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">116,870</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">93,248</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Costs and Expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 0.125in">Lease operating expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,461</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53,919</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110,649</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,714</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Accretion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,230</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,851</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">36,098</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,883</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total costs and expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,691</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">56,770</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">146,747</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">104,597</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Loss from discontinued operations</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,386</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,630</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(29,877</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,349</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: 0in; padding-left: 0.125in">Oil and natural gas properties held for sale, at cost</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,874,849</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,874,849</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0.125in">Accumulated DD&amp;A</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,874,849</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,874,849</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: 0in; padding-left: 0.125in">Total assets of discontinued operations held for sale</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0in; padding-left: 0.125in">Accrued liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">39,956</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">48,997</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in; padding-left: 0.125in">Asset retirement obligations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,368</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0.125in">Revenue payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in; padding-left: 0.25in">Current liabilities of discontinued operations held for sale</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">144,441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">153,482</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0in; padding-left: 0.125in">Asset retirement obligations -</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0.25in">Long-term liabilities of discontinued operations held for sale</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">199,046</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">162,948</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: 0in; padding-left: 0.125in">Total liabilities of discontinued operations held for sale</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">343,487</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">316,430</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 1874849 1874849 -1874849 -1874849 39956 48997 52368 52368 52117 52117 144441 153482 199046 162948 343487 316430 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Revenue -</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-left: 0.125in">Oil and gas sales</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">41,077</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">55,140</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">116,870</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">93,248</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Costs and Expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 0.125in">Lease operating expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,461</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53,919</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110,649</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,714</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Accretion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,230</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,851</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">36,098</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,883</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total costs and expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,691</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">56,770</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">146,747</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">104,597</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Loss from discontinued operations</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,386</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,630</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(29,877</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,349</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> 41077 55140 116870 93248 25461 53919 110649 94714 5230 2851 36098 9883 30691 56770 146747 104597 10386 -1630 -29877 -11349 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>13. Supplemental Cash Flow Information</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Cash paid for interest</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">50,690</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">127,812</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cash paid for taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Noncash investing and financing activities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Acquisition of certain assets of Halcyon Thruput, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in">- issuance of common shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.25in">- issuance of subordinated note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">850,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 0.25in">- assumption of Halcyon bank note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">995,614</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Series B preferred stock dividend payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60,035</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,137</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 0.125in">Issuance of common stock units previously subscribed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Issuances of common shares for exchange or conversion of debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,160,269</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Cash paid for interest</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">50,690</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">127,812</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cash paid for taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Noncash investing and financing activities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Acquisition of certain assets of Halcyon Thruput, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in">- issuance of common shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.25in">- issuance of subordinated note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">850,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 0.25in">- assumption of Halcyon bank note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">995,614</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Series B preferred stock dividend payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60,035</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,137</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 0.125in">Issuance of common stock units previously subscribed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Issuances of common shares for exchange or conversion of debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,160,269</td><td style="text-align: left"> </td></tr> </table> 50690 127812 2500000 850000 995614 60035 39137 50000 2160269 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>14. Earnings (Loss) per Share</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The following is the computation of earnings (loss) per basic and diluted share:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Amounts attributable to Generation Hemp:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td>Numerator</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Loss from continuing operations attributable to common stockholders</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,465,404</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,376,030</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(6,017,867</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,356,315</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Income (loss) from discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,736</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,528</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(28,007</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,639</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Less: preferred stock dividends</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,668</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,125</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60,035</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(56,625</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.25in">Net loss attributable to common stockholders</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,475,336</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,393,683</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(6,105,909</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4,423,579</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Weighted average shares used to compute basic EPS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,204,002</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,109,797</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,149,973</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,693,679</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Dilutive effect of convertible note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,164,773</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,164,773</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Dilutive effect of preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,950,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,913,657</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,950,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">72,641,084</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Dilutive effect of common stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">125,490</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">122,052</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Dilutive effect of common stock warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">47,560</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,042,419</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,709,576</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,126,327</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.25in">Weighted average shares used to compute diluted EPS</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">117,491,825</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">123,065,873</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">119,096,374</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">122,461,090</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in">Earnings (loss) per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Loss from continuing operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.375in">Basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.05</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.11</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.375in">Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.05</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.11</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Loss from discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.375in">Basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.375in">Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in">Earnings (loss) per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.375in">Basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.05</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.11</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.375in">Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.05</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.11</td><td style="text-align: left">)</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The computation of diluted earnings per common share excludes the assumed conversion of the Series B Preferred Stock and outstanding convertible notes and exercise of common stock options and warrants in periods when we report a loss. The dilutive effect of the assumed exercise of outstanding options and warrants was calculated using the treasury stock method.</span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Amounts attributable to Generation Hemp:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td>Numerator</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Loss from continuing operations attributable to common stockholders</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,465,404</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,376,030</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(6,017,867</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,356,315</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Income (loss) from discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,736</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,528</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(28,007</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,639</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Less: preferred stock dividends</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,668</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,125</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60,035</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(56,625</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.25in">Net loss attributable to common stockholders</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,475,336</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,393,683</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(6,105,909</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4,423,579</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Weighted average shares used to compute basic EPS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,204,002</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,109,797</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,149,973</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,693,679</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Dilutive effect of convertible note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,164,773</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,164,773</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Dilutive effect of preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,950,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,913,657</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,950,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">72,641,084</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Dilutive effect of common stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">125,490</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">122,052</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Dilutive effect of common stock warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">47,560</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,042,419</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,709,576</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,126,327</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.25in">Weighted average shares used to compute diluted EPS</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">117,491,825</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">123,065,873</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">119,096,374</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">122,461,090</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in">Earnings (loss) per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Loss from continuing operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.375in">Basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.05</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.11</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.375in">Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.05</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.11</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Loss from discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.375in">Basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.375in">Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in">Earnings (loss) per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.375in">Basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.05</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.11</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.375in">Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.05</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.11</td><td style="text-align: left">)</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> -1465404 -1376030 -6017867 -4356315 9736 -1528 -28007 -10639 -19668 -16125 -60035 -56625 -1475336 -1393683 -6105909 -4423579 113204002 54109797 113149973 38693679 1164773 1164773 2950000 59913657 2950000 72641084 125490 122052 47560 9042419 1709576 11126327 117491825 123065873 119096374 122461090 -0.01 -0.03 -0.05 -0.11 -0.01 -0.03 -0.05 -0.11 -0.01 -0.03 -0.05 -0.11 -0.01 -0.03 -0.05 -0.11 false --12-31 Q3 0001527102 May be redeemed for $0.0001 per warrant at the Company’s option with 30 days advanced notice should the weighted average market price of common stock exceed $1.00 for any five out of seven consecutive trading days with a minimum average daily trading volume for such seven-day period of at least 25,000 shares of common stock. EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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

G&=;S MTPCK^3D_N\1+F=@5MZ=25\G'3)47,_7;^H;V0W$OV7G_@.Y6R/#>1W=!>?_: MT)?7P9]"L8LS"1*VU4/!6T>7H:*\82T?%#\45XA/7"F>%A_W+(R8R 'Z^RWG MZO4A'Z"^YU[^#U!+ P04 " "S@&Y50FQ'^F,# #4%@ #0 'AL+W-T M>6QEJ_!0$ MU71.J8=&];NKY<*S5,C-AW$,];WCE&2PX:RIZ1 M(,*]SH&+L'<),/'0.4L;XX4.1NX>6A[[J\/(!W69CP99(=;5'ODVH/.3G'I/ MA _],>%L(AFP,I(SOK+A+@2F!2^DI_1MI@V%$*G^6#BT/;@#:YVW@\_RK)Y MJNP:=GJL]QS';O+Z%$S&QV\R2H[?8[WK.W:3_5,P>0K+W7NS)_M+3(:G8+)[ ME":#>D^YL7'=VK:V40]>#X;^#W@=X>NDWF3!N&*B[LU9FE+Q;/>JY169Z%?V M+7U]?4HSLN#JH06'_KK]G:9LD2?M57"C?O)CH7$RE=TG1< M=^5L8IJ>;NBL]0&$7>36'&X$XUC,C0"&Y<$<8!S+PO+\3^/IH^.Q&.:M[T3Z M**>/(7LKP-L3?=5"#92O!*QD>)S#8A[WH"1).[5QO( UL%K'8@OSL/U)2; M$T6PJI@W[ [&D23!$*A%=XW&,3([,7S#*,(0N!MQ!', M'C DBLSOX,[O4=#\3@7K_V./_@)02P,$% @ LX!N59>*NQS $P( M L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE( M2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'K;$U][!I=Q/76,$KMQ?" MUVJ23:>S2W._]89/]D$YNI)+^,$^Z M[THDK)9:UO*7J.;)-&%N;Q[^-E;^,MISM2ZM46J>I/V.;\)Z63YK7@?(.[YQ M78OGFR\<0.;); H#;J5UONO1C<^!\8> SOU6Z\TGJ;RP"^[%7]:TC=2[, R< MQ20ZC2X.PVZ\K M]E%["!);ZGXHZ!O.% Z]K/JS]H ;Q=!>2=AAEU4'3@?Y5?.VDEY4[-KH2FC7 M?W-&R0J((L@,@018(9'%.R"*"O$0@+\\)>1E!SA#( MV3DA9Q'D*P3R%2WDA]9)+9R+:%XC-*]I:=9M77-[8&;+UG*G)?R,A_18EJ:% M]!A!OD$@W]!"@O8:D-*!\9"U_VEE$WX0)^LIEJVGM'1+<*C>A8-V?+=^+RQ[ M[QRH+$9$A4)LE,]0-CBVX@<>*+^S+Z$3/!PK#JH7(TQ,*2FQ4_K0+>'1W0#= MDXFKJ4/G5QWRT&.\U!1"5T^N9B8,%)B8RQU M:6K![OC/,1/FAY18$"%W^$-,@XD@)3;!VIOR_N4'WFNJAI' L9N.\2XV%22(FML&Z;1HG0B2MVS=V>?5+FX;]R/BZ3,3UDQ'KX MR*V&A].QBQOCW NV@A2WWG,[JN,Q.63$^14YGX$C3$QP63$@CF1P(=PQIB89S+R.0B2R,?W(N:;C-@W)Q-Y M'\]XQ0/S34[LFV%^R2X6PG.I1D]-CHDF)Q8-.M<<+QEAHLG/))K'<,:8Z-+6 M.46SB'-0CHDF)Q8-BCF^Z)AH\G6,&S5PO,"XHDQ,[^^"&!.33$$L&11S'$U,,@7U\ADZ;1B]W,,\4Q![!IDVA'C&F)AV MBDX[D^$5>26V4.57G^$0#MI+KLJ59>&C7\4O+L/:W+95ZAK:;O6-X=7PQGWX MM\"[?P%02P,$% @ LX!N58YA./J] 0 >AT !H !X;"]?[0YI6ZYS;MQ#2 M?!WW=>HW;3R;^M5##H8C$)W/Z-ZG]S/[,U.;?S/Q&:Y MW,SC1S/_WL=#_F-P^&FZ;5K'F*O>K.Y6,4^K<-S=;J=PN4C_/+GJ?2ZF5?>Y MD"J4#E((TO)!!D%6/L@AR,L'#2%H6#YH!$&C\D$O$/12/N@5@E[+!XTA:%P^ M2 8HXX @Z0%K JT%N18"KP7!%@*Q!$6 KD%Z18" MNP7Q%@*]%?56 KT5]58"O?7A9YM ;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V5 M0&]%O95 ;T6]E4!O0[V-0&]#O8U ;T.]C4!O>]@L(=#;4&\CT-M0;R/0VU!O M(]#;4&\CT-M0;R/0VU!O(]#;46\GT-M1;R?0VU%O)]#;46\GT-L?-KL)]';4 MVPGT=M3;"?1VU-L)]';4VPGT=M3;GZEWRJ==3+>>ZQJ/;IY)=3Z_&V^?ORRO M-Q'GX07G $>M[[]02P,$% @ LX!N59PKTP^] 0 =QT !, !;0V]N M=&5N=%]4>7!E&ULS=G);L(P% 707T'9(F(\E X"-FVW+8O^@)L\2$02 M6[:A\/=UPB"UHJB(2KV;1(GM=U]LZ6PR?MM:\KU-735^DA0AV ?&?%90K7UJ M+#5Q9&Y\B:]]:9I) MXJCR2>]Q-['-FB3:VJK,=(CC;-WDWU(&^X0TKNSF^**TOA\G).QD0COR<\!^ MW>N:G"MSZLVT"R^ZCK/8IF(^;"ORZ?D2)WHT\WF946ZR51V7I-XZTKDOB$)= MI;NB_?/)(>XP[:[\ZORNS+G .'/FC/7QQ!Q='G&UL4$L! A0#% @ LX!N5&UL M4$L! A0#% @ LX!N59E&PO=V]R:W-H965T&UL M4$L! A0#% @ LX!N5=1N*/E2!P *Q\ !@ ("!K0T M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ LX!N M58**SLC+$ _:, !@ ("!MB 'AL+W=O&PO=V]R:W-H M965T&UL4$L! A0#% @ LX!N5>GYI_>0!P '! !@ M ("!!ST 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ LX!N57?: M#Q+: P =PD !D ("!65$ 'AL+W=O&PO=V]R:W-H965T.*P( ,L$ 9 " @>Y9 !X;"]W;W)K&UL4$L! A0#% @ LX!N54A@W@"!"0 G!0 !D M ("!4%P 'AL+W=O24# #,!@ &0 @($(9@ >&PO M=V]R:W-H965T&UL4$L! A0#% @ LX!N52GDE1X;!P 7Q( !D ("! M9'0 'AL+W=OP >&PO=V]R:W-H965T&UL4$L! A0#% M @ LX!N55PH:IS1! M@L !D ("!RX, 'AL+W=O&PO=V]R:W-H965T. !X M;"]W;W)K&UL4$L! A0#% @ LX!N59XY6K/S M @ 8@8 !D ("!8I$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ LX!N5?*SEUR$ @ E@4 !D M ("!KYL 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ LX!N5?26I*\Y! &0H !D ("! J8 M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MLX!N51."5QCM! *2 !D ("!7+( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ LX!N552:K>3L P X!@ !D M ("!Y-0 'AL+W=O6EK?P% #1' &0 @($'V0 >&PO=V]R:W-H M965T&UL4$L! M A0#% @ LX!N54C(4;)E!0 N!D !D ("!@NH 'AL M+W=O\ >&PO=V]R:W-H965T&UL4$L! A0#% @ LX!N M5:+0L[YJ P W@L !D ("!7OL 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ LX!N5<&%'KK% P ]@P M !D ("!EP8! 'AL+W=O&PO=V]R:W-H965T7!E&UL4$L%!@ Y #D A@\ %4= 0 ! $! end XML 64 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 202 326 1 true 45 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.genhempinc.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Unaudited Condensed Consolidated Balance Sheets Sheet http://www.genhempinc.com/role/ConsolidatedBalanceSheet Unaudited Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals Unaudited Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Unaudited Condensed Consolidated Statements of Operations Sheet http://www.genhempinc.com/role/ConsolidatedIncomeStatement Unaudited Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 004 - Statement - Unaudited Condensed Consolidated Statements of Equity (Deficit) Sheet http://www.genhempinc.com/role/ShareholdersEquityType2or3 Unaudited Condensed Consolidated Statements of Equity (Deficit) Statements 5 false false R6.htm 005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows Sheet http://www.genhempinc.com/role/ConsolidatedCashFlow Unaudited Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 006 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows (Parentheticals) Sheet http://www.genhempinc.com/role/ConsolidatedCashFlow_Parentheticals Unaudited Condensed Consolidated Statements of Cash Flows (Parentheticals) Statements 7 false false R8.htm 007 - Disclosure - Business Sheet http://www.genhempinc.com/role/Business Business Notes 8 false false R9.htm 008 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.genhempinc.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Property and Equipment Sheet http://www.genhempinc.com/role/PropertyandEquipment Property and Equipment Notes 10 false false R11.htm 010 - Disclosure - Intangible and Other Assets Sheet http://www.genhempinc.com/role/IntangibleandOtherAssets Intangible and Other Assets Notes 11 false false R12.htm 011 - Disclosure - Notes Payable ??? Related Parties Notes http://www.genhempinc.com/role/NotesPayableRelatedParties Notes Payable ??? Related Parties Notes 12 false false R13.htm 012 - Disclosure - Other Indebtedness Sheet http://www.genhempinc.com/role/OtherIndebtedness Other Indebtedness Notes 13 false false R14.htm 013 - Disclosure - Leases Sheet http://www.genhempinc.com/role/Leases Leases Notes 14 false false R15.htm 014 - Disclosure - Commitments and Contingencies Sheet http://www.genhempinc.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 15 false false R16.htm 015 - Disclosure - Income Taxes Sheet http://www.genhempinc.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 016 - Disclosure - Equity Sheet http://www.genhempinc.com/role/Equity Equity Notes 17 false false R18.htm 017 - Disclosure - Stock-Based Compensation Sheet http://www.genhempinc.com/role/StockBasedCompensation Stock-Based Compensation Notes 18 false false R19.htm 018 - Disclosure - Discontinued Operations Sheet http://www.genhempinc.com/role/DiscontinuedOperations Discontinued Operations Notes 19 false false R20.htm 019 - Disclosure - Supplemental Cash Flow Information Sheet http://www.genhempinc.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 20 false false R21.htm 020 - Disclosure - Earnings (Loss) Per Share Sheet http://www.genhempinc.com/role/EarningsLossPerShare Earnings (Loss) Per Share Notes 21 false false R22.htm 021 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.genhempinc.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.genhempinc.com/role/SummaryofSignificantAccountingPolicies 22 false false R23.htm 022 - Disclosure - Property and Equipment (Tables) Sheet http://www.genhempinc.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://www.genhempinc.com/role/PropertyandEquipment 23 false false R24.htm 023 - Disclosure - Intangible and Other Assets (Tables) Sheet http://www.genhempinc.com/role/IntangibleandOtherAssetsTables Intangible and Other Assets (Tables) Tables http://www.genhempinc.com/role/IntangibleandOtherAssets 24 false false R25.htm 024 - Disclosure - Notes Payable ??? Related Parties (Tables) Notes http://www.genhempinc.com/role/NotesPayableRelatedPartiesTables Notes Payable ??? Related Parties (Tables) Tables http://www.genhempinc.com/role/NotesPayableRelatedParties 25 false false R26.htm 025 - Disclosure - Equity (Tables) Sheet http://www.genhempinc.com/role/EquityTables Equity (Tables) Tables http://www.genhempinc.com/role/Equity 26 false false R27.htm 026 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.genhempinc.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.genhempinc.com/role/StockBasedCompensation 27 false false R28.htm 027 - Disclosure - Discontinued Operations (Tables) Sheet http://www.genhempinc.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://www.genhempinc.com/role/DiscontinuedOperations 28 false false R29.htm 028 - Disclosure - Supplemental Cash Flow Information (Tables) Sheet http://www.genhempinc.com/role/SupplementalCashFlowInformationTables Supplemental Cash Flow Information (Tables) Tables http://www.genhempinc.com/role/SupplementalCashFlowInformation 29 false false R30.htm 029 - Disclosure - Earnings (Loss) Per Share (Tables) Sheet http://www.genhempinc.com/role/EarningsLossPerShareTables Earnings (Loss) Per Share (Tables) Tables http://www.genhempinc.com/role/EarningsLossPerShare 30 false false R31.htm 030 - Disclosure - Business (Details) Sheet http://www.genhempinc.com/role/BusinessDetails Business (Details) Details http://www.genhempinc.com/role/Business 31 false false R32.htm 031 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.genhempinc.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details 32 false false R33.htm 032 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment Sheet http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable Property and Equipment (Details) - Schedule of property and equipment Details http://www.genhempinc.com/role/PropertyandEquipmentTables 33 false false R34.htm 033 - Disclosure - Intangible and Other Assets (Details) Sheet http://www.genhempinc.com/role/IntangibleandOtherAssetsDetails Intangible and Other Assets (Details) Details http://www.genhempinc.com/role/IntangibleandOtherAssetsTables 34 false false R35.htm 034 - Disclosure - Intangible and Other Assets (Details) - Schedule of intangible asset Sheet http://www.genhempinc.com/role/ScheduleofintangibleassetTable Intangible and Other Assets (Details) - Schedule of intangible asset Details http://www.genhempinc.com/role/IntangibleandOtherAssetsTables 35 false false R36.htm 035 - Disclosure - Notes Payable ??? Related Parties (Details) Notes http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails Notes Payable ??? Related Parties (Details) Details http://www.genhempinc.com/role/NotesPayableRelatedPartiesTables 36 false false R37.htm 036 - Disclosure - Notes Payable ??? Related Parties (Details) - Schedule of notes payable ??? related parties Notes http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable Notes Payable ??? Related Parties (Details) - Schedule of notes payable ??? related parties Details http://www.genhempinc.com/role/NotesPayableRelatedPartiesTables 37 false false R38.htm 037 - Disclosure - Other Indebtedness (Details) Sheet http://www.genhempinc.com/role/OtherIndebtednessDetails Other Indebtedness (Details) Details http://www.genhempinc.com/role/OtherIndebtedness 38 false false R39.htm 038 - Disclosure - Leases (Details) Sheet http://www.genhempinc.com/role/LeasesDetails Leases (Details) Details http://www.genhempinc.com/role/Leases 39 false false R40.htm 039 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.genhempinc.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.genhempinc.com/role/CommitmentsandContingencies 40 false false R41.htm 040 - Disclosure - Equity (Details) Sheet http://www.genhempinc.com/role/EquityDetails Equity (Details) Details http://www.genhempinc.com/role/EquityTables 41 false false R42.htm 041 - Disclosure - Equity (Details) - Schedule of warrants outstanding Sheet http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable Equity (Details) - Schedule of warrants outstanding Details http://www.genhempinc.com/role/EquityTables 42 false false R43.htm 042 - Disclosure - Equity (Details) - Schedule of outstanding stock warrants activity Sheet http://www.genhempinc.com/role/ScheduleofoutstandingstockwarrantsactivityTable Equity (Details) - Schedule of outstanding stock warrants activity Details http://www.genhempinc.com/role/EquityTables 43 false false R44.htm 043 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.genhempinc.com/role/StockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.genhempinc.com/role/StockBasedCompensationTables 44 false false R45.htm 044 - Disclosure - Stock-Based Compensation (Details) - Schedule of summarizes options outstanding Sheet http://www.genhempinc.com/role/ScheduleofsummarizesoptionsoutstandingTable Stock-Based Compensation (Details) - Schedule of summarizes options outstanding Details http://www.genhempinc.com/role/StockBasedCompensationTables 45 false false R46.htm 045 - Disclosure - Discontinued Operations (Details) - Schedule of discontinued operations to assets and liabilities held for sale Sheet http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable Discontinued Operations (Details) - Schedule of discontinued operations to assets and liabilities held for sale Details http://www.genhempinc.com/role/DiscontinuedOperationsTables 46 false false R47.htm 046 - Disclosure - Discontinued Operations (Details) - Schedule of discontinued operations shown in the consolidated statements of operations Sheet http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable Discontinued Operations (Details) - Schedule of discontinued operations shown in the consolidated statements of operations Details http://www.genhempinc.com/role/DiscontinuedOperationsTables 47 false false R48.htm 047 - Disclosure - Supplemental Cash Flow Information (Details) - Schedule of supplemental cash flow information Sheet http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable Supplemental Cash Flow Information (Details) - Schedule of supplemental cash flow information Details http://www.genhempinc.com/role/SupplementalCashFlowInformationTables 48 false false R49.htm 048 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of earnings (loss) per basic and diluted share Sheet http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable Earnings (Loss) Per Share (Details) - Schedule of earnings (loss) per basic and diluted share Details http://www.genhempinc.com/role/EarningsLossPerShareTables 49 false false All Reports Book All Reports f10q0922_generation.htm f10q0922ex10-1_generation.htm f10q0922ex10-2_generation.htm f10q0922ex10-3_generation.htm f10q0922ex10-4_generation.htm f10q0922ex31-1_generation.htm f10q0922ex32-1_generation.htm genh-20220930.xsd genh-20220930_cal.xml genh-20220930_def.xml genh-20220930_lab.xml genh-20220930_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 68 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q0922_generation.htm": { "axisCustom": 0, "axisStandard": 13, "contextCount": 202, "dts": { "calculationLink": { "local": [ "genh-20220930_cal.xml" ] }, "definitionLink": { "local": [ "genh-20220930_def.xml" ] }, "inline": { "local": [ "f10q0922_generation.htm" ] }, "labelLink": { "local": [ "genh-20220930_lab.xml" ] }, "presentationLink": { "local": [ "genh-20220930_pre.xml" ] }, "schema": { "local": [ "genh-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd" ] } }, "elementCount": 475, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 200, "http://www.genhempinc.com/20220930": 65, "http://xbrl.sec.gov/dei/2022": 4, "total": 269 }, "keyCustom": 84, "keyStandard": 242, "memberCustom": 22, "memberStandard": 21, "nsprefix": "genh", "nsuri": "http://www.genhempinc.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.genhempinc.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Property and Equipment", "role": "http://www.genhempinc.com/role/PropertyandEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Intangible and Other Assets", "role": "http://www.genhempinc.com/role/IntangibleandOtherAssets", "shortName": "Intangible and Other Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Notes Payable \u2013 Related Parties", "role": "http://www.genhempinc.com/role/NotesPayableRelatedParties", "shortName": "Notes Payable \u2013 Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MortgageNotesPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Other Indebtedness", "role": "http://www.genhempinc.com/role/OtherIndebtedness", "shortName": "Other Indebtedness", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MortgageNotesPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Leases", "role": "http://www.genhempinc.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Commitments and Contingencies", "role": "http://www.genhempinc.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Income Taxes", "role": "http://www.genhempinc.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Equity", "role": "http://www.genhempinc.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Stock-Based Compensation", "role": "http://www.genhempinc.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Discontinued Operations", "role": "http://www.genhempinc.com/role/DiscontinuedOperations", "shortName": "Discontinued Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Unaudited Condensed Consolidated Balance Sheets", "role": "http://www.genhempinc.com/role/ConsolidatedBalanceSheet", "shortName": "Unaudited Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Supplemental Cash Flow Information", "role": "http://www.genhempinc.com/role/SupplementalCashFlowInformation", "shortName": "Supplemental Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Earnings (Loss) Per Share", "role": "http://www.genhempinc.com/role/EarningsLossPerShare", "shortName": "Earnings (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://www.genhempinc.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Property and Equipment (Tables)", "role": "http://www.genhempinc.com/role/PropertyandEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Intangible and Other Assets (Tables)", "role": "http://www.genhempinc.com/role/IntangibleandOtherAssetsTables", "shortName": "Intangible and Other Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "genh:ScheduleOfNotesPayableRelatedPartiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Notes Payable \u2013 Related Parties (Tables)", "role": "http://www.genhempinc.com/role/NotesPayableRelatedPartiesTables", "shortName": "Notes Payable \u2013 Related Parties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "genh:ScheduleOfNotesPayableRelatedPartiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "genh:ScheduleOfWarrantsOutstandingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Equity (Tables)", "role": "http://www.genhempinc.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "genh:ScheduleOfWarrantsOutstandingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.genhempinc.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "genh:ScheduleOfDiscontinuedOperationsToAssetsAndLiabilitiesHeldForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Discontinued Operations (Tables)", "role": "http://www.genhempinc.com/role/DiscontinuedOperationsTables", "shortName": "Discontinued Operations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "genh:ScheduleOfDiscontinuedOperationsToAssetsAndLiabilitiesHeldForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Supplemental Cash Flow Information (Tables)", "role": "http://www.genhempinc.com/role/SupplementalCashFlowInformationTables", "shortName": "Supplemental Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c2", "decimals": "5", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals)", "role": "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Unaudited Condensed Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c2", "decimals": "5", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Earnings (Loss) Per Share (Tables)", "role": "http://www.genhempinc.com/role/EarningsLossPerShareTables", "shortName": "Earnings (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c104", "decimals": "0", "first": true, "lang": null, "name": "genh:SquareFootFacility", "reportCount": 1, "unique": true, "unitRef": "usdPersqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Business (Details)", "role": "http://www.genhempinc.com/role/BusinessDetails", "shortName": "Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c104", "decimals": "0", "first": true, "lang": null, "name": "genh:SquareFootFacility", "reportCount": 1, "unique": true, "unitRef": "usdPersqft", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueRecognitionPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c105", "decimals": "0", "first": true, "lang": null, "name": "genh:SaleOfPounds", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://www.genhempinc.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueRecognitionPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c105", "decimals": "0", "first": true, "lang": null, "name": "genh:SaleOfPounds", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment", "role": "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable", "shortName": "Property and Equipment (Details) - Schedule of property and equipment", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherAssetsNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Intangible and Other Assets (Details)", "role": "http://www.genhempinc.com/role/IntangibleandOtherAssetsDetails", "shortName": "Intangible and Other Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "lang": "en-US", "name": "genh:OptionToPurchaseDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Intangible and Other Assets (Details) - Schedule of intangible asset", "role": "http://www.genhempinc.com/role/ScheduleofintangibleassetTable", "shortName": "Intangible and Other Assets (Details) - Schedule of intangible asset", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentMaturityDateDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Notes Payable \u2013 Related Parties (Details)", "role": "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails", "shortName": "Notes Payable \u2013 Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentMaturityDateDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "genh:ScheduleOfNotesPayableRelatedPartiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Notes Payable \u2013 Related Parties (Details) - Schedule of notes payable \u2013 related parties", "role": "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable", "shortName": "Notes Payable \u2013 Related Parties (Details) - Schedule of notes payable \u2013 related parties", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "genh:ScheduleOfNotesPayableRelatedPartiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "genh:MortgagePayableDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Other Indebtedness (Details)", "role": "http://www.genhempinc.com/role/OtherIndebtednessDetails", "shortName": "Other Indebtedness (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "genh:MortgagePayableDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Leases (Details)", "role": "http://www.genhempinc.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "genh:PostharvestAndMidstreamServices", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Unaudited Condensed Consolidated Statements of Operations", "role": "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "shortName": "Unaudited Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "genh:PostharvestAndMidstreamServices", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireMachineryAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireMachineryAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredStockConvertibleSharesIssuable", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Equity (Details)", "role": "http://www.genhempinc.com/role/EquityDetails", "shortName": "Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredStockConvertibleSharesIssuable", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "genh:ScheduleOfWarrantsOutstandingTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Equity (Details) - Schedule of warrants outstanding", "role": "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable", "shortName": "Equity (Details) - Schedule of warrants outstanding", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "genh:ScheduleOfWarrantsOutstandingTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "genh:ScheduleOfOutstandingStockWarrantsActivityTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Equity (Details) - Schedule of outstanding stock warrants activity", "role": "http://www.genhempinc.com/role/ScheduleofoutstandingstockwarrantsactivityTable", "shortName": "Equity (Details) - Schedule of outstanding stock warrants activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "genh:ScheduleOfOutstandingStockWarrantsActivityTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c186", "decimals": "2", "first": true, "lang": null, "name": "genh:CommonSharesDiluted", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Stock-Based Compensation (Details)", "role": "http://www.genhempinc.com/role/StockBasedCompensationDetails", "shortName": "Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c186", "decimals": "2", "first": true, "lang": null, "name": "genh:CommonSharesDiluted", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Stock-Based Compensation (Details) - Schedule of summarizes options outstanding", "role": "http://www.genhempinc.com/role/ScheduleofsummarizesoptionsoutstandingTable", "shortName": "Stock-Based Compensation (Details) - Schedule of summarizes options outstanding", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "genh:ScheduleOfDiscontinuedOperationsToAssetsAndLiabilitiesHeldForSaleTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c196", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Discontinued Operations (Details) - Schedule of discontinued operations to assets and liabilities held for sale", "role": "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable", "shortName": "Discontinued Operations (Details) - Schedule of discontinued operations to assets and liabilities held for sale", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "genh:ScheduleOfDiscontinuedOperationsToAssetsAndLiabilitiesHeldForSaleTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c196", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c198", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Discontinued Operations (Details) - Schedule of discontinued operations shown in the consolidated statements of operations", "role": "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable", "shortName": "Discontinued Operations (Details) - Schedule of discontinued operations shown in the consolidated statements of operations", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c198", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Supplemental Cash Flow Information (Details) - Schedule of supplemental cash flow information", "role": "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable", "shortName": "Supplemental Cash Flow Information (Details) - Schedule of supplemental cash flow information", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "genh:NetLossFromContinuingOperationsAttributableToCommonStockholders", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of earnings (loss) per basic and diluted share", "role": "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable", "shortName": "Earnings (Loss) Per Share (Details) - Schedule of earnings (loss) per basic and diluted share", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "genh:NetLossFromContinuingOperationsAttributableToCommonStockholders", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c15", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Unaudited Condensed Consolidated Statements of Equity (Deficit)", "role": "http://www.genhempinc.com/role/ShareholdersEquityType2or3", "shortName": "Unaudited Condensed Consolidated Statements of Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c22", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows", "role": "http://www.genhempinc.com/role/ConsolidatedCashFlow", "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAcquiredFromAcquisition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows (Parentheticals)", "role": "http://www.genhempinc.com/role/ConsolidatedCashFlow_Parentheticals", "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAcquiredFromAcquisition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Business", "role": "http://www.genhempinc.com/role/Business", "shortName": "Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.genhempinc.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 45, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "genh_AccruedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of accrued interest.", "label": "Accrued Interest", "terseLabel": "Accrued interest" } } }, "localname": "AccruedInterest", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "genh_AcquisitionOfCertainAssetsOfHalcyonThruputLlcAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquisition Of Certain Assets Of Halcyon Thruput Llc Abstract", "terseLabel": "Acquisition of certain assets of Halcyon Thruput, LLC" } } }, "localname": "AcquisitionOfCertainAssetsOfHalcyonThruputLlcAbstract", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "stringItemType" }, "genh_AdditionalAdvances": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of additional advances.", "label": "Additional Advances", "terseLabel": "Additional advances" } } }, "localname": "AdditionalAdvances", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "genh_AdvancesTotaling": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Advances totaling.", "label": "Advances Totaling", "terseLabel": "Advances totaling" } } }, "localname": "AdvancesTotaling", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "genh_AggregateGrossProceeds": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of proceeds from the gross.", "label": "Aggregate Gross Proceeds", "terseLabel": "Aggregate gross proceeds (in Dollars)" } } }, "localname": "AggregateGrossProceeds", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "genh_AggregateIntrinsicValueGranted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Number of aggregate intrinsic value granted.", "label": "Aggregate Intrinsic Value Granted", "terseLabel": "Aggregate Intrinsic Value Granted (in Dollars)" } } }, "localname": "AggregateIntrinsicValueGranted", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsummarizesoptionsoutstandingTable" ], "xbrltype": "monetaryItemType" }, "genh_AssumptionOfHalcyonBankNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Assumption of Halcyon bank note.", "label": "Assumption Of Halcyon Bank Note", "terseLabel": "- assumption of Halcyon bank note" } } }, "localname": "AssumptionOfHalcyonBankNote", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "monetaryItemType" }, "genh_BorrowingRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowing rate percentage.", "label": "Borrowing Rate Percentage", "terseLabel": "Borrowing rate percentage" } } }, "localname": "BorrowingRatePercentage", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/LeasesDetails" ], "xbrltype": "percentItemType" }, "genh_BusinessDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business (Details) [Line Items]" } } }, "localname": "BusinessDetailsLineItems", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails" ], "xbrltype": "stringItemType" }, "genh_BusinessDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business (Details) [Table]" } } }, "localname": "BusinessDetailsTable", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails" ], "xbrltype": "stringItemType" }, "genh_ChangeInCommonStockParValueDueToChangeInCorporateDomicile": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of change in common stock par value due to change in corporate domicile.", "label": "Change In Common Stock Par Value Due To Change In Corporate Domicile", "terseLabel": "Change in common stock par value due to change in corporate domicile" } } }, "localname": "ChangeInCommonStockParValueDueToChangeInCorporateDomicile", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "genh_CommitmentsandContingenciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Line Items]" } } }, "localname": "CommitmentsandContingenciesDetailsLineItems", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "genh_CommitmentsandContingenciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "localname": "CommitmentsandContingenciesDetailsTable", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "genh_CommonSharesDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common shares diluted.", "label": "Common Shares Diluted", "terseLabel": "Diluted common shares outstanding percentage" } } }, "localname": "CommonSharesDiluted", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "genh_CommonStockForIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock for issuance.", "label": "Common Stock For Issuance", "terseLabel": "common stock for issuance" } } }, "localname": "CommonStockForIssuance", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "genh_CommonStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Units Member", "terseLabel": "Common stock units [Member]" } } }, "localname": "CommonStockUnitsMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "genh_ConversionOfSeriesAPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount conversion of preferred stock.", "label": "Conversion Of Series APreferred Stock", "terseLabel": "Conversion of Series A preferred stock" } } }, "localname": "ConversionOfSeriesAPreferredStock", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "genh_ConversionOfSeriesAPreferredStockinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of conversion of series A preferred stock.", "label": "Conversion Of Series APreferred Stockin Shares", "terseLabel": "Conversion of Series A preferred stock (in Shares)" } } }, "localname": "ConversionOfSeriesAPreferredStockinShares", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "genh_ConvertiblePromissoryNoteToCEOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Note To CEOMember", "terseLabel": "Convertible Promissory Note to CEO [Member]" } } }, "localname": "ConvertiblePromissoryNoteToCEOMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails", "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "domainItemType" }, "genh_CurrentLiabilitiesOfDiscontinuedOperationsHeldForSale": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current liabilities of discontinued operations held for sale.", "label": "Current Liabilities Of Discontinued Operations Held For Sale", "terseLabel": "Current liabilities of discontinued operations held for sale" } } }, "localname": "CurrentLiabilitiesOfDiscontinuedOperationsHeldForSale", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "genh_DecemberTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "December Two Thousand Twenty Member", "terseLabel": "Issued in December 2020 [Member]" } } }, "localname": "DecemberTwoThousandTwentyMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "genh_DecemberTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "December Two Thousand Twenty One Member", "terseLabel": "Issued in Q4 2021 [Member]" } } }, "localname": "DecemberTwoThousandTwentyOneMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "genh_DenominatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator Abstract", "terseLabel": "Denominator" } } }, "localname": "DenominatorAbstract", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "stringItemType" }, "genh_DescriptionOfBusinessDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description Of Business Description", "terseLabel": "Description of business, description" } } }, "localname": "DescriptionOfBusinessDescription", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails" ], "xbrltype": "stringItemType" }, "genh_DescriptionOfDirectorNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of Director Notes.", "label": "Description Of Director Notes", "terseLabel": "Description of director notes" } } }, "localname": "DescriptionOfDirectorNotes", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "genh_DescriptionOfSuitAgainstUNIC": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of Suit against UNIC.", "label": "Description Of Suit Against UNIC", "terseLabel": "Description of suit against UNIC" } } }, "localname": "DescriptionOfSuitAgainstUNIC", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "genh_DilutiveEffectOfCommonStockOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dilutive effect of common stock options.", "label": "Dilutive Effect Of Common Stock Options", "terseLabel": "Dilutive effect of common stock options" } } }, "localname": "DilutiveEffectOfCommonStockOptions", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "sharesItemType" }, "genh_DilutiveEffectOfCommonStockWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dilutive effect of common stock warrants.", "label": "Dilutive Effect Of Common Stock Warrants", "terseLabel": "Dilutive effect of common stock warrants" } } }, "localname": "DilutiveEffectOfCommonStockWarrants", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "sharesItemType" }, "genh_DilutiveEffectOfConvertibleNote": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dilutive effect of convertible note.", "label": "Dilutive Effect Of Convertible Note", "terseLabel": "Dilutive effect of convertible note" } } }, "localname": "DilutiveEffectOfConvertibleNote", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "sharesItemType" }, "genh_DilutiveEffectOfPreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dilutive effect of preferred stock.", "label": "Dilutive Effect Of Preferred Stock", "terseLabel": "Dilutive effect of preferred stock" } } }, "localname": "DilutiveEffectOfPreferredStock", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "sharesItemType" }, "genh_DiscontinuedOperationsDetailsScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations (Details) - Schedule of discontinued operations to assets and liabilities held for sale [Line Items]" } } }, "localname": "DiscontinuedOperationsDetailsScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleLineItems", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable" ], "xbrltype": "stringItemType" }, "genh_DiscontinuedOperationsDetailsScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations (Details) - Schedule of discontinued operations to assets and liabilities held for sale [Table]" } } }, "localname": "DiscontinuedOperationsDetailsScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable" ], "xbrltype": "stringItemType" }, "genh_DisposaGroupIncludingDiscontinuedOperationAccumulatedDDA": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accumulated DD&A.", "label": "Disposa Group Including Discontinued Operation Accumulated DDA", "terseLabel": "Accumulated DD&A" } } }, "localname": "DisposaGroupIncludingDiscontinuedOperationAccumulatedDDA", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable" ], "xbrltype": "monetaryItemType" }, "genh_DisposalGroupIncludingDiscontinuedOperationAccretion": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued pperation accretion.", "label": "Disposal Group Including Discontinued Operation Accretion", "terseLabel": "Accretion" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccretion", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "genh_DisposalGroupIncludingDiscontinuedOperationCostsAndExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs and expenses.", "label": "Disposal Group Including Discontinued Operation Costs And Expenses", "terseLabel": "Total costs and expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostsAndExpenses", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "genh_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.genhempinc.com/20220930", "xbrltype": "stringItemType" }, "genh_EarningsLossPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Loss Per Share Abstract", "terseLabel": "Earnings (loss) per share" } } }, "localname": "EarningsLossPerShareAbstract", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "genh_EarningsLossPerShareAbstract0": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Loss Per Share Abstract0", "terseLabel": "Earnings (loss) per share:" } } }, "localname": "EarningsLossPerShareAbstract0", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "stringItemType" }, "genh_EarningsLossPerShareAbstract1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Loss Per Share Abstract1", "terseLabel": "Earnings (loss) per share" } } }, "localname": "EarningsLossPerShareAbstract1", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "stringItemType" }, "genh_EnergyHunterResourcesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Energy Hunter Resources Inc Member", "terseLabel": "Energy Hunter Resources, Inc. [Member]" } } }, "localname": "EnergyHunterResourcesIncMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails" ], "xbrltype": "domainItemType" }, "genh_EquityDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity description.", "label": "Equity Description", "terseLabel": "Equity, description" } } }, "localname": "EquityDescription", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "genh_EquityDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity (Details) [Line Items]" } } }, "localname": "EquityDetailsLineItems", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "genh_EquityDetailsScheduleofwarrantsoutstandingLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity (Details) - Schedule of warrants outstanding [Line Items]" } } }, "localname": "EquityDetailsScheduleofwarrantsoutstandingLineItems", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "stringItemType" }, "genh_EquityDetailsScheduleofwarrantsoutstandingTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity (Details) - Schedule of warrants outstanding [Table]" } } }, "localname": "EquityDetailsScheduleofwarrantsoutstandingTable", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "stringItemType" }, "genh_EquityDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity (Details) [Table]" } } }, "localname": "EquityDetailsTable", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "genh_ExercisePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share.", "label": "Exercise Price Per Share", "terseLabel": "Exercise price per share (in Dollars per share)" } } }, "localname": "ExercisePricePerShare", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "perShareItemType" }, "genh_ExtensionDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension date.", "label": "Extension Date", "terseLabel": "Extension date" } } }, "localname": "ExtensionDate", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "dateItemType" }, "genh_FinancingObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of financing obligations.", "label": "Financing Obligations", "terseLabel": "Financing obligations" } } }, "localname": "FinancingObligations", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails" ], "xbrltype": "monetaryItemType" }, "genh_FinancingObligationsTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financing obligations terms.", "label": "Financing Obligations Terms", "terseLabel": "Financing obligations terms" } } }, "localname": "FinancingObligationsTerms", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails" ], "xbrltype": "durationItemType" }, "genh_GainLossChangeInFairValueOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of marketable securities.", "label": "Gain Loss Change In Fair Value Of Marketable Securities", "negatedLabel": "Change in fair value of marketable securities" } } }, "localname": "GainLossChangeInFairValueOfMarketableSecurities", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "genh_GrandTraverseHoldingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Grand Traverse Holdings LLCMember", "terseLabel": "Grand Traverse Holdings, LLC [Member]" } } }, "localname": "GrandTraverseHoldingsLLCMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "genh_HalcyonThruputLLCsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Halcyon Thruput LLCs Member", "terseLabel": "Halcyon Thruput LLC\u2019s [Member]" } } }, "localname": "HalcyonThruputLLCsMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "genh_InsuranceSettlementsReceivables": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.", "label": "Insurance Settlements Receivables", "terseLabel": "Insurance claim for replacement" } } }, "localname": "InsuranceSettlementsReceivables", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "genh_InterestExpenses": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest expense.", "label": "Interest Expenses", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenses", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "genh_InterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate.", "label": "Interest Rate", "terseLabel": "Interest rate" } } }, "localname": "InterestRate", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "percentItemType" }, "genh_IssuanceOfCommonShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common shares.", "label": "Issuance Of Common Shares", "terseLabel": "- issuance of common shares" } } }, "localname": "IssuanceOfCommonShares", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "monetaryItemType" }, "genh_IssuanceOfCommonSharesForExtensionOfSecuredNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of issuance of common shares for extension of secured note.", "label": "Issuance Of Common Shares For Extension Of Secured Note", "terseLabel": "Issuance of common shares for extension of secured note" } } }, "localname": "IssuanceOfCommonSharesForExtensionOfSecuredNote", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "genh_IssuanceOfCommonSharesForExtensionOfSecuredNoteinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The shares of issuance for common shares for extension of secured note.", "label": "Issuance Of Common Shares For Extension Of Secured Notein Shares", "terseLabel": "Issuance of common shares for extension of secured note (in Shares)" } } }, "localname": "IssuanceOfCommonSharesForExtensionOfSecuredNoteinShares", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "genh_IssuanceOfCommonStockUnits": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock units.", "label": "Issuance Of Common Stock Units", "terseLabel": "Issuance of common stock units" } } }, "localname": "IssuanceOfCommonStockUnits", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "genh_IssuanceOfCommonStockUnitsPreviouslySubscribed": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock units previously subscribed.", "label": "Issuance Of Common Stock Units Previously Subscribed", "terseLabel": "Issuance of common stock units previously subscribed" } } }, "localname": "IssuanceOfCommonStockUnitsPreviouslySubscribed", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "monetaryItemType" }, "genh_IssuanceOfSubordinatedNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of subordinated note", "label": "Issuance Of Subordinated Note", "terseLabel": "- issuance of subordinated note" } } }, "localname": "IssuanceOfSubordinatedNote", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "monetaryItemType" }, "genh_IssuancesOfCommonSharesForExchangeOrConversionOfDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuances of common shares for exchange or conversion of debt.", "label": "Issuances Of Common Shares For Exchange Or Conversion Of Debt", "terseLabel": "Issuances of common shares for exchange or conversion of debt" } } }, "localname": "IssuancesOfCommonSharesForExchangeOrConversionOfDebt", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "monetaryItemType" }, "genh_LeaseAndRentalExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease and rental expenses.", "label": "Lease And Rental Expenses", "terseLabel": "Lease and rental expense" } } }, "localname": "LeaseAndRentalExpenses", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "monetaryItemType" }, "genh_LeasesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) [Line Items]" } } }, "localname": "LeasesDetailsLineItems", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "genh_LeasesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) [Table]" } } }, "localname": "LeasesDetailsTable", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "genh_LessPreferredStockDividends": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Less: preferred stock dividends.", "label": "Less Preferred Stock Dividends", "terseLabel": "Less: preferred stock dividends" } } }, "localname": "LessPreferredStockDividends", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "monetaryItemType" }, "genh_LitigationSettlementInterestPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Litigation Settlement interest percentage.", "label": "Litigation Settlement Interest Percentage", "terseLabel": "Litigation settlement interest percentage" } } }, "localname": "LitigationSettlementInterestPercentage", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "genh_LongtermLiabilitiesOfDiscontinuedOperationsHeldForSale": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term liabilities of discontinued operations held for sale.", "label": "Longterm Liabilities Of Discontinued Operations Held For Sale", "terseLabel": "Long-term liabilities of discontinued operations held for sale" } } }, "localname": "LongtermLiabilitiesOfDiscontinuedOperationsHeldForSale", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable" ], "xbrltype": "monetaryItemType" }, "genh_LossFromContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss From Continuing Operations Abstract", "terseLabel": "Loss from continuing operations" } } }, "localname": "LossFromContinuingOperationsAbstract", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "stringItemType" }, "genh_LossFromDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss From Discontinued Operations Abstract", "terseLabel": "Loss from discontinued operations" } } }, "localname": "LossFromDiscontinuedOperationsAbstract", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "stringItemType" }, "genh_MarchTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "March Two Thousand Twenty One Member", "terseLabel": "Issued in Q1 2021 [Member]" } } }, "localname": "MarchTwoThousandTwentyOneMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "genh_MergerAndAcquisitionCosts": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Merger and acquisition costs.", "label": "Merger And Acquisition Costs", "terseLabel": "Merger and acquisition costs" } } }, "localname": "MergerAndAcquisitionCosts", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "genh_ModificationOfWarrantsForExtensionOfPromissoryNoteToInvestor": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of modification of warrants for extension of promissory note to investor.", "label": "Modification Of Warrants For Extension Of Promissory Note To Investor", "terseLabel": "Modification of warrants for extension of promissory note to investor" } } }, "localname": "ModificationOfWarrantsForExtensionOfPromissoryNoteToInvestor", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "genh_MonthlyRent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Monthly rent.", "label": "Monthly Rent", "terseLabel": "Monthly rent" } } }, "localname": "MonthlyRent", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "genh_MortgagePayableDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of mortgage payable.", "label": "Mortgage Payable Description", "terseLabel": "Mortgage payable, description" } } }, "localname": "MortgagePayableDescription", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "stringItemType" }, "genh_NetAcquiredCash": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of net acquired cash.", "label": "Net Acquired Cash", "terseLabel": "Acquisition of certain assets of Halcyon Thruput, LLC, net of acquired cash of $224,530" } } }, "localname": "NetAcquiredCash", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "genh_NetLossFromContinuingOperationsAttributableToCommonStockholders": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss from continuing operations attributable to common stockholders.", "label": "Net Loss From Continuing Operations Attributable To Common Stockholders", "terseLabel": "Loss from continuing operations attributable to common stockholders" } } }, "localname": "NetLossFromContinuingOperationsAttributableToCommonStockholders", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "monetaryItemType" }, "genh_NewEquityCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "New equity capital.", "label": "New Equity Capital", "terseLabel": "New equity capital" } } }, "localname": "NewEquityCapital", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "genh_NoncompetitionAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncompetition Agreements Member", "terseLabel": "Non-competition agreements [Member]" } } }, "localname": "NoncompetitionAgreementsMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofintangibleassetTable" ], "xbrltype": "domainItemType" }, "genh_NotePayableToDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable To Director Member", "terseLabel": "Note payable to Director [Member]" } } }, "localname": "NotePayableToDirectorMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "domainItemType" }, "genh_NotesPayableRelatedPartiesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable \u2013 Related Parties (Details) [Line Items]" } } }, "localname": "NotesPayableRelatedPartiesDetailsLineItems", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "genh_NotesPayableRelatedPartiesDetailsScheduleofnotespayablerelatedpartiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable \u2013 Related Parties (Details) - Schedule of notes payable \u2013 related parties [Line Items]" } } }, "localname": "NotesPayableRelatedPartiesDetailsScheduleofnotespayablerelatedpartiesLineItems", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "stringItemType" }, "genh_NotesPayableRelatedPartiesDetailsScheduleofnotespayablerelatedpartiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable \u2013 Related Parties (Details) - Schedule of notes payable \u2013 related parties [Table]" } } }, "localname": "NotesPayableRelatedPartiesDetailsScheduleofnotespayablerelatedpartiesTable", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "stringItemType" }, "genh_NotesPayableRelatedPartiesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable \u2013 Related Parties (Details) [Table]" } } }, "localname": "NotesPayableRelatedPartiesDetailsTable", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "genh_NumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares.", "label": "Number Of Shares", "terseLabel": "Number of shares" } } }, "localname": "NumberOfShares", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "genh_NumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator Abstract", "terseLabel": "Numerator" } } }, "localname": "NumeratorAbstract", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "stringItemType" }, "genh_OperatingLeasesFutureMinimumPaymentsRentTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Leases Future Minimum Payments Rent Twelve Months.", "label": "Operating Leases Future Minimum Payments Rent Twelve Months", "terseLabel": "Minimum future of remainder of 2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsRentTwelveMonths", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "monetaryItemType" }, "genh_OperatingLeasesFutureMinimumPaymentsRentTwoYears": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Leases Future Minimum Payments Rent Two Years.", "label": "Operating Leases Future Minimum Payments Rent Two Years", "terseLabel": "Minimum future of remainder of 2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsRentTwoYears", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "monetaryItemType" }, "genh_OptionToPurchaseDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option to purchase description.", "label": "Option To Purchase Description", "terseLabel": "Option to purchase, description" } } }, "localname": "OptionToPurchaseDescription", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/IntangibleandOtherAssetsDetails" ], "xbrltype": "stringItemType" }, "genh_OtherIndebtednessCurrent": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other indebtedness - current.", "label": "Other Indebtedness Current", "terseLabel": "Other indebtedness - current" } } }, "localname": "OtherIndebtednessCurrent", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "genh_OwnsApproximatelysPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Owns approximately Percentage.", "label": "Owns Approximatelys Percent", "terseLabel": "Percentage of common stock" } } }, "localname": "OwnsApproximatelysPercent", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails" ], "xbrltype": "percentItemType" }, "genh_OzCapitalLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Oz Capital LLCMember", "terseLabel": "Oz Capital, LLC [Member]" } } }, "localname": "OzCapitalLLCMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "genh_PaymentOfMortgagePayable": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of The fair value of transfer of mortgage payable in financing activities.", "label": "Payment Of Mortgage Payable", "negatedLabel": "Payment of mortgage payable" } } }, "localname": "PaymentOfMortgagePayable", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "genh_PostharvestAndMidstreamServices": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Post-harvest and midstream services.", "label": "Postharvest And Midstream Services", "terseLabel": "Post-harvest and midstream services" } } }, "localname": "PostharvestAndMidstreamServices", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "genh_PreferredStockStatedValues": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Preferred stock, Stated Value.", "label": "Preferred Stock Stated Values", "terseLabel": "Preferred stock, stated Value (in Dollars)", "verboseLabel": "Stated value per share (in Dollars)" } } }, "localname": "PreferredStockStatedValues", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "genh_ProceedsFromSaleOfInvestmentInCommonStock": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of investment in common stock.", "label": "Proceeds From Sale Of Investment In Common Stock", "terseLabel": "Proceeds from sale of investment in common stock" } } }, "localname": "ProceedsFromSaleOfInvestmentInCommonStock", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "genh_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Note Member", "terseLabel": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "genh_PromissoryNoteToInvestmentHunterLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Note To Investment Hunter LLCMember", "terseLabel": "Promissory Note to Investment Hunter, LLC [Member]" } } }, "localname": "PromissoryNoteToInvestmentHunterLLCMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails", "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "domainItemType" }, "genh_PropertyAndEquipmentUsefulLifeyrs": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property and equipment, Useful Life.", "label": "Property And Equipment Useful Lifeyrs", "terseLabel": "Property and equipment, useful Life (years)" } } }, "localname": "PropertyAndEquipmentUsefulLifeyrs", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "durationItemType" }, "genh_RedemptionsOfSeriesBPreferredStock": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of Redemptions preferred stock.", "label": "Redemptions Of Series BPreferred Stock", "negatedLabel": "Redemptions of Series B preferred stock" } } }, "localname": "RedemptionsOfSeriesBPreferredStock", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "genh_Rental": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of rental.", "label": "Rental", "terseLabel": "Rental" } } }, "localname": "Rental", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "genh_RepaymentOfSubordinatedNotes": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of subordinated notes.", "label": "Repayment Of Subordinated Notes", "negatedLabel": "Repayment of subordinated notes" } } }, "localname": "RepaymentOfSubordinatedNotes", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "genh_RestrictedCommonShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted common shares.", "label": "Restricted Common Shares", "terseLabel": "Restricted common shares (in Shares)" } } }, "localname": "RestrictedCommonShares", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "sharesItemType" }, "genh_RevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Abstract", "terseLabel": "Revenue -" } } }, "localname": "RevenueAbstract", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "stringItemType" }, "genh_SaleOfPounds": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shorting (or 'selling') the pound means taking a position that will earn you a profit if the value of the pound goes down in relation to other currencies.", "label": "Sale Of Pounds", "terseLabel": "Sale of pounds" } } }, "localname": "SaleOfPounds", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "genh_SaleOfPreferredStockUnits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of preffered stock units.", "label": "Sale Of Preferred Stock Units", "terseLabel": "Sale of preferred stock units (in Dollars)" } } }, "localname": "SaleOfPreferredStockUnits", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "genh_ScheduleOfDiscontinuedOperationsShownInTheConsolidatedStatementsOfOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Discontinued Operations Shown In The Consolidated Statements Of Operations Abstract" } } }, "localname": "ScheduleOfDiscontinuedOperationsShownInTheConsolidatedStatementsOfOperationsAbstract", "nsuri": "http://www.genhempinc.com/20220930", "xbrltype": "stringItemType" }, "genh_ScheduleOfDiscontinuedOperationsToAssetsAndLiabilitiesHeldForSaleAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Discontinued Operations To Assets And Liabilities Held For Sale Abstract" } } }, "localname": "ScheduleOfDiscontinuedOperationsToAssetsAndLiabilitiesHeldForSaleAbstract", "nsuri": "http://www.genhempinc.com/20220930", "xbrltype": "stringItemType" }, "genh_ScheduleOfDiscontinuedOperationsToAssetsAndLiabilitiesHeldForSaleTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Discontinued operations to assets and liabilities held for sale [Table Text Block].", "label": "Schedule Of Discontinued Operations To Assets And Liabilities Held For Sale Table Text Block", "terseLabel": "Schedule of discontinued operations to assets and liabilities held for sale" } } }, "localname": "ScheduleOfDiscontinuedOperationsToAssetsAndLiabilitiesHeldForSaleTableTextBlock", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/DiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "genh_ScheduleOfEarningsLossPerBasicAndDilutedShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Earnings Loss Per Basic And Diluted Share Abstract" } } }, "localname": "ScheduleOfEarningsLossPerBasicAndDilutedShareAbstract", "nsuri": "http://www.genhempinc.com/20220930", "xbrltype": "stringItemType" }, "genh_ScheduleOfIntangibleAssetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Intangible Asset Abstract" } } }, "localname": "ScheduleOfIntangibleAssetAbstract", "nsuri": "http://www.genhempinc.com/20220930", "xbrltype": "stringItemType" }, "genh_ScheduleOfNotesPayableRelatedPartiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Notes Payable Related Parties Abstract" } } }, "localname": "ScheduleOfNotesPayableRelatedPartiesAbstract", "nsuri": "http://www.genhempinc.com/20220930", "xbrltype": "stringItemType" }, "genh_ScheduleOfNotesPayableRelatedPartiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes payable related parties [Text Block].", "label": "Schedule Of Notes Payable Related Parties Table Text Block", "terseLabel": "Schedule of notes payable \u2013 related parties" } } }, "localname": "ScheduleOfNotesPayableRelatedPartiesTableTextBlock", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "genh_ScheduleOfOutstandingStockWarrantsActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Outstanding Stock Warrants Activity Abstract" } } }, "localname": "ScheduleOfOutstandingStockWarrantsActivityAbstract", "nsuri": "http://www.genhempinc.com/20220930", "xbrltype": "stringItemType" }, "genh_ScheduleOfOutstandingStockWarrantsActivityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Outstanding Stock Warrants Activity Text Block", "terseLabel": "Schedule of outstanding stock warrants activity" } } }, "localname": "ScheduleOfOutstandingStockWarrantsActivityTextBlock", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "genh_ScheduleOfPropertyAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Property And Equipment Abstract" } } }, "localname": "ScheduleOfPropertyAndEquipmentAbstract", "nsuri": "http://www.genhempinc.com/20220930", "xbrltype": "stringItemType" }, "genh_ScheduleOfSummarizesOptionsOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Summarizes Options Outstanding Abstract" } } }, "localname": "ScheduleOfSummarizesOptionsOutstandingAbstract", "nsuri": "http://www.genhempinc.com/20220930", "xbrltype": "stringItemType" }, "genh_ScheduleOfSupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Supplemental Cash Flow Information Abstract" } } }, "localname": "ScheduleOfSupplementalCashFlowInformationAbstract", "nsuri": "http://www.genhempinc.com/20220930", "xbrltype": "stringItemType" }, "genh_ScheduleOfWarrantsOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Warrants Outstanding Abstract" } } }, "localname": "ScheduleOfWarrantsOutstandingAbstract", "nsuri": "http://www.genhempinc.com/20220930", "xbrltype": "stringItemType" }, "genh_ScheduleOfWarrantsOutstandingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Warrants Outstanding Text Block", "terseLabel": "Schedule of warrants outstanding" } } }, "localname": "ScheduleOfWarrantsOutstandingTextBlock", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "genh_SecuredPromissoryNoteAndWarrantsToCoventryAssetManagementLTDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Promissory Note And Warrants To Coventry Asset Management LTDMember", "terseLabel": "Secured Promissory Note and Warrants to Coventry Asset Management, LTD. [Member]" } } }, "localname": "SecuredPromissoryNoteAndWarrantsToCoventryAssetManagementLTDMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "genh_SecuredPromissoryNoteToCoventryAssetManagementLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Promissory Note To Coventry Asset Management Ltd Member", "terseLabel": "Secured Promissory Note to Coventry Asset Management, LTD. [Member]" } } }, "localname": "SecuredPromissoryNoteToCoventryAssetManagementLtdMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "domainItemType" }, "genh_SeriesBPreferredStockDividendPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Series B preferred stock dividend payable.", "label": "Series BPreferred Stock Dividend Payable", "terseLabel": "Series B preferred stock dividend payable" } } }, "localname": "SeriesBPreferredStockDividendPayable", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "monetaryItemType" }, "genh_SeriesBPreferredStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series BPreferred Stock Units Member", "terseLabel": "Series B preferred units [Member]" } } }, "localname": "SeriesBPreferredStockUnitsMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "genh_SeriesBRedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series BRedeemable Preferred Stock Member", "terseLabel": "Series B Redeemable Preferred Stock" } } }, "localname": "SeriesBRedeemablePreferredStockMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "genh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCancelledInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants cancelled.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Cancelled In Period", "terseLabel": "Number of Warrants, Warrants cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCancelledInPeriod", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofoutstandingstockwarrantsactivityTable" ], "xbrltype": "sharesItemType" }, "genh_SharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of Common stock.", "label": "Shares Of Common Stock", "terseLabel": "Shares of Common stock" } } }, "localname": "SharesOfCommonStock", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "genh_SquareFootFacility": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Square Foot Facility", "label": "Square Foot Facility", "terseLabel": "Square Foot Facility (in Dollars per Square Foot)" } } }, "localname": "SquareFootFacility", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails" ], "xbrltype": "perUnitItemType" }, "genh_StockBasedCompensationDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) [Line Items]" } } }, "localname": "StockBasedCompensationDetailsLineItems", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "genh_StockBasedCompensationDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) [Table]" } } }, "localname": "StockBasedCompensationDetailsTable", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "genh_StockIssuedDuringPeriodValueIssuanceofCommonSharesForSeniorSecuredPromissoryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common shares for Senior Secured Promissory Note (in Shares)", "label": "Stock Issued During Period Value Issuanceof Common Shares For Senior Secured Promissory Shares", "terseLabel": "Issuance of common shares for Senior Secured Promissory Note (in Shares)" } } }, "localname": "StockIssuedDuringPeriodValueIssuanceofCommonSharesForSeniorSecuredPromissoryShares", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "genh_StockIssuedDuringSharesOfIssuanceOfCommonSharesForConvertiblePromissoryNote": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during shares of Issuance of common shares for Convertible Promissory Note.", "label": "Stock Issued During Shares Of Issuance Of Common Shares For Convertible Promissory Note", "terseLabel": "Issuance of common shares for Convertible Promissory Note (in Shares)" } } }, "localname": "StockIssuedDuringSharesOfIssuanceOfCommonSharesForConvertiblePromissoryNote", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "genh_StockIssuedDuringThePeriodValueIssuanceOfCommonSharesForSeniorSecuredPromissoryNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common shares for Senior Secured Promissory Note", "label": "Stock Issued During The Period Value Issuance Of Common Shares For Senior Secured Promissory Notes", "terseLabel": "Issuance of common shares for Senior Secured Promissory Note" } } }, "localname": "StockIssuedDuringThePeriodValueIssuanceOfCommonSharesForSeniorSecuredPromissoryNotes", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "genh_SubordinatedNoteToInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subordinated Note To Investor Member", "terseLabel": "Subordinated note to investor [Member]" } } }, "localname": "SubordinatedNoteToInvestorMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "genh_SubordinatedPromissoryNoteAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Subordinated promissory note amount.", "label": "Subordinated Promissory Note Amount", "terseLabel": "Subordinated promissory note amount" } } }, "localname": "SubordinatedPromissoryNoteAmount", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "genh_SubordinatedPromissoryNoteAndWarrantsToInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subordinated Promissory Note And Warrants To Investor Member", "terseLabel": "Subordinated Promissory Note and Warrants to Investor [Member]" } } }, "localname": "SubordinatedPromissoryNoteAndWarrantsToInvestorMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "genh_SubordinatedPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subordinated Promissory Note Member", "terseLabel": "Subordinated Promissory Note to Investor [Member]" } } }, "localname": "SubordinatedPromissoryNoteMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "domainItemType" }, "genh_SubordinatedPromissoryNoteToCEOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subordinated Promissory Note To CEOMember", "terseLabel": "Subordinated Promissory Note to CEO [Member]" } } }, "localname": "SubordinatedPromissoryNoteToCEOMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails", "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "domainItemType" }, "genh_SubordinatedPromissouryNoteDueDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subordinated promissoury note due date.", "label": "Subordinated Promissoury Note Due Date", "terseLabel": "Subordinated promissory note due date" } } }, "localname": "SubordinatedPromissouryNoteDueDate", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "dateItemType" }, "genh_TotalUnrecognizedCompensationCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total unrecognized compensation cost.", "label": "Total Unrecognized Compensation Cost", "terseLabel": "Total unrecognized compensation cost" } } }, "localname": "TotalUnrecognizedCompensationCost", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "genh_TwoThousandTwentyOnePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty One Plan Member", "terseLabel": "2021 Plan [Member]" } } }, "localname": "TwoThousandTwentyOnePlanMember", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "genh_WarrantToPurchaseOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant to purchase of common stock.", "label": "Warrant To Purchase Of Common Stock", "terseLabel": "Warrant to purchase shares of common stock (in Shares)" } } }, "localname": "WarrantToPurchaseOfCommonStock", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "sharesItemType" }, "genh_WarrantsAndRightsOutstandingMaturityDateDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified.", "label": "Warrants And Rights Outstanding Maturity Date Description", "terseLabel": "Expiration Date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDateDescription", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "stringItemType" }, "genh_WeightedAveragePriceExceed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "weighted average price exceed.", "label": "Weighted Average Price Exceed", "terseLabel": "Weighted average market price of common stock exceed (in Dollars per share)" } } }, "localname": "WeightedAveragePriceExceed", "nsuri": "http://www.genhempinc.com/20220930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "perShareItemType" }, "srt_MaximumMember": { "auth_ref": [ "r208", "r209", "r210", "r211", "r230", "r244", "r268", "r270", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r431", "r432", "r444", "r445" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genhempinc.com/role/LeasesDetails", "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable", "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r208", "r209", "r210", "r211", "r230", "r244", "r268", "r270", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r431", "r432", "r444", "r445" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genhempinc.com/role/LeasesDetails", "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable", "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r203", "r208", "r209", "r210", "r211", "r230", "r244", "r266", "r268", "r270", "r300", "r301", "r302", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r431", "r432", "r444", "r445" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genhempinc.com/role/LeasesDetails", "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable", "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r203", "r208", "r209", "r210", "r211", "r230", "r244", "r266", "r268", "r270", "r300", "r301", "r302", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r431", "r432", "r444", "r445" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genhempinc.com/role/LeasesDetails", "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable", "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r124", "r269" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r124", "r129", "r207", "r269" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r124", "r129", "r207", "r269", "r376" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "srt_WarehouseMember": { "auth_ref": [ "r438", "r443" ], "lang": { "en-us": { "role": { "label": "Warehouse [Member]", "terseLabel": "Warehouse [Member]" } } }, "localname": "WarehouseMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r56", "r374" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r172", "r173" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r59" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r47", "r374" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r116", "r117", "r118", "r308", "r309", "r310", "r341" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss from continuing operations to net cash from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r86", "r98", "r232", "r354" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r98", "r194" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment expense" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow", "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r41", "r112", "r158", "r161", "r167", "r175", "r214", "r215", "r216", "r218", "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r329", "r334", "r345", "r372", "r374", "r401", "r417" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets", "verboseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r34", "r55", "r112", "r175", "r214", "r215", "r216", "r218", "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r329", "r334", "r345", "r372", "r374" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r2", "r3", "r22", "r24", "r28", "r195", "r199" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Total assets of discontinued operations held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesSharesAuthorized": { "auth_ref": [ "r45", "r258" ], "lang": { "en-us": { "role": { "documentation": "The number of shares of a preferred security the entity has authorized through an auction process.", "label": "Auction Market Preferred Securities, Stock Series, Shares Authorized", "terseLabel": "Shares of preferred stock" } } }, "localname": "AuctionMarketPreferredSecuritiesStockSeriesSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r273", "r274", "r275", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r294", "r295", "r297", "r298", "r299", "r300", "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Capital": { "auth_ref": [ "r415" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of total capital as defined by regulatory framework.", "label": "Banking Regulation, Total Capital, Actual", "terseLabel": "New equity capital" } } }, "localname": "Capital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r87" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired from Acquisition", "terseLabel": "Net of acquired cash" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow_Parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r31", "r36", "r100" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r94", "r100", "r104" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r94", "r346" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Supplemental Cash Flow Information" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/SupplementalCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": { "auth_ref": [ "r94" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations", "terseLabel": "Net cash from financing activities \u2013 discontinued operations" } } }, "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r21", "r94" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "terseLabel": "Net cash from investing activities \u2013 discontinued operations" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r21", "r94" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "terseLabel": "Net cash from operating activities \u2013 discontinued operations" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r43", "r45", "r46", "r109", "r112", "r132", "r133", "r138", "r141", "r143", "r151", "r152", "r153", "r175", "r214", "r219", "r220", "r221", "r225", "r226", "r241", "r242", "r246", "r250", "r257", "r345", "r449" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r263", "r271" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise Price (each)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of Warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Number of Warrants, Warrants ending", "periodStartLabel": "Number of Warrants, Warrants beginning" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofoutstandingstockwarrantsactivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of reason for issuing warrant or right.", "label": "Warrant or Right, Reason for Issuance, Description", "terseLabel": "Method of Exercise" } } }, "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r65", "r405", "r422" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r204", "r205", "r206", "r212", "r439" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r116", "r117", "r341" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/EquityDetails", "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r46", "r257" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r46", "r374" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.00001 par value; 200,000,000 shares authorized, 113,204,002 and 113,094,002 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment and software\t[Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r154", "r416" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Major Customer and Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r44", "r45", "r253", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Converting into shares of restricted common stock" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r82", "r112", "r175", "r214", "r215", "r216", "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r345" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of revenue (exclusive of items shown separately below)" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r80" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and Expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofintangibleassetTable" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionOriginalDebtInterestRateOfDebt": { "auth_ref": [ "r102", "r103" ], "lang": { "en-us": { "role": { "documentation": "The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Original Debt, Interest Rate of Debt", "terseLabel": "Interest rate, percentage" } } }, "localname": "DebtConversionOriginalDebtInterestRateOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Indebtedness [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r229", "r233" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price per share (in Dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature": { "auth_ref": [ "r63", "r258", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Description of conversion terms for debt instrument.", "label": "Debt Instrument, Convertible, Terms of Conversion Feature", "terseLabel": "Interest rate increases" } } }, "localname": "DebtInstrumentConvertibleTermsOfConversionFeature", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r227", "r235", "r236", "r355", "r356", "r357" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r111" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt Instrument, Increase, Accrued Interest", "terseLabel": "Accrued interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r61", "r228" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Bears interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r62", "r230", "r344" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "New maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt Instrument, Maturity Date, Description", "terseLabel": "Convertible note matured, description" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption payments percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r98", "r196" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r98", "r157" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Interest rate percentage" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeMaturityDates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date the derivative contract matures, in YYYY-MM-DD format.", "label": "Derivative, Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "DerivativeMaturityDates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r272", "r273", "r304", "r305", "r306", "r311" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r8", "r9", "r10", "r11", "r12", "r19", "r77", "r425" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "terseLabel": "Income (loss) from discontinued operations" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "terseLabel": "Basic (in Dollars per share)", "verboseLabel": "Basic" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "terseLabel": "Diluted (in Dollars per share)", "verboseLabel": "Diluted" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable", "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": { "auth_ref": [ "r2", "r3", "r22", "r195", "r199" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "auth_ref": [ "r20", "r28" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Oil and gas sales" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent": { "auth_ref": [ "r2", "r3", "r22", "r195", "r199" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Deferred Revenue, Current", "terseLabel": "Revenue payable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "auth_ref": [ "r20" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "terseLabel": "Lease operating expense" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "auth_ref": [ "r2", "r3", "r22", "r195", "r199" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current", "terseLabel": "Oil and natural gas properties held for sale, at cost" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationCurrent": { "auth_ref": [ "r3", "r22", "r199" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as defined benefit non-pension postretirement plan obligations attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Postretirement Plan Benefit Obligation, Current", "terseLabel": "Asset retirement obligations" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r29", "r202" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Discontinued Operations" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/DiscontinuedOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r262", "r413" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Preferred Stock", "negatedLabel": "Series B preferred stock dividend" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r56", "r114", "r217", "r219", "r220", "r224", "r225", "r226", "r368" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Payables to related parties" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r114", "r217", "r219", "r220", "r224", "r225", "r226", "r368", "r404", "r423" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Total" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings (loss) per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r79", "r121", "r122", "r123", "r124", "r125", "r130", "r132", "r141", "r142", "r143", "r147", "r148", "r342", "r343", "r410", "r428" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in Dollars per share)", "verboseLabel": "Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r79", "r121", "r122", "r123", "r124", "r125", "r132", "r141", "r142", "r143", "r147", "r148", "r342", "r343", "r410", "r428" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in Dollars per share)", "verboseLabel": "Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r144", "r145", "r146", "r149" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings (Loss) per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/EarningsLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Employee Benefits and Share-Based Compensation", "terseLabel": "Compensation expense related to awards" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r71", "r72", "r73", "r116", "r117", "r118", "r120", "r126", "r128", "r150", "r177", "r257", "r262", "r308", "r309", "r310", "r316", "r317", "r341", "r347", "r348", "r349", "r350", "r351", "r352", "r364", "r433", "r434", "r435" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/EquityDetails", "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable", "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r98", "r239" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of marketable security" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurement" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r39", "r189" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofintangibleassetTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r185", "r186", "r189", "r190", "r385", "r386" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofintangibleassetTable" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r189", "r386" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofintangibleassetTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofintangibleassetTable" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r185", "r188" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofintangibleassetTable" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r84" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r38", "r180", "r181", "r182", "r183", "r374", "r400" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r98", "r191" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-Lived", "terseLabel": "Impairment expense" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/IntangibleandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r81", "r99", "r121", "r122", "r123", "r124", "r139", "r143", "r327" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "totalLabel": "Net loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r76", "r158", "r160", "r163", "r166", "r168", "r399", "r407", "r411", "r429" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r74", "r79", "r119", "r121", "r122", "r123", "r124", "r132", "r141", "r142", "r343", "r406", "r408", "r410", "r424" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Basic (in Dollars per share)", "verboseLabel": "Basic" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r74", "r79", "r119", "r121", "r122", "r123", "r124", "r132", "r141", "r142", "r143", "r343", "r410", "r424", "r427", "r428" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Diluted (in Dollars per share)", "verboseLabel": "Diluted" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r8", "r9", "r10", "r11", "r12", "r25", "r28", "r320", "r425" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "negatedLabel": "Loss from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r8", "r9", "r10", "r11", "r12", "r19", "r25", "r328" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "terseLabel": "Loss from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Loss from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r3", "r13", "r14", "r15", "r16", "r17", "r18", "r23", "r26", "r27", "r28", "r200", "r201" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r113", "r312", "r314", "r315", "r318", "r319", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationInterestAccrued": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination, Interest Accrued", "terseLabel": "Accrued interest" } } }, "localname": "IncomeTaxExaminationInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r97" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r97" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r97" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r97" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Other income - PPP Loan forgiveness" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r97" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InsuranceSettlementsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.", "label": "Insurance Settlements Receivable", "terseLabel": "Amount received from defendant" } } }, "localname": "InsuranceSettlementsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible and Other Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/IntangibleandOtherAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r184", "r187" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r86", "r231", "r234", "r237", "r238" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest expenses" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableAndOtherAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest receivable and assets classified as other.", "label": "Interest Receivable and Other Assets", "terseLabel": "Accrued interest" } } }, "localname": "InterestReceivableAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r32", "r52", "r374" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r98" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Common shares issued to vendor for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land [Member]" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r83" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal Fees", "terseLabel": "Amount accrued for judgment" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r58", "r112", "r162", "r175", "r214", "r215", "r216", "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r330", "r334", "r335", "r345", "r372", "r373" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r51", "r112", "r175", "r345", "r374", "r403", "r420" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Equity (Deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r35", "r60", "r112", "r175", "r214", "r215", "r216", "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r330", "r334", "r335", "r345", "r372", "r373", "r374" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r2", "r3", "r22", "r24", "r28", "r199" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "terseLabel": "Total liabilities of discontinued operations held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r2", "r3", "r22", "r24", "r28", "r195", "r199" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "terseLabel": "Current liabilities of discontinued operations held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": { "auth_ref": [ "r2", "r3", "r22", "r24", "r28", "r193", "r199" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent", "terseLabel": "Long-term liabilities of discontinued operations held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of life insurance premiums anticipated to be paid to keep the life settlement contracts accounted for under the investment method in force.", "label": "Life Settlement Contracts, Investment Method, Premiums to be Paid", "terseLabel": "Partial settlement claim" } } }, "localname": "LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount awarded from other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded from Other Party", "terseLabel": "Amount of summary judgment" } } }, "localname": "LitigationSettlementAmountAwardedFromOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails", "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r64", "r213" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails", "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_MalpracticeInsuranceAnnualCoverageLimit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Annual coverage limit provided by the insurance arrangement for malpractice claims.", "label": "Malpractice Insurance, Annual Coverage Limit", "terseLabel": "Substantial coverages" } } }, "localname": "MalpracticeInsuranceAnnualCoverageLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r68", "r112", "r175", "r214", "r219", "r220", "r221", "r225", "r226", "r345", "r402", "r419" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_MortgageNotesPayableDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for mortgage notes payable.", "label": "Mortgage Notes Payable Disclosure [Text Block]", "terseLabel": "Other Indebtedness" } } }, "localname": "MortgageNotesPayableDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtedness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows From Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "auth_ref": [ "r94" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net cash from financing activities \u2013 continuing operations" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows From Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "auth_ref": [ "r94" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Net cash from investing activities \u2013 continuing operations" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r94", "r96", "r99" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows From Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r94", "r96", "r99" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash from operating activities \u2013 continuing operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r28", "r69", "r70", "r73", "r78", "r99", "r112", "r119", "r121", "r122", "r123", "r124", "r127", "r128", "r139", "r158", "r160", "r163", "r166", "r168", "r175", "r214", "r215", "r216", "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r343", "r345", "r409", "r426" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss attributable to Generation Hemp" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r69", "r70", "r73", "r127", "r128", "r332", "r337" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less: net income (loss) attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r131", "r134", "r135", "r136", "r137", "r140", "r143" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from discontinued operations available to common shareholders.", "label": "Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic", "terseLabel": "Income (loss) from discontinued operations" } } }, "localname": "NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r116", "r117", "r118", "r262", "r325" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r85" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense (income)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r57" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Notes payable \u2013 related parties" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r114", "r368", "r423" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties.", "label": "Notes Payable, Related Parties", "terseLabel": "Total notes payable \u2013 related parties" } } }, "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r158", "r160", "r163", "r166", "r168" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r359" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability - related party" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r359" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability - related party, net of current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r361", "r362" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Lease payment" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r358" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r30", "r339" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/Business" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r54", "r374" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Current Assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet", "http://www.genhempinc.com/role/IntangibleandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCostOfOperatingRevenue": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other costs incurred during the reporting period related to other revenue generating activities.", "label": "Other Cost of Operating Revenue", "terseLabel": "Outstanding amount" } } }, "localname": "OtherCostOfOperatingRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r430" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "terseLabel": "Other income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIntangibleAssetsNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.", "label": "Other Intangible Assets, Net", "terseLabel": "Net" } } }, "localname": "OtherIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofintangibleassetTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other expense (income):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Cash for its operating activities" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForCapitalImprovements": { "auth_ref": [ "r88" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.", "label": "Payments for Capital Improvements", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsForCapitalImprovements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": { "auth_ref": [ "r91" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock", "negatedLabel": "Series B preferred stock dividends paid" } } }, "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMachineryAndEquipment": { "auth_ref": [ "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for acquisition of machinery and equipment.", "label": "Payments to Acquire Machinery and Equipment", "terseLabel": "Purchase price of equipment" } } }, "localname": "PaymentsToAcquireMachineryAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion of preferred stock.", "label": "Preferred Stock, Convertible, Shares Issuable", "terseLabel": "Converted into shares of common stock" } } }, "localname": "PreferredStockConvertibleSharesIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Dividends percentage" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r45", "r241" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionAmount": { "auth_ref": [ "r66", "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.", "label": "Preferred Stock, Redemption Amount", "terseLabel": "Redemption payments total (in Dollars)" } } }, "localname": "PreferredStockRedemptionAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r45", "r241" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r45", "r374" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.00001 par value; 200,000,000 shares authorized, none outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r33", "r53", "r178", "r179" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r89" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from warrant exercises" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r90" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from Notes Payable", "terseLabel": "Proceeds from notes payable - related parties" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfOtherAssets1": { "auth_ref": [ "r95" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from the sale of other assets as part of operating activities.", "label": "Proceeds from Sale of Other Assets", "terseLabel": "Deliveries and payment amount" } } }, "localname": "ProceedsFromSaleOfOtherAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSubordinatedShortTermDebt": { "auth_ref": [ "r90" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from an obligation which places a lender in a lien position behind debt having a higher priority of repayment (senior loan) in liquidation of the entity's assets scheduled to be repaid within one year or in the normal operating cycle of the entity, if longer.", "label": "Proceeds from Subordinated Short-Term Debt", "terseLabel": "Proceeds from subordinated notes" } } }, "localname": "ProceedsFromSubordinatedShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r28", "r69", "r70", "r73", "r93", "r112", "r119", "r127", "r128", "r158", "r160", "r163", "r166", "r168", "r175", "r214", "r215", "r216", "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r328", "r331", "r333", "r337", "r338", "r343", "r345", "r411" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 }, "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow", "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r202", "r440", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/PropertyandEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r37", "r197" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Subtotal" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r198", "r374", "r412", "r421" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "verboseLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet", "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/PropertyandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r267", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails", "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails", "http://www.genhempinc.com/role/LeasesDetails", "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r267", "r367", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable \u2013 Related Parties [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r267", "r367", "r369", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails", "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails", "http://www.genhempinc.com/role/LeasesDetails", "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r365", "r366", "r368", "r370", "r371" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Notes Payable \u2013 Related Parties" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r92" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedLabel": "Repayments of notes payable - related parties" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r92" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-Term Debt", "negatedLabel": "Repayment of Halcyon bank note" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Shares [Member]", "verboseLabel": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "terseLabel": "Restricted shares, issued" } } }, "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "terseLabel": "Restricted shares, value" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r48", "r262", "r374", "r418", "r436", "r437" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r116", "r117", "r118", "r120", "r126", "r128", "r177", "r308", "r309", "r310", "r316", "r317", "r341", "r433", "r435" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r107", "r108" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Deferred Revenue" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r75", "r112", "r155", "r156", "r159", "r164", "r165", "r169", "r170", "r171", "r175", "r214", "r215", "r216", "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r345", "r411" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale price per pound (in Dollars per share)", "verboseLabel": "Warrant per share (in Dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/EquityDetails", "http://www.genhempinc.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of supplemental cash flow information" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/SupplementalCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r3", "r13", "r14", "r15", "r16", "r17", "r18", "r23", "r26", "r27", "r28", "r200", "r201" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of discontinued operations shown in the consolidated statements of operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/DiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of earnings (loss) per basic and diluted share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/EarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r185", "r188", "r385" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofintangibleassetTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r185", "r188" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangible asset" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/IntangibleandOtherAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r276", "r293", "r296" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of summarizes options outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDiscontinuedOperationsMember": { "auth_ref": [ "r4", "r5", "r6", "r7" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Discontinued Operations [Member]", "terseLabel": "Discontinued Operations [Member]" } } }, "localname": "SegmentDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable", "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesheldforsaleTable" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r43", "r45", "r257" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r43", "r45", "r257" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r97" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Awarded options vest over year" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Volatility ranging" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "terseLabel": "Compensation expense" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofoutstandingstockwarrantsactivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Shares Granted (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsummarizesoptionsoutstandingTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsummarizesoptionsoutstandingTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r277", "r279" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Shares Ending (in Shares)", "periodStartLabel": "Shares Beginning (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsummarizesoptionsoutstandingTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)", "terseLabel": "Common stock incentive compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r277", "r279" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Ending", "periodStartLabel": "Weighted Average Exercise Price Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsummarizesoptionsoutstandingTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r273", "r274", "r275", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r294", "r295", "r297", "r298", "r299", "r300", "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsummarizesoptionsoutstandingTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "terseLabel": "Exercise price per share" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Price per share (in Dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "periodEndLabel": "Aggregate Intrinsic Value Ending (in Dollars)", "periodStartLabel": "Aggregate Intrinsic Value Beginning (in Dollars)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsummarizesoptionsoutstandingTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Stock options range" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Grant Date Fair Value Ending", "periodStartLabel": "Weighted Average Grant Date Fair Value Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsummarizesoptionsoutstandingTable" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Warrants beginning", "verboseLabel": "Weighted Average Exercise Price, Warrants ending" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofoutstandingstockwarrantsactivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r106", "r115" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r43", "r45", "r46", "r109", "r112", "r132", "r133", "r138", "r141", "r143", "r151", "r152", "r153", "r175", "r214", "r219", "r220", "r221", "r225", "r226", "r241", "r242", "r246", "r250", "r257", "r345", "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r67", "r71", "r72", "r73", "r116", "r117", "r118", "r120", "r126", "r128", "r150", "r177", "r257", "r262", "r308", "r309", "r310", "r316", "r317", "r341", "r347", "r348", "r349", "r350", "r351", "r352", "r364", "r433", "r434", "r435" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/EquityDetails", "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable", "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r116", "r117", "r118", "r150", "r384" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r45", "r46", "r262" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Acquisition of Certain Assets of Halcyon Thruput, LLC (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r45", "r46", "r257", "r258", "r262" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Shares, Conversion of Units", "terseLabel": "Series B preferred stock redemptions (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Common shares issued to vendor for services (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r45", "r46", "r257", "r262" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuances of common stock units (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r45", "r46", "r257", "r262" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r45", "r46", "r257", "r262", "r283" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Warrant exercises (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r67", "r257", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Acquisition of Certain Assets of Halcyon Thruput, LLC" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r67", "r257", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Issuance of common shares for Convertible Promissory Note" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r67", "r257", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Value, Conversion of Units", "terseLabel": "Series B preferred stock redemptions" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Common shares issued to vendor for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r45", "r46", "r257", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuances of common stock units" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Modification of warrants for extension of promissory note to investor" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r45", "r46", "r262", "r294" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r67", "r257", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Warrant exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r46", "r49", "r50", "r112", "r174", "r175", "r345", "r374" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Generation Hemp equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Equity (Deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r72", "r112", "r116", "r117", "r118", "r120", "r126", "r175", "r177", "r262", "r308", "r309", "r310", "r316", "r317", "r325", "r326", "r336", "r341", "r345", "r347", "r348", "r352", "r364", "r434", "r435" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total equity (deficit)" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet", "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r110", "r242", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r254", "r255", "r256", "r262", "r264", "r340" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubordinatedBorrowingDueDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date the payments are due on subordinated debt, in YYYY-MM-DD format.", "label": "Subordinated Borrowing, Due Date", "terseLabel": "Due date" } } }, "localname": "SubordinatedBorrowingDueDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "dateItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r353", "r375" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r353", "r375" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r353", "r375" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r214", "r219", "r220", "r221", "r225", "r226" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "terseLabel": "Series B redeemable preferred stock, no par value, $10,000 stated value, 300 shares authorized, 118 and 135 shares issued and outstanding at September 30, 2022 and December 31, 2021" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles [Member]", "terseLabel": "Vehicles [Member]" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrant term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r131", "r143" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares used to compute diluted EPS" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r130", "r143" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares used to compute basic EPS" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "https://asc.fasb.org/topic&trid=2134446" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "325", "URI": "https://asc.fasb.org/extlink&oid=73718008&loc=d3e42708-111610" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2510-110228" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r202": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r206": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r264": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=2122178" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r30": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r311": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r339": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r363": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r371": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)(1)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r446": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r447": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r448": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r449": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" } }, "version": "2.1" } ZIP 69 0001213900-22-072177-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-072177-xbrl.zip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�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end